

9-29-00

BOX 500/A

**UTILITY
PATENT APPLICATION
TRANSMITTAL**

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No. G03077017 (JRV)

First Named Inventor or Application Identifier

Stocker et al.

Express Mail Label No. EL711220885US

Date of Deposit September 28, 2000

9/28/00
JCS
U.S. PTO

9/28/00
JCS
U.S. PTO

APPLICATION ELEMENTS


See MPEP chapter 600 concerning utility patent application contents

<p>1. <input type="checkbox"/> Fee Transmittal Form (Submit an original, and a duplicate for fee processing)</p> <p>2. <input checked="" type="checkbox"/> Specification [Total pages 57] 50 - pages description 1 - pages abstract 6 - pages claims 46 - Total claims</p> <p>3. <input type="checkbox"/> Drawing(s) (35 USC 113) [Total sheets] <input type="checkbox"/> Informal <input type="checkbox"/> Formal [Total drawings]</p> <p>4. <input type="checkbox"/> Oath or Declaration [Total pages] a. <input type="checkbox"/> Newly executed (original or copy) b. <input type="checkbox"/> Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional with Box 17 completed) [Note Box 5 below]</p> <p>i. <input type="checkbox"/> DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).</p> <p>5. <input type="checkbox"/> Incorporation by Reference (useable if Box 4b is checked) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.</p>		<p>ADDRESS TO: Box Patent Application Commissioner for Patents Washington, DC 20231</p> <p>6. <input type="checkbox"/> Microfiche Computer Program (Appendix)</p> <p>7. <input checked="" type="checkbox"/> Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) a. <input checked="" type="checkbox"/> Computer Readable Copy b. <input checked="" type="checkbox"/> Paper Copy (identical to computer copy) c. <input checked="" type="checkbox"/> Statement verifying identity of above</p>
<p>ACCOMPANYING APPLICATION PARTS</p> <p>8. <input type="checkbox"/> Assignment Papers/cover sheet & documents(s)</p> <p>9. <input type="checkbox"/> 37 CFR 3.73(b) Statement (when there is an assignee) <input type="checkbox"/> Power of Attorney</p> <p>10. <input type="checkbox"/> English Translation of Document (if applicable)</p> <p>11. <input type="checkbox"/> Information Disclosure Statement PTO-1449 <input type="checkbox"/> Copies of IDS Citations</p> <p>12. <input type="checkbox"/> Preliminary Amendment</p> <p>13. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) (Should be specifically itemized)</p> <p>14. <input type="checkbox"/> Small Entity Statement(s) <input type="checkbox"/> Statement filed in prior application, Status still proper and desired</p> <p>15. <input type="checkbox"/> Certified Copy of Priority Document(s) (if foreign priority is claimed)</p>		
<p>16. Other:</p> <p>17. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information:</p> <p><input type="checkbox"/> Continuation <input type="checkbox"/> Divisional <input type="checkbox"/> Continuation-in-part (CIP) of prior application No.:</p> <p><input type="checkbox"/> Cancel in this application original claims of the prior application before calculating the filing fee.</p> <p><input type="checkbox"/> Amend the specification by inserting before the first line the sentence: This application is a <input type="checkbox"/> continuation <input type="checkbox"/> divisional of application serial no. , filed , entitled , and now .</p>		

18. CORRESPONDENCE ADDRESS*Correspondence address below*

ATTORNEY'S NAME	John R. Van Amsterdam, Reg. No. 40,212				
NAME	Wolf, Greenfield & Sacks, P.C.				
ADDRESS	600 Atlantic Avenue				
CITY	Boston	STATE	MA	ZIP	02210
COUNTRY	USA	TELEPHONE	(617) 720-3500	FAX	(617) 720-2441

19. SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED

NAME	John R. Van Amsterdam, Reg. No. 40,212
SIGNATURE	
DATE	SEPTEMBER 28, 2000

P-GLYCOPROTEINS AND USES THEREOF

Related Applications

This application claims priority under 35 U.S.C. §119 from U.S. provisional patent

5 application 60/156,510, filed September 28, 1999.

Field of the Invention

The invention pertains to P-glycoproteins of dog (*Canis familiaris*).

10

Background of the Invention

P-glycoprotein (PGP; also known as multidrug transporter, MDR1) is a member of the ABC transporter superfamily and is expressed in the human intestine, liver and other tissues. This enzyme serves as an efflux pump exporting small molecules across the cell membrane. It has been known for several years that high level expression of PGP is a mechanism for tumor resistance to cancer chemotherapy. Intestinal expression of PGP may affect the oral bioavailability of drug molecules that are substrates for this transporter. PGP can efficiently efflux drugs back into the intestinal lumen and thus reduce the amount of drug that enters into circulation.

15

The measurement of interaction with PGP can provide a better understanding of the reasons why particular drugs demonstrate low or high bioavailability. Interaction with PGP can be studied using either direct assays of drug transport in polarized cell systems or with indirect assays such as drug-stimulated ATPase activity and inhibition of the transport of fluorescent substrates.

20

Therefore there is a need for additional PGP polypeptides, preferably which are closely related to the human PGP, for use in the foregoing drug assays.

25

Summary of the Invention

Nucleic acids encoding P-glycoprotein of dog (*Canis familiaris*) have now been identified, isolated, cloned and sequenced. This PGP is closely related (has a high degree of identity) to the human PGP. The invention provides isolated nucleic acid molecules, unique fragments of those molecules, expression vectors containing the foregoing, and host cells transfected with those molecules. The invention also provides isolated polypeptides and

inhibitors of the foregoing nucleic acids and polypeptides which reduce drug transport. The PGP nucleic acids and polypeptides are useful in assays for evaluating bioavailability of drugs, as well as for the optimization or discovery of drugs. In addition, the foregoing can be used in the diagnosis or treatment of conditions characterized by PGP activity and can be used in methods in which it is therapeutically useful to increase or decrease PGP activity.

According to one aspect of the invention, an isolated nucleic acid molecule is provided which is selected from the group consisting of (a) nucleic acid molecules that code for the amino acid sequence of SEQ ID NO:2, (b) allelic variants of (a), wherein the allelic variants exclude SEQ ID NO:3 and SEQ ID NO:5, and (c) complements of (a) or (b).

Preferred allelic variants include nucleic acid molecules that encode an amino acid sequence selected from the group consisting of SEQ ID NO:23, SEQ ID NO:25 and SEQ ID NO:27, particularly nucleotide sequences selected from the group consisting of SEQ ID NO:22, SEQ ID NO:24 and SEQ ID NO:26. In preferred embodiments the isolated nucleic acid molecule codes for SEQ ID NO:2, or comprises the nucleotide sequence of SEQ ID NO:1. In particularly preferred embodiments, the nucleic acid molecules comprise or consist of the coding region of the aforementioned nucleotide sequences.

According to other aspects of the invention, isolated P-glycoprotein polypeptides or fragments thereof are provided. The polypeptides include at least one amino acid of a dog P-glycoprotein selected from the group consisting of amino acids 25, 192, 197, 212, 288, 329, 532, 696, 1273 and 1355 of SEQ ID NO:2; amino acid 25 of SEQ ID NO:23; and amino acids 25 and 1148 of SEQ ID NO:25. Other isolated P-glycoprotein polypeptides or fragments thereof include at least one amino acid of a dog P-glycoprotein selected from the group consisting of amino acids 3, 6, 8, 10, 12, 14-26, 36, 38, 48, 52, 56, 64, 74, 78, 84-92, 94, 96, 98, 99, 101, 103, 104, 106, 108, 112, 115, 147, 187, 197, 199, 233, 288, 321, 326, 347, 397, 450, 454, 455, 467, 472, 520, 633, 637, 643, 644, 650, 657, 658, 661, 666, 667, 674-677, 679, 685, 689, 691, 693, 694, 703, 707, 717, 731, 736, 740, 744, 745, 756, 759, 763, 853, 914, 920, 942, 943, 946, 968-970, 972, 974, 983, 1005, 1010, 1017, 1025, 1026, 1029, 1040, 1095, 1098, 1105, 1144, 1148, 1149, 1158, 1162, 1165, 1168, 1170, 1252 and 1279 of SEQ ID NO:2; and amino acid 329 of SEQ ID NO:27, wherein the P-glycoprotein is identical to a human P-glycoprotein except for the at least one amino acid of a dog P-glycoprotein. In certain embodiments, the human P-glycoprotein is selected from the group of SEQ ID NO:7 and SEQ ID NO:8. Still other isolated P-glycoprotein polypeptides or fragments thereof

include at least one amino acid of a dog P-glycoprotein that is different from a cynomolgous P-glycoprotein, wherein the P-glycoprotein is identical to a cynomolgous monkey P-glycoprotein except for the at least one amino acid of a dog P-glycoprotein. Yet other polypeptides include combinations of the foregoing dog, human and cynomolgous PGP 5 polypeptides. In preferred embodiments, the isolated P-glycoprotein polypeptides or fragments thereof include an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, fragments of SEQ ID NO:2, fragments of SEQ ID NO:23, fragments of SEQ ID NO:25 and fragments of SEQ ID NO:27.

According to still other embodiments of the invention, isolated nucleic acid molecules 10 are provided which encode the foregoing isolated P-glycoprotein polypeptides or fragments thereof. Also included expression vectors comprising the foregoing isolated nucleic acid molecules operably linked to a promoter, as well as host cells transformed or transfected with the expression vectors.

In another aspect of the invention, agents which selectively binds the isolated PGP 15 polypeptides are provided. Preferably the agent does not bind a human or dog P-glycoprotein, except those provided herein. In certain embodiments, the agent is a polypeptide preferably one selected from the group consisting of monoclonal antibodies, polyclonal antibodies, Fab antibody fragments, F(ab)₂ antibody fragments and antibody fragments including a CDR3 region. Also provided are agents which selectively binds the foregoing isolated nucleic acid 20 molecules, preferably antisense nucleic acid molecules which selectively binds to the isolated nucleic acid molecule.

According to another aspect of the invention, methods for predicting the bioavailability of a compound are provided. The methods include measuring the transmembrane transport of a test compound by a first P-glycoprotein, comparing the 25 transmembrane transport of the test compound by the first P-glycoprotein and a second P-glycoprotein to predict the bioavailability of the test compound, wherein the relative amount or rate of transport by the first P-glycoprotein and the second P-glycoprotein is predictive of bioavailability of the test compound. In certain embodiments the first P-glycoprotein is selected from the group consisting of dog P-glycoproteins and primate P- 30 glycoproteins, preferably one of the foregoing polypeptides. In other embodiments the second P-glycoprotein is a human P-glycoprotein.

In still other aspects of the invention, methods for inhibiting P-glycoprotein

transporter activity in a mammalian cell are provided. The methods include contacting the mammalian cell with an amount of one of the foregoing agents effective to inhibit P-glycoprotein transporter activity in the mammalian cell.

Also included in the invention are methods for increasing bioavailability of a drug in a subject. The methods include administering to a subject in need of such treatment one of the foregoing agents in an amount effective to increasing bioavailability of a drug. The inhibitor can be administered prior to administering the drug, or concurrently with the drug.

Also provided are methods for increasing P-glycoprotein transporter activity in a cell. These methods include contacting the cell with a molecule selected from the group consisting of the foregoing nucleic acid molecules, in an amount effective to increase P-glycoprotein transporter activity in the cell. The cell can be contacted under conditions whereby the P-glycoprotein is expressed.

According to yet another aspect of the invention, methods for identifying lead compounds for a pharmacological agent useful in the treatment of disease associated with P-glycoprotein transporter activity are provided. The methods include providing a cell or other membrane-encapsulated space comprising a P-glycoprotein as provided herein; contacting the cell or other membrane-encapsulated space with a candidate pharmacological agent under conditions which, in the absence of the candidate pharmacological agent, cause a first amount of P-glycoprotein transporter activity; and determining a second amount of P-glycoprotein transporter activity as a measure of the effect of the pharmacological agent on the P-glycoprotein transporter activity, wherein a second amount of P-glycoprotein transporter activity which is less than the first amount indicates that the candidate pharmacological agent is a lead compound for a pharmacological agent which reduces P-glycoprotein transporter activity and wherein a second amount of P-glycoprotein transporter activity which is greater than the first amount indicates that the candidate pharmacological agent is a lead compound for a pharmacological agent which increases P-glycoprotein transporter activity. The methods can further include a step of loading the cell or other membrane-encapsulated space with a detectable compound, wherein the compound is detected as a measure of the P-glycoprotein transporter activity.

Also included are methods for identifying compounds which selectively bind a P-glycoprotein. The methods include contacting a P-glycoprotein provided herein with a compound, and determining the binding of the compound to the P-glycoprotein. The methods

can further include determining the effect of the compound on the P-glycoprotein transporter activity of the P-glycoprotein or determining the effect of the compound on the ATPase activity of the P-glycoprotein.

Additional methods provided according to the invention include methods for

5 determining ATPase activity of a P-glycoprotein. The methods include contacting a host cell as provided above, or a membrane fraction thereof, with a test drug, and measuring ATPase activity of the P-glycoprotein. In certain embodiments, the step of measuring ATPase activity is performed at least twice at different times. Also provided methods for determining transmembrane transport of a compound by a P-glycoprotein. The methods include
10 contacting a host cell provided above, or a membrane fraction thereof, with a test drug, and measuring transport of the test drug under sink conditions in at least one direction of transport selected from the group consisting of the apical to basolateral direction and the basolateral to apical direction. In certain embodiments the step of measuring transport of the test drug is performed at least twice at different times.

15 These and other aspects of the invention are described in greater detail below.

Brief Description of the Sequences

SEQ ID NO:1 is the nucleotide sequence encoding dog P-glycoprotein (Genotype C).

SEQ ID NO:2 is the amino acid sequence of a dog P-glycoprotein encoded by SEQ ID

20 NO:1.

SEQ ID NO:3 is the nucleotide sequence encoding a prior art dog P-glycoprotein (GenBank accession number AF045016).

SEQ ID NO:4 is the amino acid sequence of a dog P-glycoprotein encoded by SEQ ID NO:3.

25 SEQ ID NO:5 is the nucleotide sequence encoding another prior art dog P-glycoprotein (GenBank accession number AF092810).

SEQ ID NO:6 is the amino acid sequence of a dog P-glycoprotein encoded by SEQ ID NO:5.

30 SEQ ID NO:7 is the amino acid sequence of a prior art human P-glycoprotein, having Genbank accession number M14758.

SEQ ID NO:8 is the amino acid sequence of a second prior art human P-glycoprotein, having Genbank accession numbers AF016535 or NM_000927.

SEQ ID NO:9 is the nucleotide sequence of a PCR primer homologous to human PGP1.

SEQ ID NO:10 is the nucleotide sequence of a PCR primer homologous to dog PGP2.

SEQ ID NO:11 is the nucleotide sequence of a PCR primer homologous to dog PGP1.

5 SEQ ID NO:12 is the nucleotide sequence of a PCR primer homologous to human PGP1.

SEQ ID NO:13 is the nucleotide sequence of a PCR primer homologous to dog PGP1.

SEQ ID NO:14 is the nucleotide sequence of a PCR primer homologous to human PGP1.

10 SEQ ID NO:15 is the nucleotide sequence of a PCR primer homologous to dog PGP1.

SEQ ID NO:16 is the nucleotide sequence of a PCR primer homologous to human PGP1.

SEQ ID NO:17 is the nucleotide sequence of a PCR primer homologous to dog PGP1.

SEQ ID NO:18 is the nucleotide sequence of a PCR primer homologous to vector.

15 SEQ ID NO:19 is the nucleotide sequence of a PCR primer homologous to dog PGP1.

SEQ ID NO:20 is the nucleotide sequence of a PCR primer homologous to human PGP1.

20

SEQ ID NO:21 is the nucleotide sequence of a PCR primer homologous to dog PGP1.

SEQ ID NO:22 is the nucleotide sequence encoding dog P-glycoprotein (Genotype A).

SEQ ID NO:23 is the amino acid sequence of a dog P-glycoprotein encoded by SEQ ID NO:22.

25 SEQ ID NO:24 is the nucleotide sequence encoding dog P-glycoprotein (Genotype B).

SEQ ID NO:25 is the amino acid sequence of a dog P-glycoprotein encoded by SEQ ID NO:24.

SEQ ID NO:26 is the nucleotide sequence encoding dog P-glycoprotein (Genotype D).

SEQ ID NO:27 is the amino acid sequence of a dog P-glycoprotein encoded by SEQ ID NO:25.

SEQ ID NO:28 is the nucleotide sequence of the cDNA synthesis primer from the Marathon cDNA Amplification Kit.

30 SEQ ID NO:29 is the nucleotide sequence of the cDNA Adapter Primer 1 from the Marathon cDNA Amplification Kit.

SEQ ID NO:30 is the nucleotide sequence of a PCR primer homologous to dog PGP1.

SEQ ID NO:31 is the nucleotide sequence of a PCR primer homologous to dog PGP1.

SEQ ID NO:32 is the nucleotide sequence of a PCR primer homologous to dog PGP1.

Detailed Description of the Invention

5 The present invention in one aspect involves the identification of novel cDNAs encoding dog P-glycoproteins, referred to herein as dog PGP. The nucleotide sequence of a dog PGP (termed "Genotype C") is presented as SEQ ID NO:1, and the amino acid sequence of this dog PGP is presented as SEQ ID NO:2.

10 Three allelic variants of Genotype C dog PGP were isolated ("Genotype A", "Genotype B" and "Genotype D"). The nucleotide and amino acid sequences of Genotype A are presented as SEQ ID NOs:20 and 21, respectively. The amino acid sequence of Genotype A differs from the amino acid sequence of Genotype C at amino acid 197 (histidine → glutamine) based on a C → A change at nucleotide 607 of SEQ ID NO:2. The nucleotide and amino acid sequences of Genotype B are presented as SEQ ID NOs:22 and 23, respectively.

15 The amino acid sequence of Genotype B differs from the amino acid sequence of Genotype C at amino acid 25 (asparagine → lysine) based on a T → A change at nucleotide 91 of SEQ ID NO:2, and at amino acid 197 (histidine → glutamine) based on a C → A change at nucleotide 607 of SEQ ID NO:2. The nucleotide and amino acid sequences of Genotype D are presented as SEQ ID NOs:24 and 25, respectively. The amino acid sequence of Genotype D differs from the amino acid sequence of Genotype C at amino acid 25 (asparagine → lysine) based on a T → A change at nucleotide 91 of SEQ ID NO:2, at amino acid 197 (histidine → glutamine) based on a C → A change at nucleotide 607 of SEQ ID NO:2, at amino acid 329 (serine → threonine) based on a T → A change at nucleotide 1001 of SEQ ID NO:2, and at amino acid 1148 (methionine → valine) based on a A → G change at nucleotide 3458 of SEQ

20 ID NO:2.

25 Two closely related dog PGP sequence were deposited in GenBank under accession numbers AF045016 (complete cDNA) and AF092810 (partial cDNA). Whereas much of the polypeptides presented herein is identical to the known dog PGPs, the dog PGPs of the invention (SEQ ID NOs:2, 21, 23 and 25) have several single amino acid differences from the prior art sequences, including at least one deletion. These allelic differences in the very highly conserved protein domains of the P-glycoprotein are entirely unexpected.

30 The invention involves in one aspect dog PGP nucleic acids and polypeptides, as well

as therapeutics relating thereto. The invention also embraces isolated functionally equivalent variants, useful analogs and fragments of the foregoing nucleic acids and polypeptides; complements of the foregoing nucleic acids; and molecules which selectively bind the foregoing nucleic acids and polypeptides.

5 The dog PGP nucleic acids and polypeptides of the invention are isolated. As used herein with respect to nucleic acids, the term "isolated" means: (i) amplified *in vitro* by, for example, polymerase chain reaction (PCR); (ii) recombinantly produced by cloning; (iii) purified, as by cleavage and gel separation; or (iv) synthesized by, for example, chemical synthesis. An isolated nucleic acid is one which is readily manipulable by recombinant DNA
10 techniques well known in the art. Thus, a nucleotide sequence contained in a vector in which 5' and 3' restriction sites are known or for which polymerase chain reaction (PCR) primer sequences have been disclosed is considered isolated but a nucleic acid sequence existing in its native state in its natural host is not. An isolated nucleic acid may be substantially purified, but need not be. For example, a nucleic acid that is isolated within a cloning or
15 expression vector is not pure in that it may comprise only a tiny percentage of the material in the cell in which it resides. Such a nucleic acid is isolated, however, as the term is used herein because it is readily manipulable by standard techniques known to those of ordinary skill in the art. An isolated nucleic acid as used herein is not a naturally occurring chromosome.

As used herein with respect to polypeptides, "isolated" means separated from its native environment and present in sufficient quantity to permit its identification or use. Isolated, when referring to a protein or polypeptide, means, for example: (i) selectively produced by expression cloning or (ii) purified as by chromatography or electrophoresis. Isolated proteins or polypeptides may be, but need not be, substantially pure. The term "substantially pure" means that the proteins or polypeptides are essentially free of other
25 substances with which they may be found in nature or *in vivo* systems to an extent practical and appropriate for their intended use. Substantially pure polypeptides may be produced by techniques well known in the art. Because an isolated protein may be admixed with a pharmaceutically acceptable carrier in a pharmaceutical preparation, the protein may comprise only a small percentage by weight of the preparation. The protein is nonetheless isolated in
30 that it has been separated from the substances with which it may be associated in living systems, i.e. isolated from other proteins.

As used herein a dog PGP nucleic acid refers to an isolated nucleic acid molecule

which codes for a dog PGP polypeptide. Such nucleic acid molecules code for dog PGP polypeptides which include the amino acid sequences of SEQ ID NO:2, 23, 25, 27 and fragments thereof. The nucleic acid molecules include the nucleotide sequences of SEQ ID NO:1, and nucleotide sequences which differ from the sequences of SEQ ID NO:1, in codon 5 sequence due to the degeneracy of the genetic code. The dog PGP nucleic acids of the invention also include alleles (e.g., SEQ ID Nos: 22, 24, 26) of the foregoing nucleic acids (except those of previously known dog PGP alleles, e.g., SEQ ID NOS:3 and 5), and encoded polypeptides, as well as fragments of the foregoing nucleic acids and polypeptides. Such fragments can be used, for example, as probes in hybridization assays and as primers in a 10 polymerase chain reaction (PCR). Preferred dog PGP nucleic acids include the nucleic acid sequences of SEQ ID NOS:1, 22, 24, 26 and fragments thereof. Complements of the foregoing nucleic acids also are embraced by the invention.

As used herein “dog PGP activity” refers to an ability of a PGP polypeptide to export small molecules across the cell membrane. A molecule which inhibits dog PGP activity (an antagonist) is one which inhibits export of small molecules via PGP and a molecule which increases dog PGP activity (an agonist) is one which increases export of small molecules via PGP. Changes in dog PGP activity can be measured by assays such as those disclosed herein, including efflux of fluorescent compounds from cells.

Alleles of the dog PGP nucleic acids of the invention can be identified by conventional techniques. For example, alleles of dog PGP can be isolated by hybridizing a probe which includes at least a fragment of SEQ ID NO:1 under stringent conditions with a cDNA library and selecting positive clones. Thus, an aspect of the invention is those nucleic acid sequences which code for dog PGP polypeptides and which hybridize to a nucleic acid molecule consisting of SEQ ID NO:1 under stringent conditions (except those of previously known dog 20 PGP alleles, e.g., SEQ ID NOS:3 and 5). The term “stringent conditions” as used herein refers to parameters with which the art is familiar. Nucleic acid hybridization parameters may be found in references which compile such methods, e.g. *Molecular Cloning: A Laboratory Manual*, J. Sambrook, et al., eds., Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989, or *Current Protocols in Molecular Biology*, F.M. Ausubel, et al., eds., John Wiley & Sons, Inc., New York. More specifically, stringent conditions, as used herein, refers, for example, to hybridization at 65°C in hybridization buffer (3.5 x SSC, 30 0.02% Ficoll, 0.02% polyvinyl pyrrolidone, 0.02% Bovine Serum Albumin, 2.5mM

NaH₂PO₄(pH7), 0.5% SDS, 2mM EDTA). SSC is 0.15M sodium chloride/0.15M sodium citrate, pH7; SDS is sodium dodecyl sulphate; and EDTA is ethylenediaminetetraacetic acid. After hybridization, the membrane upon which the DNA is transferred is washed at 2 x SSC at room temperature and then at 0.1 - 0.5 x SSC/0.1 x SDS at temperatures up to 68°C.

5 There are other conditions, reagents, and so forth which can be used, which result in a similar degree of stringency. The skilled artisan will be familiar with such conditions, and thus they are not given here. It will be understood, however, that the skilled artisan will be able to manipulate the conditions in a manner to permit the clear identification of alleles of dog PGP nucleic acids of the invention. The skilled artisan also is familiar with the
10 methodology for screening cells and libraries for expression of such molecules which then are routinely isolated, followed by isolation of the pertinent nucleic acid molecule and sequencing.

In screening for dog PGP nucleic acids, a Southern blot may be performed using the foregoing stringent conditions, together with a radioactive probe. After washing the
15 membrane to which the DNA is finally transferred, the membrane can be placed against X-ray film to detect the radioactive signal.

The dog PGP nucleic acids of the invention also include degenerate nucleic acids which include alternative codons to those present in the native materials. For example, serine residues are encoded by the codons TCA, AGT, TCC, TCG, TCT and AGC. Each of the six
20 codons is equivalent for the purposes of encoding a serine residue. Thus, it will be apparent to one of ordinary skill in the art that any of the serine-encoding nucleotide triplets may be employed to direct the protein synthesis apparatus, *in vitro* or *in vivo*, to incorporate a serine residue into an elongating dog PGP polypeptide. Similarly, nucleotide sequence triplets which encode other amino acid residues include, but are not limited to: CCA, CCC, CCG and
25 CCT (proline codons); CGA, CGC, CGG, CGT, AGA and AGG (arginine codons); ACA, ACC, ACG and ACT (threonine codons); AAC and AAT (asparagine codons); and ATA, ATC and ATT (isoleucine codons). Other amino acid residues may be encoded similarly by multiple nucleotide sequences. Thus, the invention embraces degenerate nucleic acids that differ from the biologically isolated nucleic acids in codon sequence due to the degeneracy of
30 the genetic code.

The invention also provides modified nucleic acid molecules which include additions, substitutions and deletions of one or more nucleotides. In preferred embodiments, these

modified nucleic acid molecules and/or the polypeptides they encode retain at least one activity or function of the unmodified nucleic acid molecule and/or the polypeptides, such as transporter activity, etc. In certain embodiments, the modified nucleic acid molecules encode modified polypeptides, preferably polypeptides having conservative amino acid substitutions as are described elsewhere herein. The modified nucleic acid molecules are structurally related to the unmodified nucleic acid molecules and in preferred embodiments are sufficiently structurally related to the unmodified nucleic acid molecules so that the modified and unmodified nucleic acid molecules hybridize under stringent conditions known to one of skill in the art.

For example, modified nucleic acid molecules which encode polypeptides having single amino acid changes can be prepared. Each of these nucleic acid molecules can have one, two or three nucleotide substitutions exclusive of nucleotide changes corresponding to the degeneracy of the genetic code as described herein. Likewise, modified nucleic acid molecules which encode polypeptides having two amino acid changes can be prepared which have, e.g., 2-6 nucleotide changes. Numerous modified nucleic acid molecules like these will be readily envisioned by one of skill in the art, including for example, substitutions of nucleotides in codons encoding amino acids 2 and 3, 2 and 4, 2 and 5, 2 and 6, and so on. In the foregoing example, each combination of two amino acids is included in the set of modified nucleic acid molecules, as well as all nucleotide substitutions which code for the amino acid substitutions. Additional nucleic acid molecules that encode polypeptides having additional substitutions (i.e., 3 or more), additions or deletions (e.g., by introduction of a stop codon or a splice site(s)) also can be prepared and are embraced by the invention as readily envisioned by one of ordinary skill in the art. Any of the foregoing nucleic acids or polypeptides can be tested by routine experimentation for retention of structural relation or activity to the nucleic acids and/or polypeptides disclosed herein.

The invention also provides isolated fragments of SEQ ID NO:1. The fragments can be used as probes in Southern blot assays to identify such nucleic acids, or can be used in amplification assays such as those employing PCR. Smaller fragments are those comprising 12, 13, 14, 15, 16, 17, 18, 20, 22, 25, 30, 40, 50, or 75 nucleotides, and every integer therebetween, and are useful e.g. as primers for nucleic acid amplification procedures. As known to those skilled in the art, larger probes such as 200, 250, 300, 400 or more nucleotides are preferred for certain uses such as Southern blots, while smaller fragments will be preferred

for uses such as PCR. Fragments also can be used to produce fusion proteins for generating antibodies or determining binding of the polypeptide fragments. Likewise, fragments can be employed to produce non-fused fragments of the dog PGP polypeptides, useful, for example, in the preparation of antibodies, in immunoassays, and the like. The foregoing nucleic acid
5 fragments further can be used as antisense molecules to inhibit the expression of dog PGP nucleic acids and polypeptides, particularly for therapeutic purposes as described in greater detail below.

The invention also includes functionally equivalent variants of the dog PGP, which include variant nucleic acids and polypeptides which retain one or more of the functional
10 properties of the dog PGP. For example, variants include a fusion protein which includes the extracellular and transmembrane domains of the dog PGP which retains the ability to transport molecules. Still other functionally equivalent variants include truncations, deletions, point mutations, or additions of amino acids to the sequence of SEQ ID NO:1 which retains functions of SEQ ID NOs:2, e.g., the alleles presented herein. Functionally equivalent
15 variants also include a dog PGP which has had a portion of the N-terminus removed or replaced by a similar domain from another P-glycoprotein (e.g. a “domain-swapping” variant). Other functionally equivalent variants will be known to one of ordinary skill in the art, as will methods for preparing such variants. The activity of a functionally equivalent variant can be determined using the methods provided herein, and in references that have
20 described assays using P-glycoproteins of other species. Such variants are useful, *inter alia*, for evaluating bioavailability of drugs, in assays for identification of compounds which bind and/or regulate the transporter function of the dog PGP, and for determining the portions of the dog PGP which are required for transporter activity.

Variants which are non-functional also can be prepared as described above. Such
25 variants are useful, for example, as negative controls in experiments testing transporter activity.

A dog PGP nucleic acid, in one embodiment, is operably linked to a gene expression sequence which directs the expression of the dog PGP nucleic acid within a eukaryotic or prokaryotic cell. The “gene expression sequence” is any regulatory nucleotide sequence, such
30 as a promoter sequence or promoter-enhancer combination, which facilitates the efficient transcription and translation of the dog PGP nucleic acid to which it is operably linked. The gene expression sequence may, for example, be a mammalian or viral promoter, such as a

constitutive or inducible promoter. Constitutive mammalian promoters include, but are not limited to, the promoters for the following genes: hypoxanthine phosphoribosyl transferase (HPTR), adenosine deaminase, pyruvate kinase, β -actin promoter and other constitutive promoters. Exemplary viral promoters which function constitutively in eukaryotic cells

5 include, for example, promoters from the simian virus, papilloma virus, adenovirus, human immunodeficiency virus (HIV), Rous sarcoma virus, cytomegalovirus, the long terminal repeats (LTR) of Moloney murine leukemia virus and other retroviruses, and the thymidine kinase promoter of herpes simplex virus. Other constitutive promoters are known to those of ordinary skill in the art. The promoters useful as gene expression sequences of the invention

10 also include inducible promoters. Inducible promoters are expressed in the presence of an inducing agent. For example, the metallothionein promoter is induced to promote transcription and translation in the presence of certain metal ions. Other inducible promoters are known to those of ordinary skill in the art.

In general, the gene expression sequence shall include, as necessary, 5' non-transcribing and 5' non-translating sequences involved with the initiation of transcription and translation, respectively, such as a TATA box, capping sequence, CAAT sequence, and the like. Especially, such 5' non-transcribing sequences will include a promoter region which includes a promoter sequence for transcriptional control of the operably joined dog PGP nucleic acid. The gene expression sequences optionally includes enhancer sequences or upstream activator sequences as desired.

The dog PGP nucleic acid sequence and the gene expression sequence are said to be "operably linked" when they are covalently linked in such a way as to place the transcription and/or translation of the dog PGP coding sequence under the influence or control of the gene expression sequence. If it is desired that the dog PGP sequence be translated into a functional protein, two DNA sequences are said to be operably linked if induction of a promoter in the 5' gene expression sequence results in the transcription of the dog PGP sequence and if the nature of the linkage between the two DNA sequences does not (1) result in the introduction of a frame-shift mutation, (2) interfere with the ability of the promoter region to direct the transcription of the dog PGP sequence, or (3) interfere with the ability of the corresponding RNA transcript to be translated into a protein. Thus, a gene expression sequence would be operably linked to a dog PGP nucleic acid sequence if the gene expression sequence were capable of effecting transcription of that dog PGP nucleic acid sequence such that the

resulting transcript might be translated into the desired protein or polypeptide.

The dog PGP nucleic acid molecules and the dog PGP polypeptides (including the dog PGP inhibitors described below) of the invention can be delivered to the eukaryotic or prokaryotic cell alone or in association with a vector. In its broadest sense, a "vector" is any

5 vehicle capable of facilitating: (1) delivery of a dog PGP nucleic acid or polypeptide to a target cell, (2) uptake of a dog PGP nucleic acid or polypeptide by a target cell, or (3) expression of a dog PGP nucleic acid molecule or polypeptide in a target cell. Preferably, the vectors transport the dog PGP nucleic acid or polypeptide into the target cell with reduced degradation relative to the extent of degradation that would result in the absence of the vector.

10 Optionally, a "targeting ligand" can be attached to the vector to selectively deliver the vector to a cell which expresses on its surface the cognate receptor (e.g. a receptor, an antigen recognized by an antibody) for the targeting ligand. In this manner, the vector (containing a dog PGP nucleic acid or a dog PGP polypeptide) can be selectively delivered to a specific cell. In general, the vectors useful in the invention are divided into two classes: biological 15 vectors and chemical/physical vectors. Biological vectors are more useful for delivery/uptake of dog PGP nucleic acids to/by a target cell. Chemical/physical vectors are more useful for delivery/uptake of dog PGP nucleic acids or dog PGP proteins to/by a target cell.

Biological vectors include, but are not limited to, plasmids, phagemids, viruses, other vehicles derived from viral or bacterial sources that have been manipulated by the insertion or incorporation of the nucleic acid sequences of the invention, and free nucleic acid fragments which can be linked to the nucleic acid sequences of the invention. Viral vectors are a preferred type of biological vector and include, but are not limited to, nucleic acid sequences from the following viruses: retroviruses, such as Moloney murine leukemia virus; Harvey murine sarcoma virus; murine mammary tumor virus; Rous sarcoma virus; adenovirus; adeno- 20 associated virus; SV40-type viruses; polyoma viruses; poxviruses; retroviruses; Epstein-Barr viruses; papilloma viruses; herpes virus; vaccinia virus; and polio virus. One can readily employ other vectors not named but known in the art.

Preferred viral vectors are based on non-cytopathic eukaryotic viruses in which non-essential genes have been replaced with the gene of interest. Non-cytopathic viruses include 30 retroviruses, the life cycle of which involves reverse transcription of genomic viral RNA into DNA with subsequent proviral integration into host cellular DNA. In general, the retroviruses are replication-deficient (i.e., capable of directing synthesis of the desired proteins, but

incapable of manufacturing an infectious particle). Such genetically altered retroviral expression vectors have general utility for the high-efficiency transduction of genes *in vivo*. Standard protocols for producing replication-deficient retroviruses (including the steps of incorporation of exogenous genetic material into a plasmid, transfection of a packaging cell line with plasmid, production of recombinant retroviruses by the packaging cell line, collection of viral particles from tissue culture media, and infection of the target cells with viral particles) are provided in Kriegler, M., *“Gene Transfer and Expression, A Laboratory Manual,”* W.H. Freeman C.O., New York (1990) and Murry, E.J. Ed. *“Methods in Molecular Biology,”* vol. 7, Humana Press, Inc., Clifton, New Jersey (1991).

Another preferred virus for certain applications is the adeno-associated virus, a double-stranded DNA virus. The adeno-associated virus can be engineered to be replication-deficient and is capable of infecting a wide range of cell types and species. It further has advantages, such as heat and lipid solvent stability; high transduction frequencies in cells of diverse lineages; and lack of superinfection inhibition thus allowing multiple series of transductions. Reportedly, the adeno-associated virus can integrate into human cellular DNA in a site-specific manner, thereby minimizing the possibility of insertional mutagenesis and variability of inserted gene expression. In addition, wild-type adeno-associated virus infections have been followed in tissue culture for greater than 100 passages in the absence of selective pressure, implying that the adeno-associated virus genomic integration is a relatively stable event. The adeno-associated virus can also function in an extrachromosomal fashion.

Expression vectors containing all the necessary elements for expression are commercially available and known to those skilled in the art. See, e.g., Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Second Edition, Cold Spring Harbor Laboratory Press, 1989. Cells are genetically engineered by the introduction into the cells of heterologous DNA (RNA) encoding a dog PGP polypeptide or fragment or variant thereof. That heterologous DNA (RNA) is placed under operable control of transcriptional elements to permit the expression of the heterologous DNA in the host cell.

Preferred systems for mRNA expression in mammalian cells are those such as pRc/CMV (available from Invitrogen, Carlsbad, CA) that contain a selectable marker such as a gene that confers G418 resistance (which facilitates the selection of stably transfected cell lines) and the human cytomegalovirus (CMV) enhancer-promoter sequences. Additionally, suitable for expression in primate or canine cell lines is the pCEP4 vector (Invitrogen), which

contains an Epstein Barr virus (EBV) origin of replication, facilitating the maintenance of plasmid as a multicopy extrachromosomal element. Another expression vector is the pEF-BOS plasmid containing the promoter of polypeptide Elongation Factor 1 α , which stimulates efficiently transcription *in vitro*. The plasmid is described by Mishizuma and Nagata (*Nuc.*

5 *Acids Res.* 18:5322, 1990), and its use in transfection experiments is disclosed by, for example, Demoulin (*Mol. Cell. Biol.* 16:4710-4716, 1996). Still another preferred expression vector is an adenovirus, described by Stratford-Perricaudet, which is defective for E1 and E3 proteins (*J. Clin. Invest.* 90:626-630, 1992).

In addition to the biological vectors, chemical/physical vectors may be used to deliver 10 a dog PGP nucleic acid or polypeptide to a target cell and facilitate uptake thereby. As used herein, a "chemical/physical vector" refers to a natural or synthetic molecule, other than those derived from bacteriological or viral sources, capable of delivering the isolated dog PGP nucleic acid or polypeptide to a cell.

A preferred chemical/physical vector of the invention is a colloidal dispersion system. 15 Colloidal dispersion systems include lipid-based systems including oil-in-water emulsions, micelles, mixed micelles, and liposomes. A preferred colloidal system of the invention is a liposome. Liposomes are artificial membrane vesicles which are useful as a delivery vector *in vivo* or *in vitro*. It has been shown that large unilamellar vesicles (LUV), which range in size from 0.2 - 4.0 μ can encapsulate large macromolecules. RNA, DNA, and intact virions can be 20 encapsulated within the aqueous interior and be delivered to cells in a biologically active form (Fraley, et al., *Trends Biochem. Sci.*, v. 6, p. 77 (1981)). In order for a liposome to be an efficient nucleic acid transfer vector, one or more of the following characteristics should be present: (1) encapsulation of the nucleic acid of interest at high efficiency with retention of biological activity; (2) preferential and substantial binding to a target cell in comparison to 25 non-target cells; (3) delivery of the aqueous contents of the vesicle to the target cell cytoplasm at high efficiency; and (4) accurate and effective expression of genetic information.

Liposomes may be targeted to a particular tissue by coupling the liposome to a specific 30 ligand such as a monoclonal antibody, sugar, glycolipid, or protein. Ligands which may be useful for targeting a liposome to a particular cell will depend on the particular cell or tissue type. Additionally when the vector encapsulates a nucleic acid, the vector may be coupled to a nuclear targeting peptide, which will direct the dog PGP nucleic acid to the nucleus of the host cell.

Liposomes are commercially available from Gibco BRL, for example, as LIPOFECTIN™ and LIPOFECTACE™, which are formed of cationic lipids such as N-[1-(2, 3 dioleyloxy)-propyl]-N, N-trimethylammonium chloride (DOTMA) and dimethyl dioctadecylammonium bromide (DDAB). Methods for making liposomes are well known in the art and have been described in many publications.

Other exemplary compositions that can be used to facilitate uptake by a target cell of the dog PGP nucleic acids include calcium phosphate and other chemical mediators of intracellular transport, microinjection compositions, electroporation and homologous recombination compositions (e.g., for integrating a dog PGP nucleic acid into a preselected location within a target cell chromosome).

The invention also embraces so-called expression kits, which allow the artisan to prepare a desired expression vector or vectors. Such expression kits include at least separate portions of the previously discussed coding sequences. Other components may be added, as desired, as long as the previously mentioned sequences, which are required, are included.

It will also be recognized that the invention embraces the use of the dog PGP cDNA sequences in expression vectors, as well as to transfect host cells and cell lines, be these prokaryotic (e.g., *E. coli*), or eukaryotic (e.g., COS cells, yeast expression systems and recombinant baculovirus expression in insect cells). Especially useful are mammalian cells such as human, pig, goat, primate, etc. They may be of a wide variety of tissue types, and include primary cells and cell lines. Specific examples include intestinal cells and liver cells. The expression vectors require that the pertinent sequence, i.e., those nucleic acids described *supra*, be operably linked to a promoter.

The invention also provides isolated dog PGP polypeptides which include the amino acid sequence of SEQ ID NO:2, and fragments thereof, encoded by the dog PGP nucleic acids described above. Dog PGP polypeptides also embrace alleles, such as SEQ ID NOS:23, 25 and 27 (except not SEQ ID NOS:3 and 5), functionally equivalent variants and analogs (those non-allelic polypeptides which vary in amino acid sequence from the disclosed dog PGP polypeptides by 1, 2, 3, 4, 5, or more amino acids) provided that such polypeptides retain dog PGP activity. Non-functional variants also are embraced by the invention; these are useful as antagonists of transporter function, as negative controls in assays, and the like. Such alleles, variants, analogs and fragments are useful, for example, alone or as fusion proteins for a variety of purposes including as a component of assays.

Fragments of a polypeptide preferably are those fragments which retain a distinct functional capability of the dog PGP polypeptide, in particular as a transporter of various molecules. Other functional capabilities which can be retained in a fragment of a dog PGP polypeptide include interaction with antibodies and interaction with other polypeptides (such 5 as would be found in a protein complex). Those skilled in the art are well versed in methods for selecting fragments which retain a functional capability of the dog PGP. Confirmation of the functional capability of the fragment can be carried out by synthesis of the fragment and testing of the capability according to standard methods. For example, to test the transporter 10 activity of a dog PGP fragment, one inserts or expresses the fragment in a cell in which molecular transport can be measured. Such methods, which are standard in the art, are described further herein.

The invention embraces variants of the dog PGP polypeptides described above. As used herein, a "variant" of a dog PGP polypeptide is a polypeptide which contains one or more modifications to the primary amino acid sequence of a dog PGP polypeptide.

15 Modifications which create a dog PGP variant can be made to a dog PGP polypeptide for a variety of reasons, including 1) to reduce or eliminate an activity of a dog PGP polypeptide, such as transport; 2) to enhance a property of a dog PGP polypeptide, such as protein stability in an expression system or the stability of protein-protein binding; 3) to provide a novel activity or property to a dog PGP polypeptide, such as addition of an antigenic epitope or 20 addition of a detectable moiety; or 4) to establish that an amino acid substitution does or does not affect molecular transport activity. Modifications to a dog PGP polypeptide are typically made to the nucleic acid which encodes the dog PGP polypeptide, and can include deletions, point mutations, truncations, amino acid substitutions and additions of amino acids or non-amino acid moieties. Alternatively, modifications can be made directly to the polypeptide, 25 such as by cleavage, addition of a linker molecule, addition of a detectable moiety, such as biotin, addition of a fatty acid, and the like. Modifications also embrace fusion proteins comprising all or part of the dog PGP amino acid sequence. One of skill in the art will be familiar with methods for predicting the effect on protein conformation of a change in protein sequence, and can thus "design" a variant dog PGP according to known methods. One 30 example of such a method is described by Dahiyat and Mayo in *Science* 278:82-87, 1997, whereby proteins can be designed *de novo*. The method can be applied to a known protein to vary a only a portion of the polypeptide sequence. By applying the computational methods of

Dahiyat and Mayo, specific variants of a dog PGP polypeptide can be proposed and tested to determine whether the variant retains a desired conformation.

Variants include dog PGP polypeptides which are modified specifically to alter a feature of the polypeptide unrelated to its physiological activity. For example, cysteine 5 residues can be substituted or deleted to prevent unwanted disulfide linkages. Similarly, certain amino acids can be changed to enhance expression of a dog PGP polypeptide by eliminating proteolysis by proteases in an expression system (e.g., dibasic amino acid residues in yeast expression systems in which KEX2 protease activity is present).

Mutations of a nucleic acid which encode a dog PGP polypeptide preferably preserve 10 the amino acid reading frame of the coding sequence, and preferably do not create regions in the nucleic acid which are likely to hybridize to form secondary structures, such as hairpins or loops, which can be deleterious to expression of the variant polypeptide.

Mutations can be made by selecting an amino acid substitution, or by random 15 mutagenesis of a selected site in a nucleic acid which encodes the polypeptide. Variant polypeptides are then expressed and tested for one or more activities to determine which mutation provides a variant polypeptide with a desired property. Further mutations can be made to variants (or to non-variant dog PGP polypeptides) which are silent as to the amino acid sequence of the polypeptide, but which provide preferred codons for translation in a particular host. The preferred codons for translation of a nucleic acid in, e.g., *E. coli*, are well 20 known to those of ordinary skill in the art. Still other mutations can be made to the noncoding sequences of a dog PGP gene or cDNA clone to enhance expression of the polypeptide.

The activity of variants of dog PGP polypeptides can be tested by cloning the gene 25 encoding the variant dog PGP polypeptide into a bacterial or mammalian expression vector, introducing the vector into an appropriate host cell, expressing the variant dog PGP polypeptide, and testing for a functional capability of the dog PGP polypeptides as disclosed herein. For example, the variant dog PGP polypeptide can be tested for ability to provide molecular transport (e.g., efflux), as set forth below in the examples. Preparation of other variant polypeptides may favor testing of other activities, as will be known to one of ordinary skill in the art.

30 The skilled artisan will also realize that conservative amino acid substitutions may be made in dog PGP polypeptides to provide functionally equivalent variants of the foregoing polypeptides, i.e., variants which retain the functional capabilities of the dog PGP

polypeptides. As used herein, a "conservative amino acid substitution" refers to an amino acid substitution which does not alter the relative charge or size characteristics of the polypeptide in which the amino acid substitution is made. Variants can be prepared according to methods for altering polypeptide sequence known to one of ordinary skill in the art such as 5 are found in references which compile such methods, e.g. *Molecular Cloning: A Laboratory Manual*, J. Sambrook, et al., eds., Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989, or *Current Protocols in Molecular Biology*, F.M. Ausubel, et al., eds., John Wiley & Sons, Inc., New York. Exemplary functionally equivalent variants of the dog PGP polypeptides include conservative amino acid substitutions of SEQ ID NO:2 10 or SEQ ID NO:4. Conservative substitutions of amino acids include substitutions made amongst amino acids within the following groups: (a) M, I, L, V; (b) F, Y, W; (c) K, R, H; (d) A, G; (e) S, T; (f) Q, N; and (g) E, D.

15 Conservative amino-acid substitutions in the amino acid sequence of dog PGP polypeptide to produce functionally equivalent variants of dog PGP typically are made by alteration of the nucleic acid sequence encoding dog PGP polypeptides (e.g., SEQ ID NO:1). Such substitutions can be made by a variety of methods known to one of ordinary skill in the art. For example, amino acid substitutions may be made by PCR-directed mutation, site-directed mutagenesis according to the method of Kunkel (Kunkel, *Proc. Nat. Acad. Sci. U.S.A.* 82: 488-492, 1985), or by chemical synthesis of a gene encoding a dog PGP 20 polypeptide. The activity of functionally equivalent fragments of dog PGP polypeptides can be tested by cloning the gene encoding the altered dog PGP polypeptide into a bacterial or mammalian expression vector, introducing the vector into an appropriate host cell, expressing the altered dog PGP polypeptide, and testing for the ability of the dog PGP polypeptide to mediate transmembrane transport of compounds. Peptides which are chemically synthesized 25 can be tested directly for function.

A variety of methodologies well-known to the skilled practitioner can be utilized to obtain isolated dog PGP molecules. The polypeptide may be purified from cells which naturally produce the polypeptide by chromatographic means or immunological recognition. Alternatively, an expression vector may be introduced into cells to cause production of the 30 polypeptide. In another method, mRNA transcripts may be microinjected or otherwise introduced into cells to cause production of the encoded polypeptide. Translation of mRNA in cell-free extracts such as the reticulocyte lysate system also may be used to produce

polypeptide. Those skilled in the art also can readily follow known methods for isolating dog PGP polypeptides. These include, but are not limited to, immunochromatography, HPLC, size-exclusion chromatography, ion-exchange chromatography and immune-affinity chromatography.

5 The invention as described herein has a number of uses, some of which are described elsewhere herein. For example, the invention permits isolation of the dog PGP polypeptide molecules by e.g., expression of a recombinant nucleic acid to produce large quantities of polypeptide which may be isolated using standard protocols. As another example, the isolation of the dog PGP gene makes it possible for dog PGP to be used in methods for
10 assaying of molecular transport, such as drug bioavailability studies. These methods involve determining transport of a drug by a first species' PGP (e.g., dog) in comparison to transport of the drug by other species' PGP (e.g. human) as a method for determining or predicting the bioavailability of the drug. Thus the results of whole animal studies on the metabolism of a drug can be evaluated in view of the relative rates or amounts of P-glycoprotein transport of the drug. For example, if a drug administered to a dog has good oral bioavailability and low
15 transport by dog PGP, one can predict that the oral bioavailability of the drug in humans will be good if the transport by human PGP is also low. Conversely, if the transport of the drug by human PGP is high, then the bioavailability of the drug would be predicted to be low.

20 The invention also embraces agents which bind selectively to the dog PGP nucleic acid molecules or polypeptides as well as agents which bind to variants and fragments of the polypeptides and nucleic acids as described herein. The agents include polypeptides which bind to dog PGP, and antisense nucleic acids, both of which are described in greater detail below. The agents can inhibit or increase dog PGP activity (antagonists and agonists, respectively).

25 Some of the agents are inhibitors. A dog PGP inhibitor is an agent that inhibits dog PGP mediated transport of molecules across a cell membrane. Efflux assays can be performed to screen and/or determine whether a dog PGP inhibitor has the ability to inhibit dog PGP activity, and whether the inhibition is selective. An exemplary assay of efflux is described below in the Examples.

30 In one embodiment the dog PGP inhibitor is an antisense oligonucleotide that selectively binds to a dog PGP nucleic acid molecule, to reduce the expression of dog PGP (or other species' PGPs) in a cell. This is desirable in virtually any medical condition wherein a

reduction of PGP transporter activity is desirable, e.g., to increase retention of cytotoxic agents in a cell.

As used herein, the term "antisense oligonucleotide" or "antisense" describes an oligonucleotide that is an oligoribonucleotide, oligodeoxyribonucleotide, modified oligoribonucleotide, or modified oligodeoxyribonucleotide which hybridizes under physiological conditions to DNA comprising a particular gene or to an mRNA transcript of that gene and, thereby, inhibits the transcription of that gene and/or the translation of that mRNA. The antisense molecules are designed so as to interfere with transcription or translation of a target gene upon hybridization with the target gene or transcript. Those skilled in the art will recognize that the exact length of the antisense oligonucleotide and its degree of complementarity with its target will depend upon the specific target selected, including the sequence of the target and the particular bases which comprise that sequence. It is preferred that the antisense oligonucleotide be constructed and arranged so as to bind selectively with the target under physiological conditions, i.e., to hybridize substantially more to the target sequence than to any other sequence in the target cell under physiological conditions. Based upon SEQ ID NO:1, or upon allelic (except SEQ ID NOS:3 and 5) or homologous genomic and/or cDNA sequences, one of skill in the art can easily choose and synthesize any of a number of appropriate antisense molecules for use in accordance with the present invention. In order to be sufficiently selective and potent for inhibition, such antisense oligonucleotides should comprise at least 10 and, more preferably, at least 15 consecutive bases which are complementary to the target, although in certain cases modified oligonucleotides as short as 7 bases in length have been used successfully as antisense oligonucleotides (Wagner et al., *Nature Biotechnol.* 14:840-844, 1996). Most preferably, the antisense oligonucleotides comprise a complementary sequence of 20-30 bases. Although oligonucleotides may be chosen which are antisense to any region of the gene or mRNA transcripts, in preferred embodiments the antisense oligonucleotides correspond to N-terminal or 5' upstream sites such as translation initiation, transcription initiation or promoter sites. In addition, 3'-untranslated regions may be targeted. Targeting to mRNA splicing sites has also been used in the art but may be less preferred if alternative mRNA splicing occurs. In addition, the antisense is targeted, preferably, to sites in which mRNA secondary structure is not expected (see, e.g., Sainio et al., *Cell Mol. Neurobiol.* 14(5):439-457, 1994) and at which polypeptides are not expected to bind. Thus, the present invention also provides for antisense

oligonucleotides which are complementary to allelic (except SEQ ID NOS:3 and 5) or homologous cDNAs and genomic DNAs corresponding to a dog PGP nucleic acid containing SEQ ID NO:1.

In one set of embodiments, the antisense oligonucleotides of the invention may be composed of "natural" deoxyribonucleotides, ribonucleotides, or any combination thereof. That is, the 5' end of one native nucleotide and the 3' end of another native nucleotide may be covalently linked, as in natural systems, via a phosphodiester internucleoside linkage. These oligonucleotides may be prepared by art recognized methods which may be carried out manually or by an automated synthesizer. They also may be produced recombinantly by vectors.

In preferred embodiments, however, the antisense oligonucleotides of the invention also may include "modified" oligonucleotides. That is, the oligonucleotides may be modified in a number of ways which do not prevent them from hybridizing to their target but which enhance their stability or targeting or which otherwise enhance their therapeutic effectiveness.

The term "modified oligonucleotide" as used herein describes an oligonucleotide in which (1) at least two of its nucleotides are covalently linked via a synthetic internucleoside linkage (i.e., a linkage other than a phosphodiester linkage between the 5' end of one nucleotide and the 3' end of another nucleotide) and/or (2) a chemical group not normally associated with nucleic acids has been covalently attached to the oligonucleotide. Preferred synthetic internucleoside linkages are phosphorothioates, alkylphosphonates, phosphorodithioates, phosphate esters, alkylphosphonothioates, phosphoramidates, carbamates, carbonates, phosphate triesters, acetamides, carboxymethyl esters and peptides.

The term "modified oligonucleotide" also encompasses oligonucleotides with a covalently modified base and/or sugar. For example, modified oligonucleotides include oligonucleotides having backbone sugars which are covalently attached to low molecular weight organic groups other than a hydroxyl group at the 3' position and other than a phosphate group at the 5' position. Thus modified oligonucleotides may include a 2'-O-alkylated ribose group. In addition, modified oligonucleotides may include sugars such as arabinose instead of ribose. The present invention, thus, contemplates pharmaceutical preparations containing modified antisense molecules that are complementary to and hybridizable with, under physiological conditions, nucleic acids encoding dog PGP polypeptides, together with pharmaceutically acceptable carriers.

Agents which bind dog PGP also include binding peptides and other molecules which bind to the dog PGP polypeptide and complexes containing the dog PGP polypeptide. When the binding molecules are inhibitors, the molecules bind to and inhibit the activity of dog PGP. To determine whether a dog PGP binding agent binds to dog PGP any known binding assay may be employed. For example, the binding agent may be immobilized on a surface and then contacted with a labeled dog PGP polypeptide. The amount of dog PGP which interacts with the dog PGP binding agent or the amount which does not bind to the dog PGP binding agent may then be quantitated to determine whether the dog PGP binding agent binds to dog PGP.

The dog PGP binding agents include molecules of numerous size and type that bind selectively or preferentially to dog PGP polypeptides, and complexes of both dog PGP polypeptides and their binding partners. These molecules may be derived from a variety of sources. For example, dog PGP binding agents can be provided by screening degenerate peptide libraries which can be readily prepared in solution, in immobilized form or as phage display libraries. Combinatorial libraries also can be synthesized of peptides containing one or more amino acids. Libraries further can be synthesized of peptoids and non-peptide synthetic moieties.

Phage display can be particularly effective in identifying binding peptides useful according to the invention. Briefly, one prepares a phage library (using e.g. m13, fd, or lambda phage), displaying inserts from 4 to about 80 amino acid residues using conventional procedures. The inserts may represent, for example, a completely degenerate or biased array. One then can select phage-bearing inserts which bind to the dog PGP polypeptide. This process can be repeated through several cycles of reselection of phage that bind to the dog PGP polypeptide. Repeated rounds lead to enrichment of phage bearing particular sequences.

DNA sequence analysis can be conducted to identify the sequences of the expressed polypeptides. The minimal linear portion of the sequence that binds to the dog PGP polypeptide can be determined. One can repeat the procedure using a biased library containing inserts containing part or all of the minimal linear portion plus one or more additional degenerate residues upstream or downstream thereof. Yeast two-hybrid screening methods also may be used to identify polypeptides that bind to the dog PGP polypeptides. Thus, the dog PGP polypeptides of the invention, or a fragment thereof, can be used to screen peptide libraries, including phage display libraries, to identify and select peptide binding

partners of the dog PGP polypeptides of the invention. Such molecules can be used, as described, for screening assays, for purification protocols, for interfering directly with the functioning of dog PGP and for other purposes that will be apparent to those of ordinary skill in the art.

5 Therefore the invention generally provides efficient methods of identifying pharmacological agents or lead compounds for agents useful in the treatment of conditions associated with aberrant PGP activity and the compounds and agents so identified. Generally, the screening methods involve assaying for compounds which inhibit or enhance transport of molecules through dog PGP. Such methods are adaptable to automated, high throughput screening of compounds. Examples of such methods are described in US patent 5,429,921.

10 A variety of assays for pharmacological agents are provided, including, labeled *in vitro* protein binding assays, efflux assays using detectable molecules, etc. For example, protein binding screens are used to rapidly examine the binding of candidate pharmacological agents to a dog PGP. The candidate pharmacological agents can be derived from, for example, combinatorial peptide libraries. Convenient reagents for such assays are known in the art. An exemplary cell-based assay of efflux involves contacting a cell having a dog PGP with a candidate pharmacological agent under conditions whereby the efflux of a detectably labeled molecule can occur. Specific conditions are well known in the art and are described, for example, in Sharom et al., *Biochem. Pharmacol.* 58:571-586, 1999, and references cited therein. A reduction in the efflux in the presence of the candidate pharmacological agent indicates that the candidate pharmacological agent reduces the efflux activity of dog PGP. An increase in the efflux in the presence of the candidate pharmacological agent indicates that the candidate pharmacological agent increases the efflux activity of dog PGP.

15 Dog PGP used in the methods of the invention can be added to an assay mixture as an isolated polypeptide (where binding of a candidate pharmaceutical agent is to be measured) or as a cell or other membrane-encapsulated space which includes a dog PGP polypeptide. In the latter assay configuration, the cell or other membrane-encapsulated space can contain the dog PGP as a preloaded polypeptide or as a nucleic acid (e.g. a cell transfected with an expression vector containing a dog PGP). In the assays described herein, the dog PGP polypeptide can be produced recombinantly, or isolated from biological extracts, but 20 preferably is synthesized *in vitro*. Dog PGP polypeptides encompass chimeric proteins comprising a fusion of a dog PGP polypeptide with another polypeptide, e.g., a polypeptide

capable of providing or enhancing protein-protein binding, or enhancing stability of the dog PGP polypeptide under assay conditions. A polypeptide fused to a dog PGP polypeptide or fragment thereof may also provide means of readily detecting the fusion protein, e.g., by immunological recognition or by fluorescent labeling.

5 The assay mixture also comprises a candidate pharmacological agent. Typically, a plurality of assay mixtures are run in parallel with different agent concentrations to obtain a different response to the various concentrations. Typically, one of these concentrations serves as a negative control, i.e., at zero concentration of agent or at a concentration of agent below the limits of assay detection. Candidate agents encompass numerous chemical classes,

10 10 although typically they are organic compounds. Preferably, the candidate pharmacological agents are small organic compounds, i.e., those having a molecular weight of more than 50 yet less than about 2500. Candidate agents comprise functional chemical groups necessary for structural interactions with polypeptides, and typically include at least an amine, carbonyl, hydroxyl or carboxyl group, preferably at least two of the functional chemical groups and more preferably at least three of the functional chemical groups. The candidate agents can comprise cyclic carbon or heterocyclic structure and/or aromatic or polycyclic structures substituted with one or more of the above-identified functional groups. Candidate agents also can be biomolecules such as peptides, saccharides, fatty acids, sterols, isoprenoids, purines, pyrimidines, derivatives or structural analogs of the above, or combinations thereof and the like. Where the agent is a nucleic acid, the agent typically is a DNA or RNA molecule, although modified nucleic acids having non-natural bonds or subunits are also contemplated.

15 Candidate agents are obtained from a wide variety of sources including libraries of synthetic or natural compounds. For example, numerous means are available for random and directed synthesis of a wide variety of organic compounds and biomolecules, including expression of randomized oligonucleotides, synthetic organic combinatorial libraries, phage display libraries of random peptides, and the like. Alternatively, libraries of natural compounds in the form of bacterial, fungal, plant and animal extracts are available or readily produced. Additionally, natural and synthetically produced libraries and compounds can be readily modified through conventional chemical, physical, and biochemical means. Further, 20 known pharmacological agents may be subjected to directed or random chemical modifications such as acylation, alkylation, esterification, amidification, etc. to produce structural analogs of the agents.

Therefore, a source of candidate agents are libraries of molecules based on known P-glycoprotein inhibitors, in which the structure of the inhibitor is changed at one or more positions of the molecule to contain more or fewer chemical moieties or different chemical moieties. The structural changes made to the molecules in creating the libraries of analog
5 inhibitors can be directed, random, or a combination of both directed and random substitutions and/or additions. One of ordinary skill in the art in the preparation of combinatorial libraries can readily prepare such libraries based on existing P-glycoprotein inhibitors.

A variety of other reagents also can be included in the mixture. These include
10 reagents such as salts, buffers, neutral proteins (e.g., albumin), detergents, etc. which may be used to facilitate optimal protein-protein and/or protein-nucleic acid binding. Such a reagent may also reduce non-specific or background interactions of the reaction components. Other reagents that improve the efficiency of the assay such as protease inhibitors, nuclease
15 inhibitors, antimicrobial agents, and the like may also be used.

15 The mixture of the foregoing assay materials is incubated under conditions whereby, but for the presence of the candidate pharmacological agent, the dog PGP mediates the efflux of a control amount of a compound such as a drug. For determining the binding of a candidate pharmaceutical agent to a dog PGP, the mixture is incubated under conditions which permit binding. The order of addition of components, incubation temperature, time of
20 incubation, and other parameters of the assay may be readily determined. Such experimentation merely involves optimization of the assay parameters, not the fundamental composition of the assay. Incubation temperatures typically are between 4°C and 40°C. Incubation times preferably are minimized to facilitate rapid, high throughput screening, and typically are between 1 minute and 10 hours.

25 After incubation, the level of efflux or the level of specific binding between the dog PGP polypeptide and the candidate pharmaceutical agent is detected by any convenient method available to the user. For cell free binding type assays, a separation step is often used to separate bound from unbound components. The separation step may be accomplished in a variety of ways. Conveniently, at least one of the components is immobilized on a solid
30 substrate, from which the unbound components may be easily separated. The solid substrate can be made of a wide variety of materials and in a wide variety of shapes, e.g., microtiter plate, microbead, dipstick, resin particle, etc. The substrate preferably is chosen to maximize

signal to noise ratios, primarily to minimize background binding, as well as for ease of separation and cost.

Separation may be effected for example, by removing a bead or dipstick from a reservoir, emptying or diluting a reservoir such as a microtiter plate well, rinsing a bead, 5 particle, chromatographic column or filter with a wash solution or solvent. The separation step preferably includes multiple rinses or washes. For example, when the solid substrate is a microtiter plate, the wells may be washed several times with a washing solution, which typically includes those components of the incubation mixture that do not participate in specific bindings such as salts, buffer, detergent, non-specific protein, etc. Where the solid 10 substrate is a magnetic bead, the beads may be washed one or more times with a washing solution and isolated using a magnet.

20 Detection may be effected in any convenient way for cell-based assays such as a transmembrane transport assay. The transport of a directly or indirectly detectable product, e.g., a fluorescent molecule such as calcein AM or rhodamine 123, is preferred. For cell free binding assays, one of the components usually comprises, or is coupled to, a detectable label. A wide variety of labels can be used, such as those that provide direct detection (e.g., 15 radioactivity, luminescence, optical or electron density, etc.) or indirect detection (e.g., epitope tag such as the FLAG epitope, enzyme tag such as horseradish peroxidase, etc.). The label may be bound to a dog PGP polypeptide or the candidate pharmacological agent.

25 A variety of methods may be used to detect the label, depending on the nature of the label and other assay components. For example, the label may be detected while bound to the solid substrate or subsequent to separation from the solid substrate. Labels may be directly detected through optical or electron density, radioactive emissions, nonradiative energy transfers, etc. or indirectly detected with antibody conjugates, streptavidin-biotin conjugates, etc. Methods for detecting the labels are well known in the art.

The dog PGP binding agent may also be an antibody or a functionally active antibody fragment. Antibodies are well known to those of ordinary skill in the science of immunology. As used herein, the term "antibody" means not only intact antibody molecules but also 30 fragments of antibody molecules retaining dog PGP binding ability. Such fragments are also well known in the art and are regularly employed both *in vitro* and *in vivo*. In particular, as used herein, the term "antibody" means not only intact immunoglobulin molecules but also the well-known active fragments F(ab')₂, and Fab. F(ab')₂, and Fab fragments which lack the

Fc fragment of intact antibody, clear more rapidly from the circulation, and may have less non-specific tissue binding of an intact antibody (Wahl et al., *J. Nucl. Med.* 24:316-325 (1983)).

Monoclonal antibodies may be made by any of the methods known in the art utilizing 5 dog PGP, or a fragment thereof, as an immunogen. Alternatively the antibody may be a polyclonal antibody specific for dog PGP which inhibits dog PGP activity. The preparation and use of polyclonal antibodies is also known to one of ordinary skill in the art.

Significantly, as is well known in the art, only a small portion of an antibody molecule, the paratope, is involved in the binding of the antibody to its epitope (see, in 10 general, Clark, W.R. (1986) *The Experimental Foundations of Modern Immunology* Wiley & Sons, Inc., New York; Roitt, I. (1991) *Essential Immunology*, 7th Ed., Blackwell Scientific Publications, Oxford). The pFc' and Fc regions, for example, are effectors of the complement cascade but are not involved in antigen binding. An antibody from which the pFc' region has been enzymatically cleaved, or which has been produced without the pFc' region, designated 15 an F(ab')₂ fragment, retains both of the antigen binding sites of an intact antibody. Similarly, an antibody from which the Fc region has been enzymatically cleaved, or which has been produced without the Fc region, designated an Fab fragment, retains one of the antigen binding sites of an intact antibody molecule. Proceeding further, Fab fragments consist of a covalently bound antibody light chain and a portion of the antibody heavy chain denoted Fd. The Fd fragments are the major determinant of antibody specificity (a single Fd fragment may 20 be associated with up to ten different light chains without altering antibody specificity) and Fd fragments retain epitope-binding ability in isolation.

Within the antigen-binding portion of an antibody, as is well-known in the art, there are complementarity determining regions (CDRs), which directly interact with the epitope of 25 the antigen, and framework regions (FRs), which maintain the tertiary structure of the paratope (see, in general, Clark, 1986; Roitt, 1991). In both the heavy chain Fd fragment and the light chain of IgG immunoglobulins, there are four framework regions (FR1 through FR4) separated respectively by three complementarity determining regions (CDR1 through CDR3). The CDRs, and in particular the CDR3 regions, and more particularly the heavy chain CDR3, 30 are largely responsible for antibody specificity.

In general, intact antibodies are said to contain "Fc" and "Fab" regions. The Fc regions are involved in complement activation and are not involved in antigen binding. An

antibody from which the Fc' region has been enzymatically cleaved, or which has been produced without the Fc' region, designated an "F(ab')₂" fragment, retains both of the antigen binding sites of the intact antibody. Similarly, an antibody from which the Fc region has been enzymatically cleaved, or which has been produced without the Fc region, designated an

5 "Fab" fragment, retains one of the antigen binding sites of the intact antibody. Fab' fragments consist of a covalently bound antibody light chain and a portion of the antibody heavy chain, denoted "Fd." The Fd fragments are the major determinants of antibody specificity (a single Fd fragment may be associated with up to ten different light chains without altering antibody specificity). Isolated Fd fragments retain the ability to specifically

10 bind to antigen epitopes.

The sequences of the antigen-binding Fab' portion of the anti-dog PGP monoclonal antibodies identified as being useful according to the invention in the assays provided above, as well as the relevant FR and CDR regions, can be determined using amino acid sequencing methods that are routine in the art. It is well established that non-CDR regions of a
15 mammalian antibody may be replaced with corresponding regions of non-specific or hetero-specific antibodies while retaining the epitope specificity of the original antibody. This technique is useful for the development and use of "humanized" antibodies in which non-human CDRs are covalently joined to human FR and/or Fc/pFc' regions to produce a functional antibody. Techniques to humanize antibodies are particularly useful when non-human animal (e.g., murine) antibodies which inhibit dog PGP activity are identified. These
20 non-human animal antibodies can be humanized for use in the treatment of a human subject in the methods according to the invention. Examples of methods for humanizing a murine antibody are provided in U.S. patents 4,816,567, 5,225,539, 5,585,089, 5,693,762 and 5,859,205. Other antibodies, including fragments of intact antibodies with antigen-binding
25 ability, are often referred to as "chimeric" antibodies.

Thus, as will be apparent to one of ordinary skill in the art, the present invention also provides for F(ab')₂, and Fab fragments of an anti-dog PGP monoclonal antibody; chimeric antibodies in which the Fc and/or FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions of an anti-dog PGP antibody have been replaced by homologous human or non-

30 human sequences; chimeric F(ab')₂ fragment antibodies in which the FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions of an anti-dog PGP antibody have been replaced by homologous human or non-human sequences; and chimeric Fab fragment antibodies in which

the FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions have been replaced by homologous human or non-human sequences.

According to the invention dog PGP inhibitors also include “dominant negative” polypeptides derived from SEQ ID NOS:2. A dominant negative polypeptide is an inactive 5 variant of a polypeptide, which, by interacting with the cellular machinery, displaces an active polypeptide from its interaction with the cellular machinery or competes with the active polypeptide, thereby reducing the effect of the active polypeptide. For example, a dominant negative receptor which binds a ligand but does not transmit a signal in response to binding of the ligand can reduce the biological effect of expression of the ligand.

10 The end result of the expression of a dominant negative dog PGP polypeptide of the invention in a cell is a reduction in PGP activity such as molecular transport. One of ordinary skill in the art can assess the potential for a dominant negative variant of a dog PGP polypeptide, and using standard mutagenesis techniques to create one or more dominant negative variant polypeptides. For example, given the teachings contained herein of a dog 15 PGP polypeptide, one of ordinary skill in the art can modify the sequence of the dog PGP polypeptide by site-specific mutagenesis, scanning mutagenesis, partial gene deletion or truncation, and the like. See, e.g., U.S. Patent No. 5,580,723 and Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Second Edition, Cold Spring Harbor Laboratory Press, 1989. The skilled artisan then can test the population of mutagenized polypeptides for diminution in 20 dog PGP activity and/or for retention of such an activity. Other similar methods for creating and testing dominant negative variants of a dog PGP polypeptide will be apparent to one of ordinary skill in the art.

Each of the compositions of the invention is useful for a variety of therapeutic and non-therapeutic purposes. For example, the dog PGP nucleic acids of the invention are useful 25 as oligonucleotide probes. Such oligonucleotide probes can be used herein to identify genomic or cDNA library clones possessing an identical or substantially similar nucleic acid sequence. A suitable oligonucleotide or set of oligonucleotides, which is capable of hybridizing under stringent hybridization conditions to the desired sequence, a variant or fragment thereof, or an anti-sense complement of such an oligonucleotide or set of oligonucleotides, can be synthesized by means well known in the art (see, for example, 30 *Synthesis and Application of DNA and RNA*, S.A. Narang, ed., 1987, Academic Press, San Diego, CA) and employed as a probe to identify and isolate the desired sequence, variant or

fragment thereof by techniques known in the art. Techniques of nucleic acid hybridization and clone identification are disclosed by Sambrook, et al., *Molecular Cloning, A Laboratory Manual*, 2d ed., Cold Spring Harbor Laboratory Press, Plainview, NY (1989). To facilitate the detection of a desired nucleic acid sequence, or variant or fragment thereof, whether for cloning purposes or for the mere detection of the presence of the sequence, the above-described probes may be labeled with a detectable group. Such a detectable group may be any material having a detectable physical or chemical property. Such materials have been well-developed in the field of nucleic acid hybridization and, in general, many labels useful in such methods can be applied to the present invention. Particularly useful are radioactive labels. Any radioactive label may be employed which provides for an adequate signal and has a sufficient half-life. If single stranded, the oligonucleotide may be radioactively labeled using kinase reactions. Alternatively, oligonucleotides are also useful as nucleic acid hybridization probes when labeled with a non-radioactive marker such as biotin, an enzyme or a fluorescent group. See, for example, Leary, J.J., et al., *Proc. Natl. Acad. Sci. (USA)* 80:4045 (1983); Renz, M. et al., *Nucl. Acids Res.* 12:3435 (1984); and Renz, M., *EMBO J.* 6:817 (1983).

Additionally, complements of the dog PGP nucleic acids can be useful as antisense oligonucleotides, e.g., by delivering the antisense oligonucleotide to an animal to induce a dog PGP "knockout" phenotype. The administration of antisense RNA probes to block gene expression is discussed in Lichtenstein, C., *Nature* 333:801-802 (1988).

Alternatively, the dog PGP nucleic acid of the invention can be used to prepare a non-human transgenic animal. A "transgenic animal" is an animal having cells that contain DNA which has been artificially inserted into a cell, which DNA becomes part of the genome of the animal which develops from that cell. Preferred transgenic animals are primates, mice, rats, cows, pigs, horses, goats, sheep, dogs and cats. Animals suitable for transgenic experiments can be obtained from standard commercial sources such as Charles River (Wilmington, MA), Taconic (Germantown, NY), Harlan Sprague Dawley (Indianapolis, IN), etc. Transgenic animals having a particular property associated with a particular disease can be used to study the affects of a variety of drugs and treatment methods on the disease, and thus serve as genetic models for the study of a number of human diseases. The invention, therefore, contemplates the use of dog PGP knockout and transgenic animals as models for the study of disorders involving transport of molecules across cell membranes. A variety of methods

known to one of ordinary skill in the art are available for the production of transgenic animals associated with this invention.

Inactivation or replacement of the endogenous PGP/MDR1 gene can be achieved by a homologous recombination system using embryonic stem cells. The resultant transgenic non-
5 human mammals having a PGP^{-/-} knockout phenotype may be made transgenic for the dog PGP and used as a model for screening compounds as modulators (agonists or antagonists/inhibitors) of the dog PGP. In this manner, such therapeutic drugs can be identified.

Additionally, a normal or mutant version of dog PGP can be inserted into the germ line to produce transgenic animals which constitutively or inducibly express the normal or mutant form of dog PGP. These animals are useful in studies to define the role and function
10 of dog PGP in cells.

The compositions of the invention are also useful for therapeutic purposes. Accordingly the invention encompasses a method for inhibiting dog PGP activity in a
15 mammalian cell. The invention further provides methods for reducing or increasing dog PGP activity in a cell. In one embodiment, the method involves contacting the mammalian cell with an amount of a dog PGP nucleic acid or polypeptide effective to inhibit molecular transport out of the mammalian cell. Such methods are useful *in vitro* for the purpose of, for example, elucidating the mechanisms involved in drug resistance and reduced drug
20 bioavailability.

The invention also encompasses a method for increasing PGP expression in a cell or subject. The amount of dog PGP can be increased in such cell or subject by contacting the cell with, or administering to the subject, a PGP nucleic acid or a PGP polypeptide of the invention to the subject in an amount effective to increase transmembrane transport in the cell
25 or the subject. An increase in PGP activity can be measured by the assays described herein, e.g., assays of transmembrane transport.

The preparations of the invention are administered in effective amounts. An effective amount is that amount of a pharmaceutical preparation that alone, or together with further doses, produces the desired response. Such amounts will depend, of course, on the particular
30 condition being treated, the severity of the condition, the individual patient parameters including age, physical condition, size and weight, the duration of the treatment, the nature of concurrent therapy (if any), the specific route of administration and like factors within the

knowledge and expertise of the health practitioner. It is preferred generally that a maximum dose be used, that is, the highest safe dose according to sound medical judgment. It will be understood by those of ordinary skill in the art, however, that a patient may insist upon a lower dose or tolerable dose for medical reasons, psychological reasons or for virtually any other reasons.

Generally, doses of active compounds would be from about 0.01 mg/kg per day to 1000 mg/kg per day. It is expected that doses ranging from 50-500 mg/kg will be suitable and in one or several administrations per day. Lower doses will result from other forms of administration, such as intravenous administration. In the event that a response in a subject is insufficient at the initial doses applied, higher doses (or effectively higher doses by a different, more localized delivery route) may be employed to the extent that patient tolerance permits. Multiple doses per day are contemplated to achieve appropriate systemic levels of compound, although fewer doses typically will be given when compounds are prepared as slow release or sustained release medications.

When administered, the pharmaceutical preparations of the invention are applied in pharmaceutically-acceptable amounts and in pharmaceutically-acceptably compositions. Such preparations may routinely contain salts, buffering agents, preservatives, compatible carriers, and optionally other therapeutic agents. When used in medicine, the salts should be pharmaceutically acceptable, but non-pharmaceutically acceptable salts may conveniently be used to prepare pharmaceutically-acceptable salts thereof and are not excluded from the scope of the invention. Such pharmacologically and pharmaceutically-acceptable salts include, but are not limited to, those prepared from the following acids: hydrochloric, hydrobromic, sulfuric, nitric, phosphoric, maleic, acetic, salicylic, citric, formic, malonic, succinic, and the like. Also, pharmaceutically-acceptable salts can be prepared as alkaline metal or alkaline earth salts, such as sodium, potassium or calcium salts.

The dog PGP inhibitors or dog PGP nucleic acids and polypeptides useful according to the invention may be combined, optionally, with a pharmaceutically-acceptable carrier. The term "pharmaceutically-acceptable carrier" as used herein means one or more compatible solid or liquid fillers, diluents or encapsulating substances which are suitable for administration into a human. The term "carrier" denotes an organic or inorganic ingredient, natural or synthetic, with which the active ingredient is combined to facilitate the application. The components of the pharmaceutical compositions also are capable of being co-mingled

with the molecules of the present invention, and with each other, in a manner such that there is no interaction which would substantially impair the desired pharmaceutical efficacy.

The pharmaceutical compositions may contain suitable buffering agents, including: acetic acid in a salt; citric acid in a salt; and phosphoric acid in a salt.

5 The pharmaceutical compositions also may contain, optionally, suitable preservatives, such as: benzalkonium chloride; chlorobutanol; parabens and thimerosal.

A variety of administration routes are available. The particular mode selected will depend, of course, upon the particular compound selected, the severity of the condition being treated and the dosage required for therapeutic efficacy. The methods of the invention, 10 generally speaking, may be practiced using any mode of administration that is medically acceptable, meaning any mode that produces effective levels of the active compounds without causing clinically unacceptable adverse effects. Such modes of administration include oral, rectal, topical, nasal, intradermal, or parenteral routes. The term "parenteral" includes subcutaneous, intravenous, intrathecal, intramuscular, or infusion. Intravenous or 15 intramuscular routes are not particularly suitable for long-term therapy and prophylaxis.

The pharmaceutical compositions may conveniently be presented in unit dosage form and may be prepared by any of the methods well-known in the art of pharmacy. All methods include the step of bringing the active agent into association with a carrier which constitutes one or more accessory ingredients. In general, the compositions are prepared by uniformly and intimately bringing the active compound into association with a liquid carrier, a finely 20 divided solid carrier, or both, and then, if necessary, shaping the product.

Compositions suitable for oral administration may be presented as discrete units, such as capsules, tablets, lozenges, each containing a predetermined amount of the active compound. Other compositions include suspensions in aqueous liquids or non-aqueous 25 liquids such as a syrup, elixir or an emulsion.

Compositions suitable for parenteral administration conveniently comprise a sterile aqueous preparation of the dog PGP inhibitor or dog PGP nucleic acids and polypeptides, which is preferably isotonic with the blood of the recipient. This aqueous preparation may be formulated according to known methods using suitable dispersing or wetting agents and 30 suspending agents. The sterile injectable preparation also may be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example, as a solution in 1,3-butane diol. Among the acceptable vehicles and solvents that may be

employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or di-glycerides. In addition, fatty acids such as oleic acid may be used in the preparation of injectables. Carrier 5 formulation suitable for oral, subcutaneous, intravenous, intrathecal, intramuscular, etc. administrations can be found in Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, PA.

Other delivery systems can include time-release, delayed release or sustained release delivery systems such as the biological/chemical vectors is discussed above. Such systems 10 can avoid repeated administrations of the active compound, increasing convenience to the subject and the physician. Many types of release delivery systems are available and known to those of ordinary skill in the art. Use of a long-term sustained release implant may be desirable. Long-term release, are used herein, means that the implant is constructed and arranged to delivery therapeutic levels of the active ingredient for at least 30 days, and 15 preferably 60 days. Long-term sustained release implants are well-known to those of ordinary skill in the art and include some of the release systems described above. The invention will be more fully understood by reference to the following examples. These examples, however, are merely intended to illustrate the embodiments of the invention and are not to be construed to limit the scope of the invention.

20

Examples

Example 1: Isolation of dog P-glycoprotein

cDNA libraries were prepared using dog (*Canis familiaris*) mRNA according to 25 standard procedures. The libraries were screened for P-glycoprotein clones using a human P-glycoprotein DNA probe. Clones were isolated, purified and sequenced in accordance with standard procedures, as described below.

Liver and lung tissue was excised from Beagle dog tissue samples and flash frozen in liquid nitrogen.

30 A 890bp fragment of dog PGP1 was PCRed out of a lambda gt11 vector cDNA library custom made by Stratagene. PCR was done using reagents from Clontech. Primers were custom designed, one specific for sequence homologous to human PGP1, the other

homologous to dog PGP2.

<u>Primer name</u>	<u>sequence</u>	<u>size</u>	<u>SEQ NO:</u>	<u>homology</u>
Dp1216F	5'-gaa ctg tga ttg cgt ttg gag gac-3'	24mer	9	human PGP1
Dp2133R	5'-ttc agg gcc gcc tgt acc tct g-3'	22mer	10	dog PGP2

5 PCR was performed with a Perkin Elmer 9700 thermocycler. PCR was done at 94°C for 2 minutes, followed by 40 cycles of 94°C for 30 seconds, 40°C for 20 seconds and 72°C for 2 minutes and 30 seconds, and then incubated at 72°C for 3 minutes. The PCR product was run on a 1% agarose gel, and stained with EtBr. The DNA band at 917bp was cut out, and purified using the QIAquick Gel Extraction kit from Qiagen Inc.

10 The DNA was then ligated to the vector pCR2.1 using the Original TA Cloning kit from Invitrogen. INValphaF⁺ cells were transformed with the ligation retain, a colony was selected, grown up in 100mL of L broth with ampicillin. DNA purification was done using the Plasmid Midi purification kit from Qiagen. The insert was sequenced using an ABI 377 sequencer. This sequence corresponds to an 890bp fragment of dog PGP, from base 816 to 15 base 1706 in the open reading frame.

Five other fragments were isolated, cloned and sequenced using the same method as stated above, with any differences in procedure stated below.

RNA extraction from dog lung tissue was performed using Nucliobond RNA Maxi Prep. purification kit from Clontech. cDNA was synthesized from the RNA preparation using 20 Superscript Preamplification System for First Strand cDNA Synthesis from Life Technologies.

Fragment 1: cDNA source-dog lung cDNA library prep.

<u>Primer name</u>	<u>sequence</u>	<u>size</u>	<u>SEQ NO:</u>	<u>homology</u>
Dm1766F	5'-ccc cac aga tgg cat ggt ctg t-3'	22mer	11	dog PGP1
Dp2769R	5'-cgc ttg gtg agg atc tct cca gc-3'	23mer	12	human PGP1

25 This corresponds to a 981bp fragment of dog PGP from base 1364 to base 2345 in the open reading frame.

Fragment 2: cDNA source dog - lung cDNA library prep.

<u>Primer name</u>	<u>sequence</u>	<u>size</u>	<u>SEQ NO:</u>	<u>homology</u>
Dm2037F	5'-aga aac aga gaa tcg cca ttg ctc-3'	24mer	13	dog PGP1

Dp3793R 5'-gct gca gtc aaa cag gat ggg ct-3' 23mer 14 human PGP1

This corresponds to a 1728bp fragment of dog PGP from base 1635 to base 3362 in the open reading frame.

5 Fragment 3: cDNA source dog - lung cDNA prep

<u>Primer name</u>	<u>sequence</u>	<u>size</u>	<u>SEQ NO:</u>	<u>homology</u>
--------------------	-----------------	-------------	----------------	-----------------

Dm3411F	5'-agt tca tt gct cct gac tat gcc-3'	24mer	15	dog PGP1
---------	--------------------------------------	-------	----	----------

Dp4214R	5'-gat gcc tt ctg ggc cag cag c-3'	22mer	16	human PGP1
---------	------------------------------------	-------	----	------------

This corresponds to a 779bp fragment of dog PGP from base 3004 to base 3783 in the open

10 reading frame.

An RNA preparation from dog liver tissue was performed using the same method as used previously. cDNA was made from it using the SMART RACE cDNA Amplification Kit from Clontech using SMART II oligonucleotide. PCR conditions were changed to 94°C for 5 minutes, followed by 5 cycles of 94°C for 30 seconds and 72°C for 2 minutes. Five cycles of 94°C for 30 seconds, 70°C for 45 seconds and 72°C for 2 minutes were performed next. The final 30 cycles were at 94°C for 30 seconds, 68°C for 45 seconds and 72°C for 2 minutes. The PCR was concluded with 72°C for 7 minutes.

20 Fragment 4: cDNA source - dog liver cDNA (SMART RACE) prep.

<u>Primer name</u>	<u>sequence</u>	<u>size</u>	<u>SEQ NO:</u>	<u>homology</u>
--------------------	-----------------	-------------	----------------	-----------------

Dm3612FL	5'-gag gtg aag aag ggc cag acg ctg gcc ctc-3'	30mer	17	dog PGP1
----------	---	-------	----	----------

RACE	5'-cta ata cga ctc act ata ggg caa gca gtg gta aca acg cag agt -3'	18		vector
------	--	----	--	--------

This corresponds to a 3'end fragment of dog PGP from base 3212 to base 4264 in the open

25 reading frame.

An RNA preparation from dog liver tissue was performed using the same method as used previously. cDNA was made from it using the SMART RACE cDNA Amplification Kit from Clontech using the gene specific Primer DM1680RL 5'-cgc age cac tgt tcc caa cca gcg cca ct-3', 29mer, SEQ ID NO:19, dog PGP1.

Fragment 5: cDNA source - dog liver cDNA (SMART RACE with internal primer) prep.

<u>Primer name</u>	<u>sequence</u>	<u>size</u>	<u>SEQ NO:</u>	<u>homology</u>
Dp409F	5'-gga gcg cga ggt cgg gat gga tc- 3'	23mer	20	human PGP1
Dm1355RL	5'-gga gag gac caa gga ggt ccc ata cca gaa a-3'	31mer	21	dog PGP1

This corresponds to an ATG fragment of dog PGP from base -15 to base 945 in the open
5 reading frame.

Assembly of Clones

1Kb fragment (890bp) and 981bp fragment

DNA preps were made of each fragment. Both fragments were cut with *Neol*

10 restriction enzyme. The 1Kb fragment was also cut with *EcoRI*. The 981bp fragment was also cut with *BamHI*. Each fragment was purified, ligated together, then the ends were cut, the cut molecule was gel purified and ligated into pUC19 cut with *EcoRI* and *BamHI*.

15 1Kb fragment (890bp)/981bp fragment and 1728bp fragment

These fragments were assembled as above except that both fragments were cut with *BamHI* and the 1728bp fragment was also cut with *XbaI*.

20 1Kb fragment (890bp)/981bp fragment/1728bp fragment and ATG fragment

3'end and 779bp fragment

1Kb fragment (890bp)/981bp fragment/1728bp fragment ATG fragment and
3'end/779bp fragment

All of these fragments were assembled as above except that, in some cases, the fragments were cut with different restriction enzymes according to their nucleotide sequences.

25 The nucleotide sequence of a dog P-glycoprotein is presented as SEQ ID NO:1. The coding sequence consists of nucleotides 17-3859, producing a polypeptide of 1281 amino acids (SEQ ID NO:2).

Example 2: Activity of dog P-glycoprotein

30 Materials and Methods

Dog PGP cDNA (SEQ ID NO:1) is introduced into a clonal population of LLC-PK1 cells in a vector that confers resistance to hygromycin B. LLC-PK1 cells are obtained from

the American Type Culture Collections and are propagated in Medium 199 supplemented to 7% with fetal bovine serum. LLC-PK1 cells are recloned prior to transfection in order to assure homogeneity of the cell population. Briefly, dog PGP cDNA is incorporated into the p222CMV vector. This vector is derived from the p220.2 episomal vector system based on the OriP sequences for Epstein Barr virus and the EBNA-1 gene product (Sugden et al., *Mol. Cell Biol.* 5:410-413, 1985; Yates et al., *Nature (Lond.)* 313: 812-815, 1985). The PGP cDNA is under the control of the cytomegalovirus (CMV) immediate early promoter. The vector confers resistance to hygromycin B. Cells (in 0.4 mL) and DNA (10 to 20 μ g) were transfected by electroporation using a BTX Electro cell manipulator model 600 using a 2 mm gap cell, 100V, 2500 μ F capacitance and 72 ohm resistance. After electroporation, the cells are plated in multiwell plates (48 well, Corning Costar) at 10% of confluence. One to two days after transfection hygromycin B is introduced at a final concentration of 400 to 600 μ g/ml. Cells are refed every 2 to 4 days and are propagated in 400 to 600 μ g/ml hygromycin B for 6 to 8 days at which point the bulk of the wild type cells are detached. The hygromycin B is reduced to 100 μ g/ml and maintained in this concentration of hygromycin B. After 14 to 18 days the wells are inspected and wells containing single colonies are trypsinized and scaled up to bulk cultures. Expression of PGP is measured by the polarization of vinblastine (0.1 μ M) transport in TranswellsTM.

LLC-PK1 cell based transport studies are conducted in 24 well TranswellsTM (Coming Costar, Catalog number 3415). TranswellsTM are prepared by the addition of 0.6 mL media to the basolateral space and 0.1 mL media to the apical space. Cells are seeded at 4×10^4 cells per insert (typically in 0.05 mL to 0.15 mL), refed with fresh media every 2 to 4 days and used for transport studies 4 to 8 days post seeding. Transport assays are conducted in Hank's balanced saline (HBSS) buffered with 10 mM HEPES (pH 7 to 7.2). Cell monolayers are rinsed with HBSS prior to use in transport assays. Transport is measured under sink conditions in both the apical to basolateral (A to B) and basolateral to apical (B to A) directions. At least duplicate monolayers are used per determination. At the desired time points, samples are withdrawn from the receiver chamber (apical or basolateral chambers). Quantitation of the amount of compound transported is by liquid scintillation counting (vinblastine) or HPLC with UV or mass spectrometric detection.

Dog PGP cDNA is expressed in insect cells using a baculovirus vector. Membranes are prepared according to the method of (Sarkadi et al., *J. Biol. Chem.* 267: 4854-4858, 1992)

and stored at -80°C until use. ATPase assays are conducted in 96 well microtiter plates. The assays are conducted using a modification of the methods of (Sarkadi et al., 1992 and Druekes et al., *Anal. Biochem.* 230: 173-177, 1995).

A detailed method for each well of a 96 well plate is contained below:

5 A 0.06 ml reaction mixture containing 40 µg membranes, 20 µM Verapamil (positive control) or test drug, and 3-5 mM MgATP, in buffer containing 50 mM Tris-MES, 2 mM EGTA, 50 mM KCl, 2 mM dithiothreitol, and 5 mM sodium azide, is incubated at 37°C for 20 min. An identical reaction mixture containing 100 µM sodium orthovanadate is assayed in parallel.

Orthovanadate inhibits PGP by trapping MgADP in the nucleotide binding site. Thus,

10 ATPase activity measured in the presence of orthovanadate represents non-PGP ATPase activity and can be subtracted from the activity generated without orthovanadate to yield vanadate-sensitive ATPase activity. The reaction is stopped by the addition of 30 µl of 10 % SDS + Antifoam A. Two additional reaction mixtures (+ and - orthovanadate) but without MgATP, are also prepared and incubated with the others, and then supplemented with SDS

15 and MgATP, to represent time = 0 min of reaction. The incubations are followed with addition of 200 µl of 35 mM ammonium molybdate in 15 mM zinc acetate:10 % ascorbic acid (1:4) and incubated for an additional 20 min at 37°C. The liberation of inorganic phosphate is detected by its absorbance at 800 nm and quantitated by comparing the absorbance to a phosphate standard curve.

20 Ligand binding assays and assays for measuring inhibition of fluorescent dye uptake are preformed as described by Sharom et al. (*Biochem. Pharmacol.* 58:571-586, 1999).

I. Stable PGP Expression in LLC-PK1 Cells.

Functional expression of dog PGP is measured by the polarization of transport of
25 vinblastine. Control cells typically demonstrate a B to A / A to B ratio of between 1 and 3. PGP transfected cells demonstrate a much higher ratio. The expression of cDNA-derived dog is stable.

II. Activation of ATPase Activity in PGP Membranes.

30 The stimulation of ATPase assay provides a rapid measure of the concentration dependence of any interaction of a drug with PGP. The liberated inorganic phosphate is measured by a simple spectrophotometric assay performed in a microtiter plate format. The

testing of multiple drug concentrations allows estimation of the affinity of the drug for PGP and whether saturation of the response was observed.

III. Drug Transport Across Cell Monolayers.

5 The ATPase assay does not directly measure drug transport. In order to examine the concordance between activation of ATPase and actual transport, the rates of transport of the drugs are measured in control LLC-PK1 and dog PGP cell monolayers. For each drug concentration, four measurements are made:

	A:	A to B	Control cells
10	B:	B to A	Control cells
	C:	A to B	PGP cells
	D:	B to A	PGP cells

15 The polarization of transport is calculated in control cells (B/A) and PGP cells (D/C). The intrinsic activity (IA) of PGP is calculated as the sum of the amount PGP facilitated B to A transport in PGP cells relative to control cells (D minus B) and the amount that PGP 20 impeded A to B transport in PGP cells relative to control cells (A minus C). The intrinsic clearance of PGP is calculated from a plot of the concentration dependence data by either calculating the slope of the line under non-saturating conditions or from the calculated apparent Km and Vmax values when saturation is observed. Intrinsic clearance is expressed as mL/m²/min.

25 The ATPase data provides useful concentration response data. For example, the apparent Km values for some compounds are in good agreement between the ATPase and transport systems. However, other drugs activate ATPase activity but transport by PGP is not detectable. At the least, ATPase assay can identify a concentration range below which the response to transport by PGP was linear with respect to drug concentration. This should allow simplification of the experimental design for measuring the intrinsic clearance of PGP, an important consideration if large numbers of compounds are to be tested.

IV. Bioavailability

30 Bioavailability studies are performed by performing one or more of the assays described above with two or more different PGP types. The different PGP types can be different species (e.g., dog and human, cynomolgous monkey and human, dog and

cynomolgous monkey, etc.) or can be different alleles of the same species. The results of these assays are compared to determine or estimate the bioavailability of a drug in individuals of the different species or in individuals that express different PGP alleles. The results of one determination also may be compared to a previously determined value of, e.g., ATPase or
5 transport, as an historical control.

Protocols and Procedures

Isolation of RNA

10 Frozen beagle liver tissue was ground up using a mortar and pestle. Pulverized tissue (300 mg) was transferred to a dounce homogenizer. TRIsol Reagent (3mL; Cat. # 15596 from Life Technologies) was added and the tissue was homogenized then incubated for 15 minutes at room temperature. Aliquots (1mL) of the solution were transferred to three microfuge tubes and 200 μ L of chloroform were added to each tube. Each tube was vortexed at a high setting for 15 seconds, then incubated at room temperature for 3 minutes before being
15 centrifuged at 10 000 g for 15 minutes at 4°C. The upper "aqueous" phase was transferred to a new microfuge tube while the remaining lower and inter phases were discarded. 500 μ L of Isopropanol was added to each of the new tubes and mixed by inverting the tube several times. Each tube was then incubated at room temperature for 10 minutes before being
20 centrifuged at 10 000 g for 10 more minutes at 4°C. A small white pellet was observed and the supernatant was discarded. 1mL of 75% ethanol was added to each tube. The tubes were vortexed briefly then centrifuged at 10 000 g for 10 minutes at 4°C. The supernatant was discarded and the pellet dried for 5 minutes at room temperature. 50 μ L of DEPC treated sterile deionized water was added to each tube. Each pellet was resuspended and the contents of each tube were pooled.

25 Optical density of the resuspended pellet was analyzed using a Hitachi U3010 spectrophotometer to determine the quantity of RNA that was isolated. The RNA was then diluted using DEPC treated sterile deionized water to a concentration of 0.55 μ g/ μ L. 2 mL of this RNA was split evenly into 2 microfuge tubes. Next, 100 μ L of 5 M NaCl was added to each tube. Both tubes were heated to 65°C for 15 minutes, then put on ice for 5 minutes. 500
30 μ L of Oligo (dT) Cellulose Suspension from the MessageMaker mRNA Isolation System (Cat. # 10551-018 from Life Technologies) were added to both tubes. The tubes were then incubated at 37°C for 10 minutes. The contents of the tubes were transferred to the Filter

Syringe provided with the MessageMaker mRNA Isolation System. After expelling the liquid contents, the pellet in the syringe was washed using Wash Buffer 1 and Wash Buffer 2 according to the manufacturer's instructions. The RNA pellet in the syringe was resuspended in 1 mL of DEPC treated sterile deionized water (65°C), followed by the addition of 2.5 μ L of 50 μ g/mL glycogen and 100 μ L of 7.5M ammonium acetate and mixing by inversion. The 5 contents of the tube were then transferred to a two microfuge tubes and 1 mL of ethanol was added to each tube. The contents of both tubes were mixed by inversion, followed by incubation at -20°C overnight.

The tubes were centrifuged at 10 000 g for 30 minutes at 4°C. The supernatant was 10 discarded and 200 μ L of 75% ethanol was added to each tube. The tubes were vortexed for 10 seconds followed by centrifugation at 10 000 g for 15 minutes at 4°C. The supernatant was discarded and all remaining liquid was carefully pipetted off. The pellet was resuspended in 10 μ L of DEPC treated sterile deionized water.

15 Preparation of cDNA

CDNA was prepared using the Marathon cDNA Amplification Kit (Cat. # K1802-1 from Clontech Laboratories, Inc., Palo Alto, CA) as follows. Four microliters of the 20 resuspended mRNA were transferred to a new microfuge tube, and 1 μ L of one of the following primers at 10 μ M concentration was added: Dm1680RL cgc agc cac tgt tcc caa cca gcg cca ct (SEQ ID NO:19; custom designed, synthesized by Operon Technologies, Inc.) or cDNA Synthesis Primer, nnt ttt ttt ttt ttt ttt ttt ttt ttt ttc gcc ggc gac tta aga tet t (SEQ ID NO:28), from the Marathon cDNA Amplification Kit. Tubes were incubated at 70°C for 2 minutes then placed on ice for 5 minutes. 2 μ L of 5x First-Strand Buffer, 1 μ L of 10mM dNTP Mix and 1 μ L of 20 U/ μ L AMV Reverse Transcriptase were added to each tube and 25 gently mixed. The tubes were incubated at 42°C for 1 hour, then placed on ice. 2 μ L of each single stranded cDNA were used as template in PCR (see below, "PCR conditions"). 48.4 μ L of DEPC treated deionized water, 16 μ L of 5x Second-Strand Buffer, 1.6 μ L of 10mM dNTP Mix and 4 μ L of 20x Second-Strand Enzyme Cocktail were added to the remaining cDNA sample. The tube was incubated at 16°C for 1.5 hours. 2 μ L of 5U/ μ L T4 DNA Polymerase 30 was added to the tube, which was then incubated at 16°C for an additional 45 minutes. 20x EDTA/Glycogen Mix (4 μ L) was added followed by 430 μ L of Buffer PN from the QIAquick Nucleotide Removal Kit (Cat. # 28304 from QIAGEN Inc., Valencia, CA). The sample was

then loaded into a QIAquick Spin Column and centrifuged at 10 000 g for 1 minute. The collection tube was emptied and 750 μ L of PE Buffer (QIAGEN) were added to the QIAquick Spin Column which was again centrifuged at 10 000 g for 1 minute. The collection tube was once again emptied and the QIAquick Spin Column was centrifuged at 10 000 g for 1 minute 5 to dry the column membrane. 50 μ L of sterile deionized water heated to 50°C was added to the QIAquick Spin Column and incubated at room temperature for 1 minute before being centrifuged at 10 000 g for 1 minute into a clean microfuge tube.

To precipitate nucleic acid, 10.8 μ L 7.5M ammonium acetate and 144 μ L ethanol were added to the tube before it was centrifuged at 10 000 g for 20 minutes. The supernatant was 10 removed, then 300 μ L of 75% ethanol was added. The tube was vortexed and centrifuged at 10 000 g for 20 minutes. The supernatant was removed and the sample was resuspended in 12 μ L of sterile deionized water. 5 μ L of this cDNA were placed in a clean microfuge tube. 2 μ L of 10 μ M Marathon cDNA Adapter, 2 μ L 5x DNA Ligation Buffer and 1 μ L of 400U/ μ L 15 T4 DNA Ligase, from the Marathon cDNA Amplification Kit, were added to the cDNA and mixed gently. This mixture was incubated over night at 16°C. The ligase was heat inactivated at 70°C for 5 minutes. PCR was done using this sample as a template.

PCR conditions

PCR was performed using reagents supplied with the Clontech Advantage 2 kit (Clontech, palo Alto, CA). Briefly, 2 μ L of cDNA was placed in a 200 μ L MicroAmp reaction tube (Cat. # N801-0540, PE Biosystems), then 34 μ L of sterile deionized water, 5 μ L of 10x Clontech Advantage 2 Polymerase Mix (Cat. # 4700-1 Clontech Laboratories, Inc.), 3 μ L of 10 mM Advantage UltraPure PCR Deoxynucleotide Mix (Cat. # 8430-1 Clontech Laboratories, Inc.) and 2 μ L each of a forward and reverse primer at 10mM concentration 20 were added. Primers were either Marathon cDNA Adapter Primer 1, cca tcc taa tac gac tca ctg tag ggc (SEQ ID NO:29), from the Marathon cDNA Amplification Kit or various custom gene specific primers made by Operon Technologies Inc. Custom primers include (all listed 25 as 5'-3'): Dm409FL: gga gcg cga ggt cgg gat ggt tc (SEQ ID NO:20), Dm1455RL: gca aat gct tca atg ctt ggg gat gcc tgt cca a (SEQ ID NO:30), Dm2037F: aga aac aga gaa tcg cca ttg ctc (SEQ ID NO:13), Dm3920RL: gag ctg ggt tcc ttg gtc tcc tac tct ggt gtt (SEQ ID NO:31), 30 Dp1216F: gaa ctg tga ttg cgt ttg gag gac (SEQ ID NO:9), and Dp2587R: gca aat gct ggt tgc agg cct cc (SEQ ID NO:32).

Thermocycling was done using a Perkin Elmer 9700 at 94°C for 30 seconds followed by 2 cycles of 94°C for 5 seconds and 72°C for 4 minutes, followed by 16 cycles of 94°C for 5 seconds and 68°C for 4 minutes.

Four fragments were acquired by PCR for each Genotype. Fragment 1 was generated using primers Marathon cDNA Adapter Primer 1 and Dm1455RL. Fragment 2 was generated using primers Dp1216F and Dp2587R. Fragment 3 was generated using primers Dm2037F and Dm3920RL. Fragment 4 was generated using primers Dp3612FL and Marathon cDNA Adapter Primer 1.

Post PCR sample processing

Electrophoresis was performed on all PCR products using 10x Gel-loading Buffer IV (*Molecular Cloning: A Laboratory Manual*, J. Sambrook, et al., eds., Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989, page 6.12), on a 1% agarose gel in 0.5x TBE buffer (Sambrook, et al., page B-23) containing EtBr. Fragments of gel containing the PCR products were cut out and placed in 2 mL microfuge tubes. The mass of each fragment was determined and 3 μ L/mg of Buffer QX1 from QIAquick Gel Extraction Kit (Cat. # 28704 from QIAGEN Inc.) was added. Each tube was then incubated for 10 minutes at 50°C with mixture every two minutes. 1 μ L/mg of isopropanol was added to each tube and mixed. The resulting solution was transferred to a QIAquick spin column from the QIAquick Gel Extraction Kit. These columns were centrifuged for 1 minute at 10 000 g at room temperature. 750 μ L of Buffer PE from the QIAquick Gel Extraction Kit were added to each column followed by centrifugation for 1 minute at 10 000 g at room temperature. Each column was centrifuged again for 1 minute at 10 000 g at room temperature to remove any residual buffer. 30 μ L of sterile deionized water at 50°C were added to each column and incubated for 1 minute at room temperature. Each column was then placed in a microfuge tube and centrifuged for 1 minute at 10 000 g.

Next, 6 μ L of purified PCR product was transferred to a clean microfuge tube and 1 μ L of 10x Ligation Buffer, 2 μ L of pCR 2.1 vector and 1uL of T4 DNA Ligase (all from the Original TA Cloning Kit (Cat. # K2000-J10) Invitrogen, Carlsbad, CA) were added to the microfuge tube and mixed. The reaction was incubated over night at 16°C.

One 50 μ L vial of frozen One Shot competent cells (Invitrogen) was thawed on ice for each ligation reaction. 3.5uL of ligation reaction mixture was added to the competent cells

and gently mixed. The cells incubated on ice for 30 minutes, followed by a 30 second “heat shock” at 42°C. After cooling on ice again, 250 µL of SOC medium (Invitrogen) was added to each vial and the vials were put directly into a 37°C water bath for 1 hour. 50 µL and 200 µL aliquots of each transformation reaction were plated on Luria-Bertani Medium (Sambrook et al., page A-1) containing 1% agarose, 1 mg/mL glucose, 50 ng/mL ampicillin and 1.6 ng/mL X-gal. The inoculated plates were then incubated at 37°C overnight. White colored colonies were selected and used to inoculate separate 100 mL cultures of L-B Medium containing 50 ng/mL ampicillin which were incubated at 37°C overnight while being stirred at 100 rpm.

10 Plasmid DNA was prepared using QIAGEN Midi Plasmid Kit (Cat. # 12143 from QIAGEN Inc.), according to the manufacturer’s instructions, as follows. Each 100 mL culture was aliquoted into two 50 mL conical vials and centrifuged at 3 000 g for 10 minutes at 4°C. The supernatant was poured off and 4 mL of Buffer P1 were used to resuspend the pellet in one of the two vials. This suspension was transferred to the other tube and used to resuspend that pellet. Buffer P2 (4 mL) was added, mixed and the suspension was incubated at room temperature for 5 minutes. Buffer P3 (4 mL) was added, mixed and the suspension was incubated at 4°C for 15 minutes. The samples were centrifuged at 3 000 g for 15 minutes at 4°C. All of the supernatant was transferred to a QIAgen-tip 100 that had been previously treated with 4 mL of Buffer QBT. The supernatant was allowed to drain through the column. Buffer QC (10 mL) was added to the column and allowed to drain. Another 10 mL of Buffer QC was added and allowed to drain. Finally 4 mL of Buffer QF was added to the column and allowed to drain into a clean 15 mL conical vial. 2.8 mL of isopropanol was added and mixed with this solution. This was aliquoted into microfuge tubes, incubated at 4°C for 10 minutes and centrifuged at 10 000 g for 15 minutes at 4°C. The supernatant was removed, then 1 mL of 70% ethanol was added to each microfuge tube. Each tube was vortexed briefly, then centrifuged at 10 000 g for 15 minutes at 4°C. The supernatant was removed and 100 µL of sterile 1x TE buffer (Sambrook et al., page B-20) were added.

25 Restriction digests were performed on the purified DNA. Enzymes used to cut fragments out were: fragment 1, KpnI (Cat. # R0142S from New England Biolabs, Inc., Beverly, MA) and NsiI (Cat. # R0127S from New England Biolabs, Inc.); fragment 2, NsiI and HindIII (Cat. # R0104S from New England Biolabs, Inc.); fragment 3, HindIII and PstI (Cat. # V0279S from New England Biolabs, Inc.); and fragment 4, PstI and NotI (Cat. #

R0189S from New England Biolabs, Inc.). All restriction digests were preformed at 37°C in digestion buffers recommended by New England Biolabs.

Electrophoresis was performed on all restriction digest products using 10x gel-loading buffer IV (Sambrook et al., page 6.12), on a 1% agarose gel in 0.5x TBE buffer (Sambrook et al., page B-23) containing EtBr. Fragments of gel containing the restriction digest products were cut out and placed in 2 mL microfuge tubes. DNA fragments were extracted from the gel slices using a QIAquick Gel Extraction Kit (Cat. # 28704 from QIAGEN Inc.) according to the manufacturer's instructions. The mass of each fragment was determined and 3 μ L/mg of Buffer QX1 was added. Each tube was then incubated for 10 minutes at 50°C with mixture every two minutes. One volume of isopropanol was added to each tube and mixed. The resulting solution was transferred to a QIAquick spin column and centrifuged for 1 minute at 10 000 g at room temperature. Buffer PE (750 μ L) was added to each column followed by centrifugation for 1 minute at 10 000 g at room temperature. Each column was centrifuged again for 1 minute at 10 000 g at room temperature to remove any residual buffer. 30 μ L of sterile deionized water at 50°C was added to each column and incubated for 1 minute at room temperature. Each column was then placed in a microfuge tube and centrifuged for 1 minute at 10 000 g.

Two microliters of each fragment was added to a microfuge tube as well as 1 μ L of 10x Ligation Buffer and 1 μ L of T4 DNA Ligase (Cat. # M0202S from New England Biolabs, Inc.). This reaction was incubated at 16 °C overnight. Restriction enzymes KpnI and NotI (1 μ L each) were added to the reaction and incubated at 37°C for 1 hour. Electrophoresis was performed using 10x Gel-loading Buffer IV on a 1% agarose gel in 0.5x TBE buffer containing EtBr. The fragment of gel containing the assembled product was cut out and the DNA fragment was extracted using a QIAquick Gel Extraction Kit as described above.

The fragment was ligated into a vector using an Original TA Cloning Kit, as follows: 6 μ L of purified DNA were transferred to a clean microfuge tube and 1uL of 10x Ligation Buffer, 2 μ L of pCR 2.1 vector (previously digested with KpnI and NotI), and 1 μ L of T4 DNA Ligase were added and mixed. The reaction was incubated over night at 16°C. The ligation reaction mixture (3.5 μ L) was used to transform One Shot competent cells as described above, 50uL and 200uL aliquots of the transformation reaction were plated on Luria-Bertani Medium containing 1% agarose, 1mg/mL Glucose, 50ng/mL Ampicillin and 1.6ng/mL X-gal and grown as described above. White colored colonies were selected and

grown as described above. Plasmid DNA was isolated and purified using a QIAGEN Midi Plasmid Kit as described above. DNA was resuspended in 100 μ L of sterile 1x TE buffer. This DNA was then sequenced using ABI 100 DNA sequencer (from ABI) by Tufts University Core Facility.

5

Identification of Four Genotypes of Dog P-glycoprotein

The dog P-glycoprotein identified in Example 1 is now termed genotype C.

Sequencing of the DNA isolated from beagle liver as described in this example permitted the identification of three additional allelic variants of dog P-glycoprotein, termed genotypes A, B 10 and D. the allelic differences in DNA sequence are set forth in Table 1 below.

Table 1: Nucleotide and Amino Acid Differences Between Dog P-glycoprotein Genotypes (Allelic Variants)

SEQ ID NO:	DNA	Protein	Genotype	Nucleotide position				Amino acid position			
				91	607	1001	3458	25	197	329	1148
22	23		A	T	A	T	A	N	Q	S	M
24	25		B	A	A	T	A	K	Q	S	M
1	2		C	T	C	T	A	N	H	S	M
26	27		D	A	A	A	G	K	Q	T	V

15

Genotype A has a different nucleotide at base number 607 relative to SEQ ID NO:2.

This is a base change from C to A in the DNA sequence which causes an amino acid change from Histidine to Glutamine at amino acid 197. Genotype B has different nucleotides at base number 91 and 607 relative to SEQ ID NO:2. The base change at position 91 is from T to A 20 and causes an amino acid change from Asparagine to Lysine at amino acid 25. Base change at position 607 is identical to that in Genotype A. Genotype D has different nucleotides at base number 91, 607, 1001 and 3458 relative to SEQ ID NO:2. Base changes at position 91 and 607 are identical to that in Genotype B. The base change at position 1001 is from T to A and causes an amino acid change from Serine to Threonine at amino acid 329. The base 25 change at position 3458 is from A to G and causes an amino acid change from Methionine to Valine at amino acid 1148.

A previously identified dog P-glycoprotein (SEQ ID NOs:3 and 4; GenBank Accession number AF045016), has 13 nucleotide differences from the genotype C dog P-glycoprotein nucleotide sequence (SEQ ID NO:1). There is a 3 base deletion at base 89 to

base 91 (relative to SEQ ID NO:1) leaving out AAT which causes a deletion of amino acid 25 Asparagine. There is a base change from A to G at position 590 which causes an amino acid change from Isoleucine to Valine at amino acid 192. There is a base change from C to A at position 607 which causing an amino acid change from Histidine to Glutamine at amino acid 197. There is a base change from G to C at position 651 which causes an amino acid change from Arginine to Proline at amino acid 212. There is a base change from G to A at position 878 which causes an amino acid change from Glycine to Arginine at amino acid 288. There is, a base change from T to A at position 1001 which causes an amino acid change from Serine to Threonine at amino acid 329. There is a base change from A to G at position 1012 which does not cause an amino acid change. This is a silent point mutation at Glutamine, amino acid 332. There is a base change from A to G at position 1611 which causes an amino acid change from Glutamine to Arginine at amino acid 532. There is a base change from A to T at position 2098 which does not cause an amino acid change. This is a silent point mutation at Valine, amino acid 694. There is a base change from C to T at position 2102 which causes an amino acid change from Proline to Serine at amino acid 696. There is a base change from C to T at position 3808 which does not cause an amino acid change. This is a silent point mutation at Alanine, amino acid 1264. There is a base change from G to A at position 3833 which causes an amino acid change from Valine to Isoleucine at amino acid 1273. There is a base change from C to T at position 4080 which causes an amino acid change from Threonine to Isoleucine at amino acid 1355.

Each of the foregoing patents, patent applications and references is hereby incorporated by reference. While the invention has been described with respect to certain embodiments, it should be appreciated that many modifications and changes may be made by those of ordinary skill in the art without departing from the spirit of the invention. It is intended that such modification, changes and equivalents fall within the scope of the following claims.

What is claimed is:

Claims

1. An isolated nucleic acid molecule selected from the group consisting of
(a) nucleic acid molecules that code for the amino acid sequence of SEQ ID NO:2,
5 (b) allelic variants of (a), wherein the allelic variants exclude SEQ ID NO:3 and SEQ
ID NO:5, and
(c) complements of (a) or (b).

2. The isolated nucleic acid molecule of claim 1, wherein the isolated nucleic acid
10 molecule codes for SEQ ID NO:2.

3. The isolated nucleic acid molecule of claim 1, wherein the isolated nucleic acid
comprises the nucleotide sequence of SEQ ID NO:1.

15 4. The isolated nucleic acid molecule of claim 1, wherein the isolated nucleic acid
comprises the coding region of SEQ ID NO:1.

5. The isolated nucleic acid molecule of claim 1, wherein the allelic variants are nucleic
acid molecules that code for an amino acid sequence selected from the group consisting of
20 SEQ ID NO:23, SEQ ID NO:25 and SEQ ID NO:27.

6. The isolated nucleic acid molecule of claim 5, wherein the allelic variant codes for
SEQ ID NO:23.

25 7. The isolated nucleic acid molecule of claim 5, wherein the allelic variant codes for
SEQ ID NO:25.

8. The isolated nucleic acid molecule of claim 5, wherein the allelic variant codes for
SEQ ID NO:27.

30 9. The isolated nucleic acid molecule of claim 5, wherein the nucleic acid molecule
comprises a nucleotide sequence selected from the group consisting of SEQ ID NO:22, SEQ

ID NO:24 and SEQ ID NO:26.

10. The isolated nucleic acid molecule of claim 9, wherein the nucleotide sequence comprises SEQ ID NO:22.

5

11. The isolated nucleic acid molecule of claim 9, wherein the nucleotide sequence comprises SEQ ID NO:24.

10 12. The isolated nucleic acid molecule of claim 9, wherein the nucleotide sequence comprises SEQ ID NO:26.

15 13. The isolated nucleic acid molecule of claim 5, wherein the nucleic acid molecule comprises a coding region of a nucleotide sequence selected from the group consisting of SEQ ID NO:22, SEQ ID NO:24 and SEQ ID NO:26.

15

14. An isolated P-glycoprotein polypeptide or fragment thereof which comprises at least one amino acid of a dog P-glycoprotein selected from the group consisting of amino acids 25, 192, 197, 212, 288, 329, 532, 696, 1273 and 1355 of SEQ ID NO:2; amino acid 25 of SEQ ID NO:25; and amino acids 25 and 1148 of SEQ ID NO:27.

20

15 15. An isolated P-glycoprotein polypeptide or fragment thereof which comprises at least one amino acid of a dog P-glycoprotein selected from the group consisting of amino acids 3, 6, 8, 10, 12, 14-26, 36, 38, 48, 52, 56, 64, 74, 78, 84-92, 94, 96, 98, 99, 101, 103, 104, 106, 108, 112, 115, 147, 187, 197, 199, 233, 288, 321, 326, 347, 397, 450, 454, 455, 467, 472, 520, 25 633, 637, 643, 644, 650, 657, 658, 661, 666, 667, 674-677, 679, 685, 689, 691, 693, 694, 703, 707, 717, 731, 736, 740, 744, 745, 756, 759, 763, 853, 914, 920, 942, 943, 946, 968-970, 972, 974, 983, 1005, 1010, 1017, 1025, 1026, 1029, 1040, 1095, 1098, 1105, 1144, 1148, 1149, 1158, 1162, 1165, 1168, 1170, 1252 and 1279 of SEQ ID NO:2; and amino acid 329 of SEQ ID NO:27, wherein the P-glycoprotein is identical to a human P-glycoprotein except for the at 30 least one amino acid of a dog P-glycoprotein.

16. The isolated P-glycoprotein polypeptide or fragment thereof of claim 15, wherein the

human P-glycoprotein is selected from the group of SEQ ID NO:7 and SEQ ID NO:8.

17. The isolated P-glycoprotein polypeptide or fragment thereof of any of claims 14-16, wherein the amino acid sequence of the polypeptide or fragment thereof is an amino acid

5 sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, fragments of SEQ ID NO:2, fragments of SEQ ID NO:23, fragments of SEQ ID NO:25 and fragments of SEQ ID NO:27.

18. An isolated nucleic acid molecule which encodes the isolated P-glycoprotein

10 polypeptide or fragment thereof of any of claims 14-17.

19. An expression vector comprising the isolated nucleic acid molecule of claim 1 operably linked to a promoter.

15 20. An expression vector comprising the isolated nucleic acid molecule of claim 18 operably linked to a promoter.

21. A host cell transformed or transfected with the expression vector of claim 19.

20 22. A host cell transformed or transfected with the expression vector of claim 20.

23. An agent which selectively binds the isolated polypeptide of claim 14.

24. The method of claim 23, wherein the agent does not bind a human or dog P-glycoprotein.

25. The agent of claim 23, wherein the agent is a polypeptide.

26. The agent of claim 25, wherein the polypeptide is selected from the group consisting 30 of monoclonal antibodies, polyclonal antibodies, Fab antibody fragments, F(ab)₂, antibody fragments and antibody fragments including a CDR3 region.

27. An agent which selectively binds the isolated nucleic acid molecule of claim 1 or
claim 18.

28. The agent of claim 27, wherein the agent is an antisense nucleic acid which selectively
5 binds to the isolated nucleic acid molecule.

29. A method for predicting the bioavailability of a compound, comprising
measuring the transmembrane transport of a test compound by a first P-glycoprotein,
comparing the transmembrane transport of the test compound by the first
10 P-glycoprotein and a second P-glycoprotein to predict the bioavailability of the test
compound, wherein the relative amount or rate of transport by the first P-glycoprotein and the
second P-glycoprotein is predictive of bioavailability of the test compound.

30. The method of claim 29, wherein the first P-glycoprotein is selected from the group
15 consisting of dog P-glycoproteins and primate P-glycoproteins.

31. The method of claim 29, wherein the first P-glycoprotein is the polypeptide of claims
14-17.

20 32. The method of claim 29, wherein the second P-glycoprotein is a human P-
glycoprotein.

33. A method for inhibiting P-glycoprotein transporter activity in a mammalian cell
comprising
25 contacting the mammalian cell with an amount of the agent of claim 27 effective to
inhibit P-glycoprotein transporter activity in the mammalian cell.

34. A method for increasing bioavailability of a drug in a subject comprising
administering to a subject in need of such treatment the agent of claim 27 in an amount
30 effective to increasing bioavailability of a drug.

35. The method of claim 34, wherein the inhibitor is administered prior to administering

the drug.

36. The method of claim 34, wherein the inhibitor is administered concurrently with the drug.

5

37. A method for increasing P-glycoprotein transporter activity in a cell comprising contacting the cell with a molecule selected from the group consisting of the nucleic acid molecule of claim 1 and the nucleic acid molecule of claim 18, in an amount effective to increase P-glycoprotein transporter activity in the cell.

10

38. A method for identifying lead compounds for a pharmacological agent useful in the treatment of disease associated with P-glycoprotein transporter activity comprising providing a cell or other membrane-encapsulated space comprising a P-glycoprotein as claimed in claim 14 or 15;

15

contacting the cell or other membrane-encapsulated space with a candidate pharmacological agent under conditions which, in the absence of the candidate pharmacological agent, cause a first amount of P-glycoprotein transporter activity;

20

determining a second amount of P-glycoprotein transporter activity as a measure of the effect of the pharmacological agent on the P-glycoprotein transporter activity, wherein a second amount of P-glycoprotein transporter activity which is less than the first amount indicates that the candidate pharmacological agent is a lead compound for a pharmacological agent which reduces P-glycoprotein transporter activity and wherein a second amount of P-glycoprotein transporter activity which is greater than the first amount indicates that the candidate pharmacological agent is a lead compound for a pharmacological agent which increases P-glycoprotein transporter activity.

25

39. The method of claim 38, further comprising the step of loading the cell or other membrane-encapsulated space with a detectable compound, wherein the compound is detected as a measure of the P-glycoprotein transporter activity.

30

40. A method for identifying compounds which selectively bind a P-glycoprotein comprising,

contacting the P-glycoprotein claimed in claim 14 or 15 with a compound,
determining the binding of the compound to the P-glycoprotein.

41. The method of claim 40 further comprising determining the effect of the compound on

5 the P-glycoprotein transporter activity of the P-glycoprotein.

42. The method of claim 40 further comprising determining the effect of the compound on

the ATPase activity of the P-glycoprotein.

10 43. A method for determining ATPase activity of a P-glycoprotein comprising

contacting the host cell of claim 20 or 22, or a membrane fraction thereof, with

a test drug, and

measuring ATPase activity of the P-glycoprotein.

15 44. The method of claim 43, wherein the step of measuring ATPase activity is performed

at least twice at different times.

45. A method for determining transmembrane transport of a compound by a P-

glycoprotein, comprising

20 contacting the host cell of claim 20 or 22, or a membrane fraction thereof, with

a test drug, and

measuring transport of the test drug under sink conditions in at least one direction of
transport selected from the group consisting of the apical to basolateral direction and the
basolateral to apical direction.

25

46. The method of claim 45, wherein the step of measuring transport of the test drug is

performed at least twice at different times.

Abstract

The invention pertains to dog P-glycoproteins and related P-glycoproteins which include dog-specific amino acids, as well as nucleic acids which encode those polypeptides.

5 The present invention also includes fragments and biologically functional variants of the dog P-glycoprotein. The invention further relates to methods of using such dog P-glycoprotein nucleic acids and polypeptides, especially in methods for determining bioavailability of drugs and for screening for inhibitors of dog PGP. Also included are dog PGP inhibitors which inhibit dog PGP activity by inhibiting the expression or function of dog PGP.

10

10
9
8
7
6
5
4
3
2
1

SEQUENCE LISTING

5 <110> Stocker, Penny J.
 Steinel-Crespi, Dorothy T.
 Crespi, Charles L.
 Rief, Timothy C
 Patten, Christopher J.
 10 <120> P-GLYCOPROTEINS AND USES THEREOF
 15 <130> G0307/7017
 15 <150> US 60/156,510
 <151> 1999-09-28
 20 <160> 32
 20 <170> FastSEQ for Windows Version 3.0
 25 <210> 1
 <211> 4279
 <212> DNA
 <213> Canis familiaris
 30 <220>
 <221> CDS
 <222> (17) ... (3859)
 30 <400> 1
 ggagcgcgag gtcggg atg gat cct gaa gga ggc cgt aag ggg agt gca gag 52
 Met Asp Pro Glu Gly Gly Arg Lys Ser Ala Glu
 1 5 10
 35 aag aac ttc tgg aaa atg ggc aaa aaa agt aaa aaa aat gag aag aaa 100
 Lys Asn Phe Trp Lys Met Gly Lys Ser Lys Lys Asn Glu Lys Lys
 15 20 25
 40 gaa aag aaa cca act gtc agc acg ttt gca atg ttt cgc tat tca aat 148
 Glu Lys Pro Thr Val Ser Thr Phe Ala Met Phe Arg Tyr Ser Asn
 30 35 40
 45 tgg ctt gat agg ttg tat atg ttg gtg ggg aca atg gct gcc atc atc 196
 Trp Leu Asp Arg Leu Tyr Met Leu Val Gly Thr Met Ala Ala Ile Ile
 45 50 55 60
 50 cat gga gct gca ctc cct ctc atg atg ctg gtt ttt gga aac atg aca 244
 His Gly Ala Ala Leu Pro Leu Met Met Leu Val Phe Gly Asn Met Thr
 65 70 75
 55 gat agc ttt gca aat gca gga att tca aga aac aaa act ttt cca gtt 292
 Asp Ser Phe Ala Asn Ala Gly Ile Ser Arg Asn Lys Thr Phe Pro Val
 80 85 90
 55 ata att aat gaa agt att acg aac aat aca caa cat ttc atc aac cat 340
 Ile Ile Asn Glu Ser Ile Thr Asn Asn Thr Gln His Phe Ile Asn His
 95 100 105
 60 ctg gag gag gaa atg acc acg tat gcc tat tat tac agt ggg atc ggt 388

Leu Glu Glu Glu Met Thr Thr Tyr Ala Tyr Tyr Tyr Ser Gly Ile Gly
 110 115 120

5	gct ggc gtc gtc gtc gtc gtc tac atc cag gtt tca ttc tgg tgc ctg Ala Gly Val Leu Val Ala Ala Tyr Ile Gln Val Ser Phe Trp Cys Leu 125 130 135 140	436
10	gca gca gga aga cag ata ctc aaa att aga aaa caa ctt ttt cat gtc Ala Ala Gly Arg Gln Ile Leu Lys Ile Arg Lys Gln Phe Phe His Ala 145 150 155	484
	atc atg cga cag gag att ggc tgg ttt gac gtc cat gac gtt ggg gag Ile Met Arg Gln Glu Ile Gly Trp Phe Asp Val His Asp Val Gly Glu 160 165 170	532
15	ctt aac acc cgg ctc aca gac gat gtc tcc aaa atc aat gaa gga att Leu Asn Thr Arg Leu Thr Asp Asp Val Ser Lys Ile Asn Glu Gly Ile 175 180 185	580
20	ggc gac aaa att gga atg ttc ttt cac tca ata gca aca ttt ttc acc Gly Asp Lys Ile Gly Met Phe Phe His Ser Ile Ala Thr Phe Phe Thr 190 195 200	628
25	ggt ttt ata gtc ggg ttt aca cgt ggt tgg aag cta acc ctt gtg att Gly Phe Ile Val Gly Phe Thr Arg Gly Trp Lys Leu Thr Leu Val Ile 205 210 215 220	676
30	ttg gcc atc agc cct gtt ctt gga ctt tca gcc gcc atc tgg gca aag Leu Ala Ile Ser Pro Val Leu Gly Leu Ser Ala Ala Ile Trp Ala Lys 225 230 235	724
	ata cta tct tca ttt act gat aaa gaa ctc ttg gcc tat gca aaa gct Ile Leu Ser Ser Phe Thr Asp Lys Glu Leu Leu Ala Tyr Ala Lys Ala 240 245 250	772
35	gga gca gta gct gaa gaa gtc tta gca gca atc aga act gtg att gcc Gly Ala Val Ala Glu Glu Val Leu Ala Ala Ile Arg Thr Val Ile Ala 255 260 265	820
40	ttt gga gga caa aag aaa gaa ctt gaa agg tac aac aaa aat tta gaa Phe Gly Gly Gln Lys Lys Glu Leu Glu Arg Tyr Asn Lys Asn Leu Glu 270 275 280	868
45	gaa gct aaa gga att ggg ata aag aaa gct atc acg gcc aac att tct Glu Ala Lys Gly Ile Gly Ile Lys Lys Ala Ile Thr Ala Asn Ile Ser 285 290 295 300	916
50	att ggt gcc gct ttc tta ttg atc tat gca tca tat gct ctg gct ttc Ile Gly Ala Ala Phe Leu Leu Ile Tyr Ala Ser Tyr Ala Leu Ala Phe 305 310 315	964
	tgg tat ggg acc tcc ttg gtc ctc tcc agt gaa tat tct att gga caa Trp Tyr Gly Thr Ser Leu Val Leu Ser Ser Glu Tyr Ser Ile Gly Gln 320 325 330	1012
55	gta ctc act gtc ttc ttt tct gta tta att ggg gct ttt agt att gga Val Leu Thr Val Phe Phe Ser Val Leu Ile Gly Ala Phe Ser Ile Gly 335 340 345	1060
60	cag gca tcc cca agc att gaa gca ttt gca aac gca aga gga gca gct	1108

Gln Ala Ser Pro Ser Ile Glu Ala Phe Ala Asn Ala Arg Gly Ala Ala
 350 355 360

5	tat gaa atc ttc aag ata att gac aat aaa cca agc att gac agc tat Tyr Glu Ile Phe Lys Ile Ile Asp Asn Lys Pro Ser Ile Asp Ser Tyr 365 370 375 380	1156
10	tcg aag agt gga cat aaa cca gat aat att aag gga aat ttg gaa ttc Ser Lys Ser Gly His Lys Pro Asp Asn Ile Lys Gly Asn Leu Glu Phe 385 390 395	1204
	aaa aat gtt cac ttc agt tac cct tct cga aaa gaa gtt aag atc tta Lys Asn Val His Phe Ser Tyr Pro Ser Arg Lys Glu Val Lys Ile Leu 400 405 410	1252
15	aag ggt ctc aac ctg aag gtt cag agt ggg cag aca gtc gcg ctg gtt Lys Gly Leu Asn Leu Lys Val Gln Ser Gly Gln Thr Val Ala Leu Val 415 420 425	1300
20	ggg aac agt ggc tgc ggg aag aac acg acc gtc cag ctg atg cag agg Gly Asn Ser Gly Cys Gly Lys Ser Thr Thr Val Gln Leu Met Gln Arg 430 435 440	1348
25	ctc tat gac ccc aca gat ggc atg gtc tgt att gat gga cag gac att Leu Tyr Asp Pro Thr Asp Gly Met Val Cys Ile Asp Gly Gln Asp Ile 445 450 455 460	1396
30	agg acc ata aat gta agg cat ctt cgg gaa att act ggt gtc gtc agt Arg Thr Ile Asn Val Arg His Leu Arg Glu Ile Thr Gly Val Val Ser 465 470 475	1444
	cag gag cct gtg ttg ttt gcc acc acg ata gct gaa aac att cgc tat Gln Glu Pro Val Leu Phe Ala Thr Thr Ile Ala Glu Asn Ile Arg Tyr 480 485 490	1492
35	ggc cgc gaa aat gtc acc atg gat gag att gag aaa gct gtt aag gaa Gly Arg Glu Asn Val Thr Met Asp Glu Ile Glu Lys Ala Val Lys Glu 495 500 505	1540
40	gcc aat gcc tat gat ttt atc atg aaa cta cct aat aaa ttt gac act Ala Asn Ala Tyr Asp Phe Ile Met Lys Leu Pro Asn Lys Phe Asp Thr 510 515 520	1588
45	ctg gtt gga gag aga ggg gcc cag ctg agt ggt gga cag aaa cag aga Leu Val Gly Glu Arg Gly Ala Gln Leu Ser Gly Gly Gln Lys Gln Arg 525 530 535 540	1636
50	atc gcc att gct cgg gcc ctg gtt cgc aac ccc aag att ctt ctg ctg Ile Ala Ile Ala Arg Ala Leu Val Arg Asn Pro Lys Ile Leu Leu 545 550 555	1684
	gat gag gca acg tca gct ctg gac act gaa agt gaa gca gtc gtt cag Asp Glu Ala Thr Ser Ala Leu Asp Thr Glu Ser Glu Ala Val Val Gln 560 565 570	1732
55	gtg gcc ctg gat aag gcc aga aaa ggc cgg act acc att gtc ata gct Val Ala Leu Asp Lys Ala Arg Lys Gly Arg Thr Thr Ile Val Ile Ala 575 580 585	1780
60	cat cgt ttg tct aca gtt cgt aat gcc gat gtc att gct ggt ttt gat	1828

His Arg Leu Ser Thr Val Arg Asn Ala Asp Val Ile Ala Gly Phe Asp
 590 595 600

5	gat gga gtc att gtg gag aaa gga aat cat gat gaa ctc atg aaa gag Asp Gly Val Ile Val Glu Lys Gly Asn His Asp Glu Leu Met Lys Glu 605 610 615 620	1876
10	aag ggc att tac ttc aaa ctt gtc aca atg cag aca aga gga aat gaa Lys Gly Ile Tyr Phe Lys Leu Val Thr Met Gln Thr Arg Gly Asn Glu 625 630 635	1924
	att gag tta gaa aat gcc act ggt gaa tcc aaa agt gaa agt gat gcc Ile Glu Leu Asn Ala Thr Gly Glu Ser Lys Ser Glu Ser Asp Ala 640 645 650	1972
15	ttg gaa atg tct cca aaa gat tca ggg tcc agt tta ata aaa aga aga Leu Glu Met Ser Pro Lys Asp Ser Gly Ser Ser Leu Ile Lys Arg Arg 655 660 665	2020
20	tca act cgc agg agt ata cat gca cca caa ggc caa gac aga aag ctt Ser Thr Arg Arg Ser Ile His Ala Pro Gin Gly Gln Asp Arg Lys Leu 670 675 680	2068
25	ggg aca aaa gag gac ttg aat gag aat gta cct cca gtt tcc ttc tgg Gly Thr Lys Glu Asp Leu Asn Glu Asn Val Pro Pro Val Ser Phe Trp 685 690 695 700	2116
30	agg att ctg aag ctg aac tca act gaa tgg cct tat ttt gtg gtt ggt Arg Ile Leu Lys Leu Asn Ser Thr Glu Trp Pro Tyr Phe Val Val Gly 705 710 715	2164
	ata ttt tgt gct att ata aac gga ggc ctg caa cca gca ttt tca ata Ile Phe Cys Ala Ile Ile Asn Gly Gly Leu Gln Pro Ala Phe Ser Ile 720 725 730	2212
35	ata ttt tca agg att ata ggg atc ttt acc cga gat gag gat cct gaa Ile Phe Ser Arg Ile Ile Gly Ile Phe Thr Arg Asp Glu Asp Pro Glu 735 740 745	2260
40	aca aaa cga cag aat agt aac atg ttt tct gta ttg ttt cta gtc ctt Thr Lys Arg Gln Asn Ser Asn Met Phe Ser Val Leu Phe Leu Val Leu 750 755 760	2308
45	gga att att tct ttt att aca ttt ttc ctc cag ggc ttc aca ttt ggc Gly Ile Ile Ser Phe Ile Thr Phe Phe Leu Gln Gly Phe Thr Phe Gly 765 770 775 780	2356
50	aaa gct ggg gag atc ctc act aag cgg ctt cga tac atg gtt ttc aga Lys Ala Gly Glu Ile Leu Thr Lys Arg Leu Arg Tyr Met Val Phe Arg 785 790 795	2404
	tcc atg ctg aga cag gat gtc agc tgg ttt gat gac cct aaa aac acc Ser Met Leu Arg Gln Asp Val Ser Trp Phe Asp Asp Pro Lys Asn Thr 800 805 810	2452
55	act gga gca ttg aca acc agg ctt gcc aat gat gcg gct caa gtt aaa Thr Gly Ala Leu Thr Thr Arg Leu Ala Asn Asp Ala Ala Gln Val Lys 815 820 825	2500
60	ggg gct ata ggt tcc agg ctt gct gtc att acc cag aat ata gca aat	2548

Gly Ala Ile Gly Ser Arg Leu Ala Val Ile Thr Gln Asn Ile Ala Asn
 830 835 840

5	ctt ggg aca ggc att att ata tcc tta atc tat ggt tgg caa tta aca Leu Gly Thr Gly Ile Ile Ile Ser Leu Ile Tyr Gly Trp Gln Leu Thr 845 850 855 860	2596
10	ctt tta ctc tta gca att gta ccc atc att gca ata gca gga gtt gtt Leu Leu Leu Ala Ile Val Pro Ile Ile Ala Ile Ala Gly Val Val 865 870 875	2644
	gaa atg aaa atg ttg tct gga caa gca ctg aaa gat aag aaa gag cta Glu Met Lys Met Leu Ser Gly Gln Ala Leu Lys Asp Lys Lys Glu Leu 880 885 890	2692
15	gaa gga gct ggg aag att gct aca gaa gcc atc gaa aac ttc cga act Glu Gly Ala Gly Lys Ile Ala Thr Glu Ala Ile Glu Asn Phe Arg Thr 895 900 905	2740
20	gtt gtt tct ttg act cgg gag cag aag ttt gaa tac atg tat gca cag Val Val Ser Leu Thr Arg Glu Gln Lys Phe Glu Tyr Met Tyr Ala Gln 910 915 920	2788
25	agt ttg caa gta cca tac aga aac tct ttg agg aaa gca cac atc ttc Ser Leu Gln Val Pro Tyr Arg Asn Ser Leu Arg Lys Ala His Ile Phe 925 930 935 940	2836
30	ggg gtc tca ttt tct atc acc cag gca atg atg tat ttt tcc tat gct Gly Val Ser Phe Ser Ile Thr Gln Ala Met Met Tyr Phe Ser Tyr Ala 945 950 955	2884
	ggc tgg ttc cgg ttt ggt gcc tac ttg gtg gca aat gag ttc atg aac Gly Cys Phe Arg Phe Gly Ala Tyr Leu Val Ala Asn Glu Phe Met Asn 960 965 970	2932
35	ttt cag gat gtt ctt ttg gta ttc tca gct att gtc ttt ggt gcc atg Phe Gln Asp Val Leu Val Phe Ser Ala Ile Val Phe Gly Ala Met 975 980 985	2980
40	gca gtg ggg cag gtc agt tca ttt gct cct gac tat gcc aaa gcc aaa Ala Val Gly Gln Val Ser Ser Phe Ala Pro Asp Tyr Ala Lys Ala Lys 990 995 1000	3028
45	gta tca gca gcc cac gtc atc atg atc att gaa aaa agc cct ctg att Val Ser Ala Ala His Val Ile Met Ile Ile Glu Lys Ser Pro Leu Ile 1005 1010 1015 1020	3076
50	gac agc tac agc cct cac ggc ctc aag cca aat acg ttg gaa gga aat Asp Ser Tyr Ser Pro His Gly Leu Lys Pro Asn Thr Leu Glu Gly Asn 1025 1030 1035	3124
	gtg aca ttt aat gag gtc gtg ttc aac tat ccc act cga cca gac atc Val Thr Phe Asn Glu Val Val Phe Asn Tyr Pro Thr Arg Pro Asp Ile 1040 1045 1050	3172
55	ccc gtg ctc cag ggg ctg agc ctc gag gtg aag aag ggc cag acg ctg Pro Val Leu Gln Gly Leu Ser Leu Glu Val Lys Lys Gly Gln Thr Leu 1055 1060 1065	3220
60	gcc ctc gta ggt agc agt ggc tgt ggg aag aac gca gtt gtt cag ctc	3268

	Ala Leu Val Gly Ser Ser Gly Cys Gly Lys Ser Thr Val Val Gln Leu		
	1070	1075	1080
5	ctt gag cgc ttc tat gac ccc ttg gct ggt tca gtc cta att gat ggc Leu Glu Arg Phe Tyr Asp Pro Leu Ala Gly Ser Val Leu Ile Asp Gly		3316
	1085	1090	1095
	1100		
10	aaa gag ata aag cac ctg aat gtc cag tgg ctc cga gca cac ctg ggc Lys Glu Ile Lys His Leu Asn Val Gln Trp Leu Arg Ala His Leu Gly		3364
	1105	1110	1115
	1115		
15	atc gtg tct cag gag ccc atc ctg ttt gac tgc agc att gcc gag aac Ile Val Ser Gin Glu Pro Ile Leu Phe Asp Cys Ser Ile Ala Glu Asn		3412
	1120	1125	1130
	1130		
20	att gcc tat gga gac aac agc cgg gtc gta tca cat gaa gag att atg Ile Ala Tyr Gly Asp Asn Ser Arg Val Val Ser His Glu Glu Ile Met		3460
	1135	1140	1145
	1145		
25	cag gca gcc aag gag gcc aac ata cac cac ttc atc gag aca ctc cct Gln Ala Ala Lys Glu Ala Asn Ile His His Phe Ile Glu Thr Leu Pro		3508
	1150	1155	1160
	1160		
30	gag aaa tac aac acc aga gta gga gac aaa gga acc cag ctc tct ggt Glu Lys Tyr Asn Thr Arg Val Gly Asp Lys Gly Thr Gln Leu Ser Gly		3556
	1165	1170	1175
	1180		
35	ggc cag aaa cag cgc att gcc ata gct cgc gct ctt gtt aga cag cct Gly Gln Lys Gln Arg Ile Ala Ile Ala Arg Ala Leu Val Arg Gln Pro		3604
	1185	1190	1195
	1195		
40	cat att ttg ctt ttg gat gaa gct aca tca gct ctg gat aca gaa agt His Ile Leu Leu Asp Glu Ala Thr Ser Ala Leu Asp Thr Glu Ser		3652
	1200	1205	1210
	1210		
45	gaa aag gtt gtc caa gaa gcc ctg gac aaa gcc aga gaa ggc cgc acc Glu Lys Val Val Gln Glu Ala Leu Asp Lys Ala Arg Glu Gly Arg Thr		3700
	1215	1220	1225
	1225		
50	tgc att gtg atc gcc cac cgc ttg tcc acc atc cag aat gca gat tta Cys Ile Val Ile Ala His Arg Leu Ser Thr Ile Gln Asn Ala Asp Leu		3748
	1230	1235	1240
	1240		
55	ata gtg gtg ttt cag aat ggc aaa gtc aag gag cat ggc aca cat caa Ile Val Val Phe Gln Asn Gly Lys Val Lys Glu His Gly Thr His Gln		3796
	1245	1250	1255
	1260		
60	cag ctg ctg gcc cag aaa ggc atc tat ttt tcc atg gtc agt gtc cag Gln Leu Leu Ala Gln Lys Gly Ile Tyr Phe Ser Met Val Ser Val Gln		3844
	1265	1270	1275
	1275		
	gct gga gca aag cgc tagtgaactg tggccatatg agctgttaaa tattttttaa Ala Gly Ala Lys Arg		3899
	1280		
65	tatttgtgtt aaacatggc attaaatcaa agttaaaaagg tgagcactta ctggaaaaac tatgttggaaat tacctgttta acatttctt ctgcaactga agatcattcc accaaagtta		3959
	4019		
	4079		
	4139		
	4199		

ggtaaaaaagt actgaatgtt tgaataaagt gctagctata ataaaactaa acttttatat 4259
 caaaaaaaaaaaaaaaa aaaaaaaaaaaa

5 <210> 2
 <211> 1281
 <212> PRT
 <213> Canis familiaris

10 <400> 2
 Met Asp Pro Glu Gly Gly Arg Lys Gly Ser Ala Glu Lys Asn Phe Trp
 1 5 10 15
 Lys Met Gly Lys Lys Ser Lys Lys Asn Glu Lys Lys Glu Lys Pro
 20 20 25 30
 Thr Val Ser Thr Phe Ala Met Phe Arg Tyr Ser Asn Trp Leu Asp Arg
 15 35 40 45
 Leu Tyr Met Leu Val Gly Thr Met Ala Ala Ile Ile His Gly Ala Ala
 50 55 60
 Leu Pro Leu Met Met Leu Val Phe Gly Asn Met Thr Asp Ser Phe Ala
 65 70 75 80
 20 Asn Ala Gly Ile Ser Arg Asn Lys Thr Phe Pro Val Ile Ile Asn Glu
 85 85 90 95
 Ser Ile Thr Asn Asn Thr Gln His Phe Ile Asn His Leu Glu Glu
 100 100 105 110
 25 Met Thr Thr Tyr Ala Tyr Tyr Ser Gly Ile Gly Ala Gly Val Leu
 115 115 120 125
 Val Ala Ala Tyr Ile Gln Val Ser Phe Trp Cys Leu Ala Ala Gly Arg
 130 130 135 140
 Gln Ile Leu Lys Ile Arg Lys Gln Phe Phe His Ala Ile Met Arg Gln
 145 145 150 155 160
 30 Glu Ile Gly Trp Phe Asp Val His Asp Val Gly Glu Leu Asn Thr Arg
 165 165 170 175
 Leu Thr Asp Asp Val Ser Lys Ile Asn Glu Gly Ile Gly Asp Lys Ile
 180 180 185 190
 Gly Met Phe Phe His Ser Ile Ala Thr Phe Phe Thr Gly Phe Ile Val
 195 195 200 205
 Gly Phe Thr Arg Gly Trp Lys Leu Thr Leu Val Ile Leu Ala Ile Ser
 210 210 215 220
 Pro Val Leu Gly Leu Ser Ala Ala Ile Trp Ala Lys Ile Leu Ser Ser
 225 225 230 235 240
 40 Phe Thr Asp Lys Glu Leu Leu Ala Tyr Ala Lys Ala Val Ala
 245 245 250 255
 Glu Glu Val Leu Ala Ala Ile Arg Thr Val Ile Ala Phe Gly Gly Gln
 260 260 265 270
 Lys Lys Glu Leu Glu Arg Tyr Asn Lys Asn Leu Glu Ala Lys Gly
 275 275 280 285
 Ile Gly Ile Lys Lys Ala Ile Thr Ala Asn Ile Ser Ile Gly Ala Ala
 290 290 295 300
 Phe Leu Leu Ile Tyr Ala Ser Tyr Ala Leu Ala Phe Trp Tyr Gly Thr
 305 305 310 315 320
 50 Ser Leu Val Leu Ser Ser Glu Tyr Ser Ile Gly Gln Val Leu Thr Val
 325 325 330 335
 Phe Phe Ser Val Leu Ile Gly Ala Phe Ser Ile Gly Gln Ala Ser Pro
 340 340 345 350
 Ser Ile Glu Ala Phe Ala Asn Ala Arg Gly Ala Ala Tyr Glu Ile Phe
 355 355 360 365
 Lys Ile Ile Asp Asn Lys Pro Ser Ile Asp Ser Tyr Ser Lys Ser Gly
 370 370 375 380
 His Lys Pro Asp Asn Ile Lys Gly Asn Leu Glu Phe Lys Asn Val His
 385 385 390 395 400
 60 Phe Ser Tyr Pro Ser Arg Lys Glu Val Lys Ile Leu Lys Gly Leu Asn

	405	410	415
	Leu Lys Val Gln Ser Gly Gln Thr Val Ala Leu Val Gly Asn Ser Gly		
	420	425	430
5	Cys Gly Lys Ser Thr Thr Val Gln Leu Met Gln Arg Leu Tyr Asp Pro		
	435	440	445
	Thr Asp Gly Met Val Cys Ile Asp Gly Gln Asp Ile Arg Thr Ile Asn		
	450	455	460
	Val Arg His Leu Arg Glu Ile Thr Gly Val Val Ser Gln Glu Pro Val		
	465	470	475
10	Leu Phe Ala Thr Thr Ile Ala Glu Asn Ile Arg Tyr Gly Arg Glu Asn		
	485	490	495
	Val Thr Met Asp Glu Ile Glu Lys Ala Val Lys Glu Ala Asn Ala Tyr		
	500	505	510
	Asp Phe Ile Met Lys Leu Pro Asn Lys Phe Asp Thr Leu Val Gly Glu		
15	515	520	525
	Arg Gly Ala Gln Leu Ser Gly Gly Gln Lys Gln Arg Ile Ala Ile Ala		
	530	535	540
	Arg Ala Leu Val Arg Asn Pro Lys Ile Leu Leu Leu Asp Glu Ala Thr		
	545	550	555
20	Ser Ala Leu Asp Thr Glu Ser Glu Ala Val Val Gln Val Ala Leu Asp		
	565	570	575
	Lys Ala Arg Lys Gly Arg Thr Thr Ile Val Ile Ala His Arg Leu Ser		
	580	585	590
	Thr Val Arg Asn Ala Asp Val Ile Ala Gly Phe Asp Asp Gly Val Ile		
25	595	600	605
	Val Glu Lys Gly Asn His Asp Glu Leu Met Lys Glu Lys Gly Ile Tyr		
	610	615	620
	Phe Lys Leu Val Thr Met Gln Thr Arg Gly Asn Glu Ile Glu Leu Glu		
	625	630	635
30	Asn Ala Thr Gly Glu Ser Lys Ser Glu Ser Asp Ala Leu Glu Met Ser		
	645	650	655
	Pro Lys Asp Ser Gly Ser Ser Leu Ile Lys Arg Arg Ser Thr Arg Arg		
	660	665	670
	Ser Ile His Ala Pro Gln Gly Gln Asp Arg Lys Leu Gly Thr Lys Glu		
35	675	680	685
	Asp Leu Asn Glu Asn Val Pro Pro Val Ser Phe Trp Arg Ile Leu Lys		
	690	695	700
	Leu Asn Ser Thr Glu Trp Pro Tyr Phe Val Val Gly Ile Phe Cys Ala		
	705	710	715
40	Ile Ile Asn Gly Glu Leu Gln Pro Ala Phe Ser Ile Ile Phe Ser Arg		
	725	730	735
	Ile Ile Gly Ile Phe Thr Arg Asp Glu Asp Pro Glu Thr Lys Arg Gln		
	740	745	750
45	Asn Ser Asn Met Phe Ser Val Leu Phe Leu Val Leu Gly Ile Ile Ser		
	755	760	765
	Phe Ile Thr Phe Phe Leu Gln Gly Phe Thr Phe Gly Lys Ala Gly Glu		
	770	775	780
	Ile Leu Thr Lys Arg Leu Arg Tyr Met Val Phe Arg Ser Met Leu Arg		
	785	790	795
50	Gln Asp Val Ser Trp Phe Asp Asp Pro Lys Asn Thr Thr Gly Ala Leu		
	805	810	815
	Thr Thr Arg Leu Ala Asn Asp Ala Ala Gln Val Lys Gly Ala Ile Gly		
	820	825	830
	Ser Arg Leu Ala Val Ile Thr Gln Asn Ile Ala Asn Leu Gly Thr Gly		
55	835	840	845
	Ile Ile Ile Ser Leu Ile Tyr Gly Trp Gln Leu Thr Leu Leu Leu		
	850	855	860
	Ala Ile Val Pro Ile Ala Ile Ala Gly Val Val Glu Met Lys Met		
	865	870	875
60	Leu Ser Gly Gln Ala Leu Lys Asp Lys Lys Glu Leu Glu Gly Ala Gly		

	885	890	895
	Lys Ile Ala Thr Glu Ala Ile Glu Asn Phe Arg Thr Val Val Ser Leu		
	900	905	910
5	Thr Arg Glu Gln Lys Phe Glu Tyr Met Tyr Ala Gln Ser Leu Gln Val		
	915	920	925
	Pro Tyr Arg Asn Ser Leu Arg Lys Ala His Ile Phe Gly Val Ser Phe		
	930	935	940
	Ser Ile Thr Gln Ala Met Met Tyr Phe Ser Tyr Ala Gly Cys Phe Arg		
10	945	950	955
	Phe Gly Ala Tyr Leu Val Ala Asn Glu Phe Met Asn Phe Gln Asp Val		
	965	970	975
	Leu Leu Val Phe Ser Ala Ile Val Phe Gly Ala Met Ala Val Gly Gln		
	980	985	990
	Val Ser Ser Phe Ala Pro Asp Tyr Ala Lys Ala Lys Val Ser Ala Ala		
15	995	1000	1005
	His Val Ile Met Ile Ile Glu Lys Ser Pro Leu Ile Asp Ser Tyr Ser		
	1010	1015	1020
	Pro His Gly Leu Lys Pro Asn Thr Leu Glu Gly Asn Val Thr Phe Asn		
	1025	1030	1035
20	Glu Val Val Phe Asn Tyr Pro Thr Arg Pro Asp Ile Pro Val Leu Gln		104
	1045	1050	1055
	Gly Leu Ser Leu Glu Val Lys Lys Gly Gln Thr Leu Ala Leu Val Gly		
	1060	1065	1070
25	Ser Ser Gly Cys Gly Lys Ser Thr Val Val Gln Leu Leu Glu Arg Phe		
	1075	1080	1085
	Tyr Asp Pro Leu Ala Gly Ser Val Leu Ile Asp Gly Lys Glu Ile Lys		
	1090	1095	1100
	His Leu Asn Val Gln Trp Leu Arg Ala His Leu Gly Ile Val Ser Gln		
	1105	1110	1115
30	Glu Pro Ile Leu Phe Asp Cys Ser Ile Ala Glu Asn Ile Ala Tyr Gly		1120
	1125	1130	1135
	Asp Asn Ser Arg Val Val Ser His Glu Glu Ile Met Gln Ala Ala Lys		
	1140	1145	1150
	Glu Ala Asn Ile His His Phe Ile Glu Thr Leu Pro Glu Lys Tyr Asn		
35	1155	1160	1165
	Thr Arg Val Gly Asp Lys Gly Thr Gln Leu Ser Gly Gly Gln Lys Gln		
	1170	1175	1180
	Arg Ile Ala Ile Ala Arg Ala Leu Val Arg Gln Pro His Ile Leu Leu		
	1185	1190	1195
40	Leu Asp Glu Ala Thr Ser Ala Leu Asp Thr Glu Ser Glu Lys Val Val		1200
	1205	1210	1215
	Gln Glu Ala Leu Asp Lys Ala Arg Glu Gly Arg Thr Cys Ile Val Ile		
	1220	1225	1230
	Ala His Arg Leu Ser Thr Ile Gln Asn Ala Asp Leu Ile Val Val Phe		
45	1235	1240	1245
	Gln Asn Gly Lys Val Lys Glu His Gly Thr His Gln Gln Leu Leu Ala		
	1250	1255	1260
	Gln Lys Gly Ile Tyr Phe Ser Met Val Ser Val Gln Ala Gly Ala Lys		
50	1265	1270	1275
	Arg		1280

<210> 3
 <211> 4317
 <212> DNA
 <213> Canis familiaris

 <220>
 <221> CDS
 60 <222> (70)...(3912)

<400> 3
 ctaagtccga gatctttttt cccaaatcc ctctcggtt gagggtgcga agggaaagccc 60
 gaggtgcacg atg gat cct gaa gga ggc cgt aag ggg agt gca gag aag aac 111
 5 Met Asp Pro Glu Gly Gly Arg Lys Gly Ser Ala Glu Lys Asn
 1 5 10

ttc tgg aaa atg ggc aaa aaa aat gac aaa gag aag aaa gaa aag aaa 159
 Phe Trp Lys Met Gly Lys Ser Lys Lys Glu Lys Lys Glu Lys Lys 15
 10 20 25 30

cca act gtc acg ttt gca atg ttt cgc tat tca aat tgg ctt gat 207
 Pro Thr Val Ser Thr Phe Ala Met Phe Arg Tyr Ser Asn Trp Leu Asp 35 40 45

15 agg ttg tat atg ttg gtg ggg aca atg gct gcc atc atc cat gga gct 255
 Arg Leu Tyr Met Leu Val Gly Thr Met Ala Ala Ile Ile His Gly Ala 50 55 60

20 gca ctc cct ctc atg atg ctg gtt ttt gga aac atg aca gat agc ttt 303
 Ala Leu Pro Leu Met Met Leu Val Phe Gly Asn Met Thr Asp Ser Phe 65 70 75

25 gca aat gca gga att tca aga aac aaa act ttt cca gtt ata att aat 351
 Ala Asn Ala Gly Ile Ser Arg Asn Lys Thr Phe Pro Val Ile Ile Asn 80 85 90

30 gaa agt att acg aac aat aca caa cat ttc atc aac cat ctg gag gag 399
 Glu Ser Ile Thr Asn Asn Thr Gln His Phe Asn His Leu Glu Glu 95 100 105 110

35 gaa atg acc acg tat gcc tat tat tac agt ggg atc ggt gct ggc gtg 447
 Glu Met Thr Thr Tyr Ala Tyr Tyr Ser Gly Ile Gly Ala Gly Val 115 120 125

40 ctg gtg gct tac atc cag gtt tca ttc tgg tgc ctg gca gca gga 495
 Leu Val Ala Ala Tyr Ile Gln Val Ser Phe Trp Cys Leu Ala Ala Gly 130 135 140

45 cag gag att ggc tgg ttt gac gtg cat gac gtt ggg gag ctt aac acc 531
 Gln Glu Ile Gly Trp Phe Asp Val His Asp Val Gly Glu Leu Asn Thr 160 165 170

50 cgg ctc aca gac gat gtc tcc aaa atc aat gaa gga att ggc gac aaa 639
 Arg Leu Thr Asp Asp Val Ser Lys Ile Asn Glu Gly Ile Gly Asp Lys 175 180 185 190

55 gtt gga atg ttc ttt caa tca ata gca aca ttt ttc acc ggt ttt ata 687
 Val Gly Met Phe Phe Gln Ser Ile Ala Thr Phe Phe Thr Gly Phe Ile 195 200 205

60 gtc ggg ttt aca cct ggt tgg aag cta acc ctt gtg att ttg gcc atc 735
 Val Gly Phe Thr Pro Gly Trp Lys Leu Thr Leu Val Ile Leu Ala Ile 210 215 220

65 agc cct gtt ctt gga ctt tca gca gcc atc tgg gca aag ata cta tct 783

Ser Pro Val Leu Gly Leu Ser Ala Ala Ile Trp Ala Lys Ile Leu Ser
225 230 235

5	tca ttt act gat aaa gaa ctc ttg gcc tat gca aaa gct gga gca gta Ser Phe Thr Asp Lys Glu Leu Leu Ala Tyr Ala Lys Ala Gly Ala Val 240 245 250	831
10	gct gaa gaa gtc tta gca gca atc aga act gtg att gcc ttt gga gga Ala Glu Glu Val Leu Ala Ala Ile Arg Thr Val Ile Ala Phe Gly Gly 255 260 265 270	879
	caa aag aaa gaa ctt gaa agg tac aac aaa aat tta gaa gaa gct aaa Gln Lys Lys Glu Leu Glu Arg Tyr Asn Lys Asn Leu Glu Glu Ala Lys 275 280 285	927
15	aga att ggg ata aag aaa gct atc acg gcc aac att tct att ggt gcc Arg Ile Gly Ile Lys Lys Ala Ile Thr Ala Asn Ile Ser Ile Gly Ala 290 295 300	975
20	gct ttc tta ttg atc tat gca tca tat gct ctg gct ttc tgg tat ggg Ala Phe Leu Leu Ile Tyr Ala Ser Tyr Ala Leu Ala Phe Trp Tyr Gly 305 310 315	1023
25	acc tcc ttg gtc ctc tcc agt gaa tat act att gga cag gta ctc act Thr Ser Leu Val Leu Ser Ser Glu Tyr Thr Ile Gly Gln Val Leu Thr 320 325 330	1071
30	gtc ttc ttt tct gta tta att ggg gct ttt agt att gga cag gca tcc Val Phe Phe Ser Val Leu Ile Gly Ala Phe Ser Ile Gly Gln Ala Ser 335 340 345 350	1119
	cca agc att gaa gca ttt gca aac gca aga gga gca gct tat gaa atc Pro Ser Ile Glu Ala Phe Ala Asn Ala Arg Gly Ala Ala Tyr Glu Ile 355 360 365	1167
35	ttc aag ata att gac aat aaa cca agc att gac agc tat tcg aag agt Phe Lys Ile Ile Asp Asn Lys Pro Ser Ile Asp Ser Tyr Ser Lys Ser 370 375 380	1215
40	gga cat aaa cca gat aat att aag gga aat ttg gaa ttc aaa aat gtt Gly His Lys Pro Asp Asn Ile Lys Gly Asn Leu Glu Phe Lys Asn Val 385 390 395	1263
45	cac ttc agt tac cct tct cga aaa gaa gtt aag atc tta aag ggt ctc His Phe Ser Tyr Pro Ser Arg Lys Glu Val Lys Ile Leu Lys Gly Leu 400 405 410	1311
50	aac ctg aag gtt cag agt ggg cag aca gtg gcg ctg gtt ggg aac agt Asn Leu Lys Val Gln Ser Gly Gln Thr Val Ala Leu Val Gly Asn Ser 415 420 425 430	1359
	ggc tgc ggg aag agc acg acc gtg cag ctg atg cag agg ctc tat gac Gly Cys Gly Lys Ser Thr Thr Val Gln Leu Met Gln Arg Leu Tyr Asp 435 440 445	1407
55	ccc aca gat ggc atg gtc tgt att gat gga cag gac att agg acc ata Pro Thr Asp Gly Met Val Cys Ile Asp Gly Gln Asp Ile Arg Thr Ile 450 455 460	1455
60	aat gta agg cat ctt cgg gaa att act ggt gtg gtg agt cag gag cct	1503

Asn	Val	Arg	His	Leu	Arg	Glu	Ile	Thr	Gly	Val	Val	Ser	Gln	Glu	Pro
465							470								

5	gtg	ttg	ttt	gcc	acc	acg	ata	gct	gaa	aac	att	cgc	tat	ggc	cgc	gaa	1551
	Val	Leu	Phe	Ala	Thr	Thr	Ile	Ala	Glu	Asn	Ile	Arg	Tyr	Gly	Arg	Glu	
	480						485					490					
10	aat	gtc	acc	atg	gat	gag	att	gag	aaa	gct	gtt	aag	gaa	gcc	aat	gcc	1599
	Asn	Val	Thr	Met	Asp	Glu	Ile	Glu	Lys	Ala	Val	Lys	Glu	Ala	Asn	Ala	
	495						500				505					510	
15	tat	gat	ttt	atc	atg	aaa	cta	cct	aat	aaa	ttt	gac	act	ctg	gtt	gga	1647
	Tyr	Asp	Phe	Ile	Met	Lys	Leu	Pro	Asn	Lys	Phe	Asp	Thr	Leu	Val	Gly	
	515						520				525						
20	gag	aga	ggg	gcc	cgg	ctg	agt	ggt	gga	cag	aaa	cag	aga	atc	gcc	att	1695
	Glu	Arg	Gly	Ala	Arg	Leu	Ser	Gly	Gly	Gln	Lys	Gln	Arg	Ile	Ala	Ile	
	530						535					540					
25	gct	cg	gcc	ctg	gtt	cgc	aa	ccc	aag	att	ctt	ctg	ctg	gt	gag	gca	1743
	Ala	Arg	Ala	Leu	Val	Arg	Asn	Pro	Lys	Ile	Leu	Leu	Leu	Asp	Glu	Ala	
	545						550				555						
30	acg	tca	gct	ctg	gac	act	gaa	agt	gaa	gca	gtg	gtt	cag	gtg	gcc	ctg	1791
	Thr	Ser	Ala	Leu	Asp	Thr	Glu	Ser	Glu	Ala	Val	Val	Gln	Val	Ala	Leu	
	560						565				570						
35	gat	aag	gcc	aga	aaa	ggc	cgg	act	acc	att	gtg	ata	gct	cat	cgt	ttg	1839
	Asp	Lys	Ala	Arg	Lys	Gly	Arg	Thr	Thr	Ile	Val	Ile	Ala	His	Arg	Leu	
	575						580				585				590		
40	tct	aca	gtt	cgt	aat	gcc	gat	gtc	att	gt	ttt	gat	gat	gga	gtc		1887
	Ser	Thr	Val	Arg	Asn	Ala	Asp	Val	Ile	Ala	Gly	Phe	Asp	Asp	Gly	Val	
	595						600					605					
45	att	gtg	gag	aaa	gga	aat	cat	gat	gaa	ctc	atg	aaa	gag	aag	ggc	att	1935
	Ile	Val	Glu	Lys	Gly	Asn	His	Asp	Glu	Leu	Met	Lys	Glu	Lys	Gly	Ile	
	610						615					620					
50	tac	ttc	aaa	ctt	gtc	aca	atg	cag	aca	aga	gga	aat	gaa	att	gag	tta	1983
	Tyr	Phe	Lys	Leu	Val	Thr	Met	Gln	Thr	Arg	Gly	Asn	Glu	Ile	Glu	Leu	
	625						630				635						
55	gaa	aat	gcc	act	gg	gaa	tcc	aaa	agt	gaa	agt	gt	gcc	ttg	gaa	atg	2031
	Glu	Asn	Ala	Thr	Gly	Glu	Ser	Iys	Ser	Glu	Ser	Asp	Ala	Leu	Glu	Met	
	640						645					650					
60	tct	cca	aaa	gat	tca	ggg	tcc	agg	tta	ata	aaa	aga	aga	tca	act	cgc	2079
	Ser	Pro	Lys	Asp	Ser	Gly	Ser	Ser	Leu	Ile	Lys	Arg	Arg	Ser	Thr	Arg	
	655						660				665				670		
65	agg	agt	ata	cat	gca	cca	caa	ggc	caa	gac	aga	aag	ctt	gg	tca	aaa	2127
	Arg	Ser	Ile	His	Ala	Pro	Gln	Gly	Gln	Asp	Arg	Lys	Leu	Gly	Thr	Lys	
	675						680				685						
70	gag	gac	ttg	aat	gag	aat	gtt	cct	tca	gtt	tcc	tgg	agg	att	ctg		2175
	Glu	Asp	Leu	Asn	Glu	Asn	Val	Pro	Ser	Val	Ser	Phe	Trp	Arg	Ile	Leu	
	690						695				700						
75	aag	ctg	aac	tca	act	gaa	tgg	cct	tat	ttt	gtg	gtt	ggt	ata	ttt	tgt	2223

Lys	Leu	Asn	Ser	Thr	Glu	Trp	Pro	Tyr	Phe	Val	Val	Gly	Ile	Phe	Cys
705															

5	gct	att	ata	aac	gga	ggc	ctg	caa	cca	gca	ttt	tca	ata	ata	ttt	tca	2271
	Ala	Ile	Ile	Asn	Gly	Gly	Leu	Gln	Pro	Ala	Phe	Ser	Ile	Ile	Phe	Ser	
	720				725						730						
10	agg	att	ata	ggg	atc	ttt	acc	cga	gat	gag	gat	cct	gaa	aca	aaa	cga	2319
	Arg	Ile	Ile	Gly	Ile	Phe	Thr	Arg	Asp	Glu	Asp	Pro	Glu	Thr	Lys	Arg	
	735				740					745					750		
15	cag	aat	agt	aac	atg	ttt	tct	gtt	ttt	cta	gtc	ctt	gga	att	att		2367
	Gln	Asn	Ser	Asn	Met	Phe	Ser	Val	Leu	Phe	Leu	Val	Leu	Gly	Ile	Ile	
	755				760					765							
20	tct	ttt	att	aca	ttt	ttc	ctc	cag	ggc	ttc	aca	ttt	ggc	aaa	gct	ggg	2415
	Ser	Phe	Ile	Phe	Phe	Leu	Gln	Gly	Phe	Thr	Phe	Gly	Lys	Ala	Gly		
	770				775					780							
25	gag	atc	ctc	act	aag	cgg	ctt	cga	tac	atg	gtt	ttc	aga	tcc	atg	ctg	2463
	Glu	Ile	Leu	Thr	Lys	Arg	Leu	Arg	Tyr	Met	Val	Phe	Arg	Ser	Met	Leu	
	785				790					795							
30	aga	cag	gtc	agc	tgg	ttt	gat	gac	cct	aaa	aac	acc	act	gga	gca		2511
	Arg	Gln	Asp	Val	Ser	Trp	Phe	Asp	Asp	Pro	Lys	Asn	Thr	Thr	Gly	Ala	
	800				805					810							
35	ttg	aca	acc	agg	ctt	gcc	aat	gat	gcg	gtc	caa	gtt	aaa	ggg	gct	ata	2559
	Leu	Thr	Thr	Arg	Ile	Ala	Asn	Asp	Ala	Ala	Gln	Val	Lys	Gly	Ile	Ile	
	815				820					825			830				
40	ggc	att	att	ata	tcc	tta	atc	tat	ggc	caa	tta	aca	ttt	ggg	aca		2607
	Gly	Ile	Ile	Ile	Ser	Leu	Ile	Tyr	Gly	Tyr	Gly	Tyr	Leu	Leu	Leu		
	835				840					845							
45	ttt	gca	att	gtc	ccc	atc	att	gca	ata	gca	gga	gtt	gtt	gaa	atg	aaa	2703
	Leu	Ala	Ile	Val	Pro	Ile	Ile	Ala	Ile	Ala	Gly	Val	Val	Glu	Met	Lys	
	865				870					875							
50	atg	ttg	tct	gga	caa	gca	ctg	aaa	gat	aag	aaa	gag	cta	gaa	gga	gct	2751
	Met	Leu	Ser	Gly	Gln	Ala	Leu	Lys	Asp	Lys	Lys	Glu	Leu	Glu	Gly	Ala	
	880				885					890							
55	ggg	aag	att	gct	aca	gaa	gcc	atc	gaa	aac	ttc	cga	act	gtt	gtt	tct	2799
	Gly	Lys	Ile	Ala	Thr	Glu	Ala	Ile	Glu	Asn	Phe	Arg	Thr	Val	Val	Ser	
	895				900					905			910				
60	ttg	act	cg	gag	cag	aag	ttt	gaa	tac	atg	tat	gca	cag	agt	ttg	caa	2847
	Leu	Thr	Arg	Glu	Gln	Lys	Phe	Glu	Tyr	Met	Tyr	Ala	Gln	Ser	Leu	Gln	
	915				920					925							
65	gta	cca	ta	ca	aa	gac	tct	ttg	agg	aaa	gca	cac	atc	ttc	ggg	gtc	2895
	Val	Pro	Tyr	Arg	Asn	Ser	Leu	Arg	Lys	Ala	His	Ile	Phe	Gly	Val	Ser	
	930				935					940							
70	ttt	tct	atc	acc	cag	gca	atg	atg	tat	ttt	tcc	tat	gtc	ggc	tgt	ttc	2943

Phe Ser Ile Thr Gln Ala Met Met Tyr Phe Ser Tyr Ala Gly Cys Phe
945 950 955

5	Arg Phe Gly Ala Tyr Leu Val Ala Asn Glu Phe Met Asn Phe Gln Asp 960 965 970	2991
10	gtt ctt ttg gta ttc tca gct att gtc ttt ggt gcc atg gca gtg ggg Val Leu Leu Val Phe Ser Ala Ile Val Phe Gly Ala Met Ala Val Gly 975 980 985 990	3039
	cag gtc agt tca ttt gct cct gac tat gcc aaa gcc aaa gta tca gca Gln Val Ser Ser Phe Ala Pro Asp Tyr Ala Lys Ala Lys Val Ser Ala 995 1000 1005	3087
15	gcc cac gtc atc atg atc att gaa aaa agc cct ctg att gac agc tac Ala His Val Ile Met Ile Ile Glu Lys Ser Pro Leu Ile Asp Ser Tyr 1010 1015 1020	3135
20	agc cct cac ggc ctc aag cca aat acg ttg gaa gga aat gtg aca ttt Ser Pro His Gly Leu Lys Pro Asn Thr Leu Glu Gly Asn Val Thr Phe 1025 1030 1035	3183
25	aat gag gtc gtg ttc aac tat ccc act cga cca gac atc ccc gtg ctc Asn Glu Val Val Phe Asn Tyr Pro Thr Arg Pro Asp Ile Pro Val Leu 1040 1045 1050	3231
30	cag ggg ctg agc ctc gag gtg aag aag ggc cag acg ctg gcc ctc gta Gln Gly Leu Ser Leu Glu Val Lys Lys Gly Gln Thr Leu Ala Leu Val 1055 1060 1065 1070	3279
	ggt agc agt ggc tgt ggg aag agc aca gtt gtt cag ctc cta gag cgc Gly Ser Ser Gly Cys Gly Lys Ser Thr Val Val Gln Leu Leu Glu Arg 1075 1080 1085	3327
35	ttc tat gac ccc ttg gct ggt tca gtg cta att gat ggc aaa gag ata Phe Tyr Asp Pro Leu Ala Gly Ser Val Leu Ile Asp Gly Lys Glu Ile 1090 1095 1100	3375
40	aag cac ctg aat gtc cag tgg ctc cga gca cac ctg ggc atc gtg tct Lys His Leu Asn Val Gln Trp Leu Arg Ala His Leu Gly Ile Val Ser 1105 1110 1115	3423
45	cag gag ccc atc ctg ttt gac tgc agc att gcc gag aac att gcc tat Gln Glu Pro Ile Leu Phe Asp Cys Ser Ile Ala Glu Asn Ile Ala Tyr 1120 1125 1130	3471
50	gga gac aac agc cgg gtc gta tca cat gaa gag att atg cag gca gcc Gly Asp Asn Ser Arg Val Val Ser His Glu Glu Ile Met Gln Ala Ala 1135 1140 1145 1150	3519
	aag gag gcc aac ata cac cac ttc atc gag aca ctc cct gag aaa tac Lys Glu Ala Asn Ile His His Phe Ile Glu Thr Leu Pro Glu Lys Tyr 1155 1160 1165	3567
55	aac acc aga gta gga gac aaa gga acc cag ctc tct ggt ggc cag aaa Asn Thr Arg Val Gly Asp Lys Gly Thr Gln Leu Ser Gly Gly Gln Lys 1170 1175 1180	3615
60	cag cgc att gcc ata gct cgc gct ctt gtt aga cag cct cat att ttg	3663

Gln Arg Ile Ala Ile Ala Arg Ala Leu Val Arg Gln Pro His Ile Leu
 1185 1190 1195

5 ctt ttg gat gaa gct aca tca gct ctg gat aca gaa agt gaa aag gtt 3711
 Leu Leu Asp Glu Ala Thr Ser Ala Leu Asp Thr Glu Ser Glu Lys Val
 1200 1205 1210

10 gtc caa gaa gcc ctg gac aaa gcc aga gaa ggc cgc acc tgc att gtg 3759
 Val Gin Glu Ala Leu Asp Lys Ala Arg Glu Gly Arg Thr Cys Ile Val
 1215 1220 1225 1230

15 atc gcc cac cgc ttg tcc acc atc cag aat gca gat tta ata gtg gtg 3807
 Ile Ala His Arg Leu Ser Thr Ile Gln Asn Ala Asp Leu Ile Val Val
 1235 1240 1245

20 ttt cag aat ggc aaa gtc aag gag cat ggc aca cat caa cag ctg ctg 3855
 Phe Gln Asn Gly Lys Val Lys Glu His Gly Thr His Gln Gln Leu Leu
 1250 1255 1260

25 aag cgc tag tgaactgtgg ccatatgagc tggtaataat tttttataat 3952
 Lys Arg
 1280

30 ttgtgttaaa acatggcatt taatcaaagt taaaaggta gcaacttactg gaaaaactat 4012
 gtgaaactac ctgtttaaca ttctctgtgtc caactgaaat tcatccacc aagtccagag 4072
 ttctcaggat ttataatcaa aggaacccaa agaaacatca tctgtatggaa taaaatgtt 4132
 gtgttaattt cattataaaa ttatagata attcaaagtta attgtttgttataaaatgtt 4192
 taatttttgtt ttatataat tttgttaactt actgtcttcg tggaaagatata tagaaatgtt 4252
 aaaaatgttactt gaatgttgg ataaatgttactt agctatataaaatcaatcaatataat 4312
 aaaaaa 1

35 <210> 4
 <211> 1280
 <212> PRT
 <213> Canis familiaris

40 <400> 4
 Met Asp Pro Glu Gly Gly Arg Lys Gly Ser Ala Glu Lys Asn Phe Trp
 1 5 10 15
 Lys Met Gly Lys Lys Ser Lys Lys Glu Lys Lys Glu Lys Pro Thr
 20 25 30
 Val Ser Thr Phe Ala Met Phe Arg Tyr Ser Asn Trp Leu Asp Arg Leu
 35 40 45
 Tyr Met Leu Val Gly Thr Met Ala Ala Ile Ile His Gly Ala Ala Leu
 50 55 60

45 Pro Leu Met Met Leu Val Phe Gly Asn Met Thr Asp Ser Phe Ala Asn
 65 70 75 80
 Ala Gly Ile Ser Arg Asn Lys Thr Phe Pro Val Ile Ile Asn Glu Ser
 85 90 95
 Ile Thr Asn Asn Thr Gln His Phe Ile Asn His Leu Glu Glu Met
 100 105 110
 Thr Thr Tyr Ala Tyr Tyr Tyr Ser Gly Ile Gly Ala Gly Val Leu Val
 115 120 125
 Ala Ala Tyr Ile Gln Val Ser Phe Trp Cys Leu Ala Ala Gly Arg Gln
 130 135 140
 60 Ile Leu Lys Ile Arg Lys Gln Phe Phe His Ala Ile Met Arg Gln Glu

145	150	155	160
Ile Gly Trp Phe Asp Val His Asp Val	Gly Glu Leu Asn Thr Arg Leu		
165	170	175	
Thr Asp Asp Val Ser Lys Ile Asn Glu	Gly Ile Gly Asp Lys Val Gly		
180	185	190	
Met Phe Phe Gln Ser Ile Ala Thr Phe	Phe Thr Gly Phe Ile Val Gly		
195	200	205	
Phe Thr Pro Gly Trp Lys Leu Thr Leu	Val Ile Leu Ala Ile Ser Pro		
210	215	220	
10 Val Leu Gly Leu Ser Ala Ala Ile	Trp Ala Lys Ile Leu Ser Ser Phe		
225	230	235	240
Thr Asp Lys Glu Leu Leu Ala Tyr Ala	Lys Ala Gly Ala Val Ala Glu		
245	250	255	
Glu Val Leu Ala Ala Ile Arg Thr Val	Ile Ala Phe Gly Gly Gln Lys		
260	265	270	
Lys Glu Leu Glu Arg Tyr Asn Lys	Asn Leu Glu Glu Ala Lys Arg Ile		
275	280	285	
Gly Ile Lys Lys Ala Ile Thr Ala Asn	Ile Ser Ile Gly Ala Ala Phe		
290	295	300	
20 Leu Leu Ile Tyr Ala Ser Tyr Ala	Leu Ala Phe Trp Tyr Gly Thr Ser		
305	310	315	320
Leu Val Leu Ser Ser Glu Tyr Thr Ile	Gly Gln Val Leu Thr Val Phe		
325	330	335	
25 Phe Ser Val Leu Ile Gly Ala Phe	Ser Ile Gly Gln Ala Ser Pro Ser		
340	345	350	
Ile Glu Ala Phe Ala Asn Ala Arg	Gly Ala Ala Tyr Glu Ile Phe Lys		
355	360	365	
Ile Ile Asp Asn Lys Pro Ser Ile Asp	Ser Tyr Ser Lys Ser Gly His		
370	375	380	
30 Lys Pro Asp Asn Ile Lys Gly Asn	Leu Glu Phe Lys Asn Val His Phe		
385	390	395	400
Ser Tyr Pro Ser Arg Lys Glu Val Lys	Ile Leu Lys Gly Leu Asn Leu		
405	410	415	
35 Lys Val Gln Ser Gly Gln Thr Val	Ala Leu Val Gly Asn Ser Gly Cys		
420	425	430	
Gly Lys Ser Thr Thr Val Gln Leu Met	Gln Arg Leu Tyr Asp Pro Thr		
435	440	445	
Asp Gly Met Val Cys Ile Asp Gly Gln	Asp Ile Arg Thr Ile Asn Val		
450	455	460	
40 Arg His Leu Arg Glu Ile Thr Gly Val	Val Ser Gln Glu Pro Val Leu		
465	470	475	480
Phe Ala Thr Thr Ile Ala Glu Asn	Ile Arg Tyr Gly Arg Glu Asn Val		
485	490	495	
45 Thr Met Asp Glu Ile Glu Lys Ala Val	Lys Glu Ala Asn Ala Tyr Asp		
500	505	510	
Phe Ile Met Lys Leu Pro Asn Lys Phe	Asp Thr Leu Val Gly Glu Arg		
515	520	525	
Gly Ala Arg Leu Ser Gly Gly Gln	Lys Gln Arg Ile Ala Ile Ala Arg		
530	535	540	
50 Ala Leu Val Arg Asn Pro Lys Ile	Leu Leu Asp Glu Ala Thr Ser		
545	550	555	560
Ala Leu Asp Thr Glu Ser Glu Ala Val	Val Val Gln Val Ala Leu Asp Lys		
565	570	575	
Ala Arg Lys Gly Arg Thr Thr Ile Val	Ile Ala His Arg Leu Ser Thr		
580	585	590	
Val Arg Asn Ala Asp Val Ile Ala	Gly Phe Asp Asp Gly Val Ile Val		
595	600	605	
Glu Lys Gly Asn His Asp Glu Leu Met	Lys Glu Lys Gly Ile Tyr Phe		
610	615	620	
60 Lys Leu Val Thr Met Gln Thr Arg	Gly Asn Glu Ile Glu Leu Asn		

625	630	635	640
Ala Thr Gly Glu Ser Lys Ser Glu Ser Asp Ala Leu Glu Met Ser Pro			
645	650	655	655
Lys Asp Ser Gly Ser Ser Leu Ile Lys Arg Arg Ser Thr Arg Arg Ser			
660	665	670	670
Ile His Ala Pro Gln Gly Gln Asp Arg Lys Leu Gly Thr Lys Glu Asp			
675	680	685	685
Leu Asn Glu Asn Val Pro Ser Val Ser Phe Trp Arg Ile Leu Lys Leu			
690	695	700	700
10 Asn Ser Thr Glu Trp Pro Tyr Phe Val Val Gly Ile Phe Cys Ala Ile			
705	710	715	720
Ile Asn Gly Gly Leu Gln Pro Ala Phe Ser Ile Ile Phe Ser Arg Ile			
725	730	735	735
Ile Gly Ile Phe Thr Arg Asp Glu Asp Pro Glu Thr Lys Arg Gln Asn			
15 740	745	750	750
Ser Asn Met Phe Ser Val Leu Phe Leu Val Leu Gly Ile Ile Ser Phe			
755	760	765	765
Ile Thr Phe Phe Leu Gln Gly Phe Thr Phe Gly Lys Ala Gly Glu Ile			
770	775	780	780
20 Leu Thr Lys Arg Leu Arg Tyr Met Val Phe Arg Ser Met Leu Arg Gln			
785	790	795	800
Asp Val Ser Trp Phe Asp Asp Pro Lys Asn Thr Thr Gly Ala Leu Thr			
805	810	815	815
25 Thr Arg Leu Ala Asn Asp Ala Ala Gln Val Lys Gly Ala Ile Gly Ser			
820	825	830	830
Arg Leu Ala Val Ile Thr Gln Asn Ile Ala Asn Leu Gly Thr Gly Ile			
835	840	845	845
Ile Ile Ser Leu Ile Tyr Gly Trp Gln Leu Thr Leu Leu Leu Ala			
850	855	860	860
30 Ile Val Pro Ile Ile Ala Ile Ala Gly Val Val Glu Met Lys Met Leu			
865	870	875	880
Ser Gly Gln Ala Leu Lys Asp Lys Lys Glu Leu Glu Gly Ala Gly Lys			
885	890	895	895
Ile Ala Thr Glu Ala Ile Glu Asn Phe Arg Thr Val Val Ser Leu Thr			
900	905	910	910
Arg Glu Gln Lys Phe Glu Tyr Met Tyr Ala Gln Ser Leu Gln Val Pro			
915	920	925	925
Tyr Arg Asn Ser Leu Arg Lys Ala His Ile Phe Gly Val Ser Phe Ser			
930	935	940	940
40 Ile Thr Gln Ala Met Met Tyr Phe Ser Tyr Ala Gly Cys Phe Arg Phe			
945	950	955	960
Gly Ala Tyr Leu Val Ala Asn Glu Phe Met Asn Phe Gln Asp Val Leu			
965	970	975	975
Leu Val Phe Ser Ala Ile Val Phe Gly Ala Met Ala Val Gly Gln Val			
980	985	990	990
45 Ser Ser Phe Ala Pro Asp Tyr Ala Lys Ala Lys Val Ser Ala Ala His			
995	1000	1005	1005
Val Ile Met Ile Ile Glu Lys Ser Pro Leu Ile Asp Ser Tyr Ser Pro			
1010	1015	1020	1020
50 His Gly Leu Lys Pro Asn Thr Leu Glu Gly Asn Val Thr Phe Asn Glu			
1025	1030	1035	1040
Val Val Phe Asn Tyr Pro Thr Arg Pro Asp Ile Pro Val Leu Gln Gly			
1045	1050	1055	1055
Leu Ser Leu Glu Val Lys Lys Gly Gln Thr Leu Ala Leu Val Gly Ser			
1060	1065	1070	1070
55 Ser Gly Cys Gly Lys Ser Thr Val Val Gln Leu Leu Glu Arg Phe Tyr			
1075	1080	1085	1085
Asp Pro Leu Ala Gly Ser Val Leu Ile Asp Gly Lys Glu Ile Lys His			
1090	1095	1100	1100
60 Leu Asn Val Gln Trp Leu Arg Ala His Leu Gly Ile Val Ser Gln Glu			

1105	1110	1115	1120
Pro Ile Leu Phe Asp Cys Ser Ile Ala Glu Asn Ile Ala Tyr Gly Asp			
1125	1130	1135	
Asn Ser Arg Val Val Ser His Glu Glu Ile Met Gln Ala Ala Lys Glu			
5 1140	1145	1150	
Ala Asn Ile His His Phe Ile Glu Thr Leu Pro Glu Lys Tyr Asn Thr			
1155	1160	1165	
Arg Val Gly Asp Lys Gly Thr Glu Ser Gly Gly Gln Lys Gln Arg			
1170	1175	1180	
10 Ile Ala Ile Ala Arg Ala Leu Val Arg Gln Pro His Ile Leu Leu			
1185	1190	1195	1200
Asp Glu Ala Thr Ser Ala Leu Asp Thr Glu Ser Glu Lys Val Val Gln			
1205	1210	1215	
Glu Ala Leu Asp Lys Ala Arg Glu Gly Arg Thr Cys Ile Val Ile Ala			
1220	1225	1230	
His Arg Leu Ser Thr Ile Gln Asn Ala Asp Leu Ile Val Val Phe Gln			
1235	1240	1245	
Asn Gly Lys Val Lys Glu His Gly Thr His Gln Gln Leu Leu Ala Gln			
1250	1255	1260	
20 Lys Gly Ile Tyr Phe Ser Met Ile Ser Val Gln Ala Gly Ala Lys Arg			
1265	1270	1275	1280

<210> 5
 <211> 1107
 <212> DNA
 <213> Canis familiaris

<220>
 <221> CDS
 30 <222> (1)....(1107)

4000 5			
acg tca gct ctg gac act gaa agt gaa gca gtc gtt cag gtc gcc ctg			
Thr Ser Ala Leu Asp Thr Glu Ser Glu Ala Val Val Gln Val Ala Leu			
35 1 5 10 15			
gat aag gcc aga aaa ggc cgg act acc att gtc ata gct cat cgt ttg			
Asp Lys Ala Arg Lys Gly Arg Thr Thr Ile Val Ile Ala His Arg Leu			
20 25 30			
40 tct aca gtt cgt aat gcc gat gtc att gct ggt ttt gat gat gga gtc			
Ser Thr Val Arg Asn Ala Asp Val Ile Ala Gly Phe Asp Asp Gly Val			
35 40 45			
45 att gtg gag aaa gga aat cat gat gaa ctc atg aag gaa ggc att			
Ile Val Glu Lys Gly Asn His Asp Glu Leu Met Lys Glu Lys Gly Ile			
50 55 60			
50 tac ttc aaa ctt gtc aca atg cag aca aga gga aat gaa att gac tta			
Tyr Phe Lys Leu Val Thr Met Gln Thr Arg Gly Asn Glu Ile Asp Leu			
55 65 70 75 80			
55 gaa aat gcc act ggt gaa tcc aaa aat gaa aat gat gcc ttg gaa atg			
Glu Asn Ala Thr Gly Glu Ser Lys Ser Glu Ser Asp Ala Leu Glu Met			
65 85 90 95			
55 tct cca aaa gat tca ggg tcc aat gaa aat gat gca ttg gaa atg			
Ser Pro Lys Asp Ser Gly Ser Ser Leu Ile Lys Arg Arg Ser Thr Arg			
100 105 110			

agg agt ata cat gca cca caa ggc caa gac aga aag ctt ggt aca aaa	384
Arg Ser Ile His Ala Pro Gln Gly Gin Asp Arg Lys Leu Gly Thr Lys	
115 120 125	
5 gag gac ttg aat gag aat gta cct cca gtt tcc ttc tgg agg att ctg	432
Glu Asp Leu Asn Glu Asn Val Pro Pro Val Ser Phe Trp Arg Ile Leu	
130 135 140	
10 aag ctg aac tca act gaa tgg cct tat ttt gtg gtt ggt ata ttt tgt	480
Lys Leu Asn Ser Thr Glu Trp Pro Tyr Phe Val Val Gly Ile Phe Cys	
145 150 155 160	
15 gct att ata aac gga ggc ctg cag cca gca ttt tca ata ata ttt tca	528
Ala Ile Ile Asn Gly Gly Leu Gln Pro Ala Phe Ser Ile Ile Phe Ser	
165 170 175	
20 agg att ata ggg atc ttt acc cga gat gag gat cct gaa aca aaa cga	576
Arg Ile Ile Gly Ile Phe Thr Arg Asp Glu Asp Pro Glu Thr Lys Arg	
180 185 190	
cag att agt aac atg ttt tct gta ttg ttt cta gtc ctt gga att att	624
Gln Ile Ser Asn Met Phe Ser Val Leu Phe Leu Val Leu Gly Ile Ile	
195 200 205	
25 tct ttt att aca ttt ttc ctt cag ggt ttc aca ttt ggc aaa gct gga	672
Ser Phe Ile Thr Phe Phe Leu Gln Gly Phe Thr Phe Gly Lys Ala Gly	
210 215 220	
30 gag atc ctc act aag cgg ctt cga tac atg gtt ttc aga tcc atg ctg	720
Glu Ile Leu Thr Lys Arg Leu Arg Tyr Met Val Phe Arg Ser Met Leu	
225 230 235 240	
35 aga cag gat gtc agc tgg ttt gat gac ctt aaa aac acc act gga gca	768
Arg Gln Asp Val Ser Trp Phe Asp Asp Leu Lys Asn Thr Thr Gly Ala	
245 250 255	
40 ttg acc acc agg ctt gcc aat gat gct gct caa gtt aaa ggg gct ata	816
Leu Thr Thr Arg Leu Ala Asn Asp Ala Ala Gln Val Lys Gly Ala Ile	
260 265 270	
45 ggt tcc agg ctt gct gtc att acc cag aat ata gca aat ctt ggg aca	864
Gly Ser Arg Leu Ala Val Ile Thr Gln Asn Ile Ala Asn Leu Gly Thr	
275 280 285	
50 tta gca att gta ccc atc att gca ata gca gga gtt gtt gaa atg aaa	960
Leu Ala Ile Val Pro Ile Ile Ala Ile Ala Gly Val Val Glu Met Lys	
305 310 315 320	
55 atg ttg tct gga caa gca ctg aaa gat aag aaa gag cta gaa gga gct	1008
Met Leu Ser Gly Gln Ala Leu Lys Asp Lys Lys Glu Leu Glu Gly Ala	
325 330 335	
ggg aag att gct aca gaa gcc atc gaa aac ttc cga act gtt gtt tct	1056
Gly Lys Ile Ala Thr Glu Ala Ile Glu Asn Phe Arg Thr Val Val Ser	
340 345 350	

ttg act cag gag cag aag ttt gaa cac atg tat gca cag agt ttg cag	1104		
Leu Thr Gln Glu Gln Lys Phe Glu His Met Tyr Ala Gln Ser Leu Gln			
355	360		365
	365		

5 gta	1107
<210> 6 <211> 368 <212> PRT 10 <213> Canis familiaris	
<400> 6 Thr Ser Ala Leu Asp Thr Glu Ser Glu Ala Val Val Gln Val Ala Leu 1 5 10 15 15 Asp Lys Ala Arg Lys Gly Arg Thr Thr Ile Val Ile Ala His Arg Leu 20 25 30 Ser Thr Val Arg Asn Ala Asp Val Ile Ala Gly Phe Asp Asp Gly Val 35 40 45 Ile Val Glu Lys Gly Asn His Asp Glu Leu Met Lys Glu Lys Gly Ile 20 50 55 60 Tyr Phe Lys Leu Val Thr Met Gln Thr Arg Gly Asn Glu Ile Asp Leu 65 70 75 80 Glu Asn Ala Thr Gly Glu Ser Lys Ser Glu Ser Asp Ala Leu Glu Met 85 90 95 25 Ser Pro Lys Asp Ser Gly Ser Ser Leu Ile Lys Arg Arg Ser Thr Arg 100 105 110 Arg Ser Ile His Ala Pro Gln Gly Gln Asp Arg Lys Leu Gly Thr Lys 115 120 125 Glu Asp Leu Asn Glu Asn Val Pro Pro Val Ser Phe Trp Arg Ile Leu 130 135 140 30 Lys Leu Asn Ser Thr Glu Trp Pro Tyr Phe Val Val Gly Ile Phe Cys 145 150 155 160 Ala Ile Ile Asn Gly Gly Leu Gln Pro Ala Phe Ser Ile Ile Phe Ser 165 170 175 35 Arg Ile Ile Gly Ile Phe Thr Arg Asp Glu Asp Pro Glu Thr Lys Arg 180 185 190 Gln Ile Ser Asn Met Phe Ser Val Leu Phe Leu Val Leu Gly Ile Ile 195 200 205 40 Ser Phe Ile Thr Phe Phe Leu Gln Gly Phe Thr Phe Gly Lys Ala Gly 210 215 220 Glu Ile Leu Thr Lys Arg Leu Arg Tyr Met Val Phe Arg Ser Met Leu 225 230 235 240 Arg Gln Asp Val Ser Trp Phe Asp Asp Leu Lys Asn Thr Thr Gly Ala 245 250 255 45 Leu Thr Thr Arg Leu Ala Asn Asp Ala Ala Gln Val Lys Gly Ala Ile 260 265 270 Gly Ser Arg Leu Ala Val Ile Thr Gln Asn Ile Ala Asn Leu Gly Thr 275 280 285 50 Gly Ile Ile Ile Ser Leu Ile Tyr Gly Trp Gln Leu Thr Leu Leu 290 295 300 Leu Ala Ile Val Pro Ile Ile Ala Ile Ala Gly Val Val Glu Met Lys 305 310 315 320 Met Leu Ser Gly Gln Ala Leu Lys Asp Lys Lys Glu Leu Glu Gly Ala 325 330 335 55 Gly Lys Ile Ala Thr Glu Ala Ile Glu Asn Phe Arg Thr Val Val Ser 340 345 350 Leu Thr Gln Glu Gln Lys Phe Glu His Met Tyr Ala Gln Ser Leu Gln 355 360 365	
60 <210> 7	

<211> 1280
<212> PRT
<213> Homo sapiens

5 <400> 7
Met Asp Leu Glu Gly Asp Arg Asn Gly Gly Ala Lys Lys Lys Asn Phe
1 5 10 15
Phe Lys Leu Asn Asn Lys Ser Glu Lys Asp Lys Lys Glu Lys Lys Pro
20 25 30
10 Thr Val Ser Val Phe Ser Met Phe Arg Tyr Ser Asn Trp Leu Asp Lys
35 40 45
Leu Tyr Met Val Val Gly Thr Leu Ala Ala Ile Ile His Gly Ala Gly
50 55 60
Leu Pro Leu Met Met Leu Val Phe Gly Glu Met Thr Asp Ile Phe Ala
15 65 70 75 80
Asn Ala Gly Asn Leu Glu Asp Leu Met Ser Asn Ile Thr Asn Arg Ser
85 90 95
Asp Ile Asn Asp Thr Gly Phe Phe Met Asn Leu Glu Glu Asp Met Thr
100 105 110
20 Arg Tyr Ala Tyr Tyr Tyr Ser Gly Ile Gly Ala Gly Val Leu Val Ala
115 120 125
Ala Tyr Ile Gln Val Ser Phe Trp Cys Leu Ala Ala Gly Arg Gln Ile
130 135 140
25 His Lys Ile Arg Lys Gln Phe Phe His Ala Ile Met Arg Gln Glu Ile
145 150 155 160
Gly Trp Phe Asp Val His Asp Val Gly Glu Leu Asn Thr Arg Leu Thr
165 170 175
Asp Asp Val Ser Lys Ile Asn Glu Val Ile Gly Asp Lys Ile Gly Met
180 185 190
30 Phe Phe Gln Ser Met Ala Thr Phe Phe Thr Gly Phe Ile Val Gly Phe
195 200 205
Thr Arg Gly Trp Lys Leu Thr Leu Val Ile Leu Ala Ile Ser Pro Val
210 215 220
35 Leu Gly Leu Ser Ala Ala Val Trp Ala Lys Ile Leu Ser Ser Phe Thr
225 230 235 240
Asp Lys Glu Leu Leu Ala Tyr Ala Lys Ala Gly Ala Val Ala Glu Glu
245 250 255
Val Leu Ala Ala Ile Arg Thr Val Ile Ala Phe Gly Gln Lys Lys
260 265 270
40 Glu Leu Glu Arg Tyr Asn Lys Asn Leu Glu Glu Ala Lys Arg Ile Gly
275 280 285
Ile Lys Lys Ala Ile Thr Ala Asn Ile Ser Ile Gly Ala Ala Phe Leu
290 295 300
Leu Ile Tyr Ala Ser Tyr Ala Leu Ala Phe Trp Tyr Gly Thr Thr Leu
45 305 310 315 320
Val Leu Ser Gly Glu Tyr Ser Ile Gly Gln Val Leu Thr Val Phe Phe
325 330 335
Ser Val Leu Ile Gly Ala Phe Ser Val Gly Gln Ala Ser Pro Ser Ile
340 345 350
50 Glu Ala Phe Ala Asn Ala Arg Gly Ala Ala Tyr Glu Ile Phe Lys Ile
355 360 365
Ile Asp Asn Lys Pro Ser Ile Asp Ser Tyr Ser Lys Ser Gly His Lys
370 375 380
Pro Asp Asn Ile Lys Gly Asn Leu Glu Phe Arg Asn Val His Phe Ser
385 390 395 400
Tyr Pro Ser Arg Lys Glu Val Lys Ile Leu Lys Gly Leu Asn Leu Lys
405 410 415
Val Gln Ser Gly Gln Thr Val Ala Leu Val Gly Asn Ser Gly Cys Gly
420 425 430
60 Lys Ser Thr Thr Val Gln Leu Met Gln Arg Leu Tyr Asp Pro Thr Glu

	435	440	445	
	Gly Met Val Ser Val Asp Gly Gln Asp Ile Arg Thr Ile Asn Val Arg			
	450	455	460	
5	Phe Leu Arg Glu Ile Ile Gly Val Val Ser Gln Glu Pro Val Leu Phe			
	465	470	475	480
	Ala Thr Thr Ile Ala Glu Asn Ile Arg Tyr Gly Arg Glu Asn Val Thr			
	485	490	495	
	Met Asp Glu Ile Glu Lys Ala Val Lys Glu Ala Asn Ala Tyr Asp Phe			
10	500	505	510	
	Ile Met Lys Leu Pro His Lys Phe Asp Thr Leu Val Gly Glu Arg Gly			
	515	520	525	
	Ala Gln Leu Ser Gly Gly Gln Lys Gln Arg Ile Ala Ile Ala Arg Ala			
	530	535	540	
15	Leu Val Arg Asn Pro Lys Ile Leu Leu Leu Asp Glu Ala Thr Ser Ala			
	545	550	555	560
	Leu Asp Thr Glu Ser Glu Ala Val Val Gln Val Ala Leu Asp Lys Ala			
	565	570	575	
	Arg Lys Gly Arg Thr Thr Ile Val Ile Ala His Arg Leu Ser Thr Val			
	580	585	590	
20	Arg Asn Ala Asp Val Ile Ala Gly Phe Asp Asp Gly Val Ile Val Glu			
	595	600	605	
	Lys Gly Asn His Asp Glu Leu Met Lys Glu Lys Gly Ile Tyr Phe Lys			
	610	615	620	
25	Leu Val Thr Met Gln Thr Ala Gly Asn Glu Val Glu Leu Glu Asn Ala			
	625	630	635	640
	Ala Asp Glu Ser Lys Ser Glu Ile Asp Ala Leu Glu Met Ser Ser Asn			
	645	650	655	
	Asp Ser Arg Ser Ser Leu Ile Arg Lys Arg Ser Thr Arg Arg Ser Val			
	660	665	670	
30	Arg Gly Ser Gln Ala Gln Asp Arg Lys Leu Ser Thr Lys Glu Ala Leu			
	675	680	685	
	Asp Glu Ser Ile Pro Pro Val Ser Phe Trp Arg Ile Met Lys Leu Asn			
	690	695	700	
	Leu Thr Glu Trp Pro Tyr Phe Val Val Gly Val Phe Cys Ala Ile Ile			
35	705	710	715	720
	Asn Gly Gly Leu Gln Pro Ala Phe Ala Ile Ile Phe Ser Lys Ile Ile			
	725	730	735	
	Gly Val Phe Thr Arg Ile Asp Asp Pro Glu Thr Lys Arg Gln Asn Ser			
	740	745	750	
40	Asn Leu Phe Ser Leu Leu Phe Leu Ala Leu Gly Ile Ile Ser Phe Ile			
	755	760	765	
	Thr Phe Phe Leu Gln Gly Phe Thr Phe Gly Lys Ala Gly Glu Ile Leu			
	770	775	780	
	Thr Lys Arg Leu Arg Tyr Met Val Phe Arg Ser Met Leu Arg Gln Asp			
45	785	790	795	800
	Val Ser Trp Phe Asp Asp Pro Lys Asn Thr Thr Gly Ala Leu Thr Thr			
	805	810	815	
	Arg Leu Ala Asn Asp Ala Ala Gln Val Lys Gly Ala Ile Gly Ser Arg			
	820	825	830	
50	Leu Ala Val Ile Thr Gln Asn Ile Ala Asn Leu Gly Thr Gly Ile Ile			
	835	840	845	
	Ile Ser Phe Ile Tyr Gly Trp Gln Leu Thr Leu Leu Leu Ala Ile			
	850	855	860	
	Val Pro Ile Ile Ala Ile Ala Gly Val Val Glu Met Lys Met Leu Ser			
55	865	870	875	880
	Gly Gln Ala Leu Lys Asp Lys Lys Glu Leu Glu Gly Ala Gly Lys Ile			
	885	890	895	
	Ala Thr Glu Ala Ile Glu Asn Phe Arg Thr Val Val Ser Leu Thr Gln			
	900	905	910	
60	Glu Gln Lys Phe Glu His Met Tyr Ala Gln Ser Leu Gln Val Pro Tyr			

	915	920	925		
Arg Asn Ser Leu Arg Lys Ala His Ile Phe Gly Ile Thr Phe Ser Phe	930	935	940		
5	945	950	955	960	
Thr Gln Ala Met Met Tyr Phe Ser Tyr Ala Gly Cys Phe Arg Phe Gly	950	955	960		
Ala Tyr Leu Val Ala His Lys Leu Met Ser Phe Glu Asp Val Leu Leu	965	970	975		
965	970	975			
Val Phe Ser Ala Val Val Phe Gly Ala Met Ala Val Gly Gln Val Ser	980	985	990		
980	985	990			
10	Ser Phe Ala Pro Asp Tyr Ala Lys Ala Lys Ile Ser Ala Ala His Ile	995	1000	1005	
Ile Met Ile Ile Glu Lys Thr Pro Leu Ile Asp Ser Tyr Ser Thr Glu	1010	1015	1020		
15	Gly Leu Met Pro Asn Thr Leu Glu Gly Asn Val Thr Phe Gly Glu Val	1025	1030	1035	1040
Val Phe Asn Tyr Pro Thr Arg Pro Asp Ile Pro Val Leu Gln Gly Leu	1045	1050	1055		
Ser Leu Glu Val Lys Gly Gln Thr Leu Ala Leu Val Gly Ser Ser	1060	1065	1070		
20	Gly Cys Gly Lys Ser Thr Val Val Gln Leu Leu Glu Arg Phe Tyr Asp	1075	1080	1085	
Pro Leu Ala Gly Lys Val Leu Leu Asp Gly Lys Glu Ile Lys Arg Leu	1090	1095	1100		
25	Asn Val Gln Trp Leu Arg Ala His Leu Gly Ile Val Ser Gln Glu Pro	1105	1110	1115	1120
Ile Leu Phe Asp Cys Ser Ile Ala Glu Asn Ile Ala Tyr Gly Asp Asn	1125	1130	1135		
Ser Arg Val Val Ser Gln Glu Glu Ile Val Arg Ala Ala Lys Glu Ala	1140	1145	1150		
30	Asn Ile His Ala Phe Ile Glu Ser Leu Pro Asn Lys Tyr Ser Thr Lys	1155	1160	1165	
Val Gly Asp Lys Gly Thr Gln Leu Ser Gly Gly Gln Lys Gln Arg Ile	1170	1175	1180		
35	Ala Ile Ala Arg Ala Leu Val Arg Gln Pro His Ile Leu Leu Asp	1185	1190	1195	1200
Glu Ala Thr Ser Ala Leu Asp Thr Glu Ser Glu Lys Val Val Gln Glu	1205	1210	1215		
Ala Leu Asp Lys Ala Arg Glu Gly Arg Thr Cys Ile Val Ile Ala His	1220	1225	1230		
40	Arg Leu Ser Thr Ile Gln Asn Ala Asp Leu Ile Val Val Phe Gln Asn	1235	1240	1245	
Gly Arg Val Lys Glu His Gly Thr His Gln Gln Leu Leu Ala Gln Lys	1250	1255	1260		
Gly Ile Tyr Phe Ser Met Val Ser Val Gln Ala Gly Thr Lys Arg Gln	1265	1270	1275	1280	
45	<210> 8				
<211> 1279					
<212> PRT					
50	<213> Homo sapiens				
	<400> 8				
Met Asp Leu Glu Gly Asp Arg Asn Gly Gly Ala Lys Lys Asn Phe	1	5	10	15	
55	Phe Lys Leu Asn Asn Lys Ser Glu Lys Asp Lys Lys Glu Lys Lys Pro	20	25	30	
Thr Val Ser Val Phe Ser Met Phe Arg Tyr Ser Asn Trp Leu Asp Lys	35	40	45		
Leu Tyr Met Val Val Gly Thr Leu Ala Ala Ile Ile His Gly Ala Gly	50	55	60		
60					

Leu Pro Leu Met Met Leu Val Phe Gly Glu Met Thr Asp Ile Phe Ala
 65 70 75 80
 Asn Ala Gly Asn Leu Glu Asp Leu Met Ser Asn Ile Thr Asn Arg Ser
 85 90 95
 5 Asp Ile Asn Asp Thr Gly Phe Met Asn Leu Glu Glu Asp Met Thr
 100 105 110
 Arg Tyr Ala Tyr Tyr Tyr Ser Gly Ile Gly Ala Gly Val Leu Val Ala
 115 120 125
 Ala Tyr Ile Gln Val Ser Phe Trp Cys Leu Ala Ala Gly Arg Gln Ile
 10 130 135 140
 His Lys Ile Arg Lys Gln Phe Phe His Ala Ile Met Arg Gln Glu Ile
 145 150 155 160
 Gly Trp Phe Asp Val His Asp Val Gly Glu Leu Asn Thr Arg Leu Thr
 165 170 175
 15 Asp Asp Val Ser Lys Ile Asn Glu Gly Ile Gly Asp Lys Ile Gly Met
 180 185 190
 Phe Phe Gln Ser Met Ala Thr Phe Phe Thr Gly Phe Ile Val Gly Phe
 195 200 205
 Thr Arg Gly Trp Lys Leu Thr Leu Val Ile Leu Ala Ile Ser Pro Val
 20 210 215 220
 Leu Gly Leu Ser Ala Ala Val Trp Ala Lys Ile Leu Ser Ser Phe Thr
 225 230 235 240
 Asp Lys Glu Leu Leu Ala Tyr Ala Lys Ala Gly Ala Val Ala Glu Glu
 245 250 255
 25 Val Leu Ala Ala Ile Arg Thr Val Ile Ala Phe Gly Gly Gln Lys Lys
 260 265 270
 Glu Leu Glu Arg Tyr Asn Lys Asn Leu Glu Glu Ala Lys Arg Ile Gly
 275 280 285
 Ile Lys Lys Ala Ile Thr Ala Asn Ile Ser Ile Gly Ala Ala Phe Leu
 30 290 295 300
 Leu Ile Tyr Ala Ser Tyr Ala Leu Ala Phe Trp Tyr Gly Thr Thr Leu
 305 310 315 320
 Val Leu Ser Gly Glu Tyr Ser Ile Gly Gin Val Leu Thr Val Phe Ser
 325 330 335
 35 Val Leu Ile Gly Ala Phe Ser Val Gly Gln Ala Ser Pro Ser Ile Glu
 340 345 350
 Ala Phe Ala Asn Ala Arg Gly Ala Ala Tyr Glu Ile Phe Lys Ile Ile
 355 360 365
 40 Asp Asn Lys Pro Ser Ile Asp Ser Tyr Ser Lys Ser Gly His Lys Pro
 370 375 380
 Asp Asn Ile Lys Gly Asn Leu Glu Phe Arg Asn Val His Phe Ser Tyr
 385 390 395 400
 Pro Ser Arg Lys Glu Val Lys Ile Leu Lys Gly Leu Asn Leu Lys Val
 405 410 415
 45 Gln Ser Gly Gln Thr Val Ala Leu Val Gly Asn Ser Gly Cys Gly Lys
 420 425 430
 Ser Thr Thr Val Gln Leu Met Gln Arg Leu Tyr Asp Pro Thr Glu Gly
 435 440 445
 50 Met Val Ser Val Asp Gly Gln Asp Ile Arg Thr Ile Asn Val Arg Phe
 450 455 460
 Leu Arg Glu Ile Ile Gly Val Val Ser Gln Glu Pro Val Leu Phe Ala
 465 470 475 480
 Thr Thr Ile Ala Glu Asn Ile Arg Tyr Gly Arg Glu Asn Val Thr Met
 485 490 495
 55 Asp Glu Ile Glu Lys Ala Val Lys Glu Ala Asn Ala Tyr Asp Phe Ile
 500 505 510
 Met Lys Leu Pro His Lys Phe Asp Thr Leu Val Gly Glu Arg Gly Ala
 515 520 525
 Gln Leu Ser Gly Gly Gln Lys Gln Arg Ile Ala Ile Ala Arg Ala Leu
 60 530 535 540

Val Arg Asn Pro Lys Ile Leu Leu Leu Asp Glu Ala Thr Ser Ala Leu
 545 550 555 560
 Asp Thr Glu Ser Glu Ala Val Val Gln Val Ala Leu Asp Lys Ala Arg
 565 570 575
 5 Lys Gly Arg Thr Thr Ile Val Ile Ala His Arg Leu Ser Thr Val Arg
 580 585 590
 Asn Ala Asp Val Ile Ala Gly Phe Asp Asp Gly Val Ile Val Glu Lys
 595 600 605
 Gly Asn His Asp Glu Leu Met Lys Glu Lys Gly Ile Tyr Phe Lys Leu
 10 610 615 620
 Val Thr Met Gln Thr Ala Gly Asn Glu Val Glu Leu Glu Asn Ala Ala
 625 630 635 640
 Asp Glu Ser Lys Ser Glu Ile Asp Ala Leu Glu Met Ser Ser Asn Asp
 645 650 655
 15 Ser Arg Ser Ser Leu Ile Arg Lys Arg Ser Thr Arg Arg Ser Val Arg
 660 665 670
 Gly Ser Gln Ala Gln Asp Arg Lys Leu Ser Thr Lys Glu Ala Leu Asp
 675 680 685
 Glu Ser Ile Pro Pro Val Ser Phe Trp Arg Ile Met Lys Leu Asn Leu
 20 690 695 700
 Thr Glu Trp Pro Tyr Phe Val Val Gly Val Phe Cys Ala Ile Ile Asn
 705 710 715 720
 Gly Gly Leu Gln Pro Ala Phe Ala Ile Ile Phe Ser Lys Ile Ile Gly
 725 730 735
 25 Val Phe Thr Arg Ile Asp Asp Pro Glu Thr Lys Arg Gln Asn Ser Asn
 740 745 750
 Leu Phe Ser Leu Leu Phe Leu Ala Leu Gly Ile Ile Ser Phe Ile Thr
 755 760 765
 Phe Phe Leu Gln Gly Phe Thr Phe Gly Lys Ala Gly Glu Ile Leu Thr
 770 775 780
 30 Lys Arg Leu Arg Tyr Met Val Phe Arg Ser Met Leu Arg Gln Asp Val
 785 790 795 800
 Ser Trp Phe Asp Asp Pro Lys Asn Thr Thr Gly Ala Leu Thr Thr Arg
 805 810 815
 35 Leu Ala Asn Asp Ala Ala Gln Val Lys Gly Ala Ile Gly Ser Arg Leu
 820 825 830
 Ala Val Ile Thr Gln Asn Ile Ala Asn Leu Gly Thr Gly Ile Ile Ile
 835 840 845
 40 Ser Phe Ile Tyr Gly Trp Gln Leu Thr Leu Leu Leu Ala Ile Val
 850 855 860
 Pro Ile Ile Ala Ile Ala Gly Val Val Glu Met Lys Met Leu Ser Gly
 865 870 875 880
 Gln Ala Leu Lys Asp Lys Lys Glu Leu Glu Gly Ala Gly Lys Ile Ala
 885 890 895
 45 Thr Glu Ala Ile Glu Asn Phe Arg Thr Val Val Ser Leu Thr Gln Glu
 900 905 910
 Gln Lys Phe Glu His Met Tyr Ala Gln Ser Leu Gln Val Pro Tyr Arg
 915 920 925
 50 Asn Ser Leu Arg Lys Ala His Ile Phe Gly Ile Thr Phe Ser Phe Thr
 930 935 940
 Gln Ala Met Met Tyr Phe Ser Tyr Ala Gly Cys Phe Arg Phe Gly Ala
 945 950 955 960
 Tyr Leu Val Ala His Lys Leu Met Ser Phe Glu Asp Val Leu Leu Val
 965 970 975
 55 Phe Ser Ala Val Val Phe Gly Ala Met Ala Val Gly Gln Val Ser Ser
 980 985 990
 Phe Ala Pro Asp Tyr Ala Lys Ala Lys Ile Ser Ala Ala His Ile Ile
 995 1000 1005
 60 Met Ile Ile Glu Lys Thr Pro Leu Ile Asp Ser Tyr Ser Thr Glu Gly
 1010 1015 1020

Leu Met Pro Asn Thr Leu Glu Gly Asn Val Thr Phe Gly Glu Val Val
 1025 1030 1035 1040

Phe Asn Tyr Pro Thr Arg Pro Asp Ile Pro Val Leu Gln Gly Leu Ser
 1045 1050 1055

5 Leu Glu Val Lys Lys Gly Gln Thr Leu Ala Leu Val Gly Ser Ser Gly
 1060 1065 1070

Cys Gly Lys Ser Thr Val Val Gln Leu Leu Glu Arg Phe Tyr Asp Pro
 1075 1080 1085

Leu Ala Gly Lys Val Leu Leu Asp Gly Lys Glu Ile Lys Arg Leu Asn
 1090 1095 1100

10 Val Gln Trp Leu Arg Ala His Leu Gly Ile Val Ser Gln Glu Pro Ile
 1105 1110 1115 1120

Leu Phe Asp Cys Ser Ile Ala Glu Asn Ile Ala Tyr Gly Asp Asn Ser
 1125 1130 1135

15 Arg Val Val Ser Gln Glu Glu Ile Val Arg Ala Ala Lys Glu Ala Asn
 1140 1145 1150

Ile His Ala Phe Ile Glu Ser Leu Pro Asn Lys Tyr Ser Thr Lys Val
 1155 1160 1165

20 Gly Asp Lys Gly Thr Gln Leu Ser Gly Gly Gln Lys Gln Arg Ile Ala
 1170 1175 1180

Ile Ala Arg Ala Leu Val Arg Gln Pro His Ile Leu Leu Leu Asp Glu
 1185 1190 1195 1200

Ala Thr Ser Ala Leu Asp Thr Glu Ser Glu Lys Val Val Gln Glu Ala
 1205 1210 1215

25 Leu Asp Lys Ala Arg Glu Gly Arg Thr Cys Ile Val Ile Ala His Arg
 1220 1225 1230

Leu Ser Thr Ile Gln Asn Ala Asp Leu Ile Val Val Phe Gln Asn Gly
 1235 1240 1245

30 Arg Val Lys Glu His Gly Thr His Gln Gln Leu Leu Ala Gln Lys Gly
 1250 1255 1260

Ile Tyr Phe Ser Met Val Ser Val Gln Ala Gly Thr Lys Arg Gln
 1265 1270 1275

<210> 9

<211> 24

<212> DNA

<213> Homo sapiens

<400> 9

40 gaactgtat tgcgttgg a ggac

24

<210> 10

<211> 22

<212> DNA

45 <213> Canis familiaris

<400> 10

ttcaggccg cctgtacctc tg

22

<210> 11

<211> 22

<212> DNA

<213> Canis familiaris

55 <400> 11

ccccacagat ggcatgtct gt

22

<210> 12

<211> 23

<212> DNA

60

	<213> Homo sapiens	
	<400> 12	
5	cgcttggtga ggatctctcc agc	23
	<210> 13	
	<211> 24	
	<212> DNA	
	<213> Canis familiaris	
10		
	<400> 13	24
	agaaaacagag aatcgccatt gctc	
	<210> 14	
15	<211> 23	
	<212> DNA	
	<213> Homo sapiens	
	<400> 14	
20	gctgcagtc aacaggatgg gct	23
	<210> 15	
	<211> 24	
25	<212> DNA	
	<213> Canis familiaris	
	<400> 15	
	agttcatttg ctccctgacta tgcc	24
30	<210> 16	
	<211> 22	
	<212> DNA	
	<213> Homo sapiens	
35	<400> 16	
	gatgccttcc tggggccagca gc	22
	<210> 17	
	<211> 30	
40	<212> DNA	
	<213> Canis familiaris	
	<400> 17	
	gaggtgaaga agggccagac gctggccctc	30
45	<210> 18	
	<211> 45	
	<212> DNA	
	<213> Artificial Sequence	
50	<220>	
	<223> Synthetic oligonucleotide	
	<400> 18	
55	ctaatacgc tcactatagg gcaaggcagt gtaacaacgc agagt	45
	<210> 19	
	<211> 29	
	<212> DNA	
60	<213> Canis familiaris	

DRAFT 2/22/960

	<400> 19		
	cgcagccact gttcccaacc agcgccact		29
5	<210> 20		
	<211> 23		
	<212> DNA		
	<213> Homo sapiens		
10	<400> 20		
	ggagcgcgag gtcggatgg atc		23
	<210> 21		
	<211> 31		
15	<212> DNA		
	<213> Canis familiaris		
	<400> 21		
	ggagaggacc aaggaggatcc cataccagaa a		31
20	<210> 22		
	<211> 4279		
	<212> DNA		
	<213> Canis familiaris		
25	<220>		
	<221> CDS		
	<222> (17)...(3859)		
30	<400> 22		
	ggagcgcgag gtcggg atg gat cct gaa gga ggc cgt aag ggg agt gca gag		52
	Met Asp Pro Glu Gly Gly Arg Lys Gly Ser Ala Glu		
	1 5 10		
35	aag aac ttc tgg aaa atg ggc aaa aaa agt aaa aaa aat gag aag aaa		100
	Lys Asn Phe Trp Lys Met Gly Lys Ser Lys Lys Asn Glu Lys Lys		
	15 20 25		
40	gaa aag aaa cca act gtc agc acg ttt gca atg ttt cgc tat tca aat		148
	Glu Lys Pro Thr Val Ser Thr Phe Ala Met Phe Arg Tyr Ser Asn		
	30 35 40		
45	tgg ctt gat agg ttg tat atg ttg gtg ggg aca atg gct gcc atc atc		196
	Trp Leu Asp Arg Leu Tyr Met Leu Val Gly Thr Met Ala Ala Ile Ile		
	45 50 55 60		
50	cat gga gct gca ctc cct ctc atg atg ctg gtt ttt gga aac atg aca		244
	His Gly Ala Ala Leu Pro Leu Met Met Leu Val Phe Gly Asn Met Thr		
	65 70 75		
55	gat agc ttt gca aat gca gga att tca aga aac aaa act ttt cca gtt		292
	Asp Ser Phe Ala Asn Ala Gly Ile Ser Arg Asn Lys Thr Phe Pro Val		
	80 85 90		
60	ata att aat gaa agt att acg aac aat aca caa cat ttc atc aac cat		340
	Ile Ile Asn Glu Ser Ile Thr Asn Asn Thr Gln His Phe Ile Asn His		
	95 100 105		
	ctg gag gag gaa atg acc acg tat gcc tat tat tac agt ggg atc ggt		388
	Leu Glu Glu Glu Met Thr Thr Tyr Ala Tyr Tyr Ser Gly Ile Gly		

110

115

120

5	gct ggc gtg ctg gtg gct gct tac atc cag gtt tca ttc tgg tgc ctg Ala Gly Val Leu Val Ala Ala Tyr Ile Gln Val Ser Phe Trp Cys Leu 125 130 135 140	436
10	gca gca gga aga cag ata ctc aaa att aga aaa caa ttt ttt cat gct Ala Ala Gly Arg Gln Ile Leu Lys Ile Arg Lys Gln Phe Phe His Ala 145 150 155	484
15	atc atg cga cag gag att ggc tgg ttt gac gtg cat gac gtt ggg gag Ile Met Arg Gln Glu Ile Gly Trp Phe Asp Val His Asp Val Gly Glu 160 165 170	532
20	ctt aac acc cgg ctc aca gac gat gtc tcc aaa atc aat gaa gga att Leu Asn Thr Arg Leu Thr Asp Asp Val Ser Lys Ile Asn Glu Gly Ile 175 180 185	580
25	ggc gac aaa att gga atg ttc ttt caa tca ata gca aca ttt ttc acc Gly Asp Lys Ile Gly Met Phe Phe Gln Ser Ile Ala Thr Phe Phe Thr 190 195 200	628
30	ggt ttt ata gtg ggg ttt aca cgt ggt tgg aag cta acc ctt gtg att Gly Phe Ile Val Gly Phe Thr Arg Gly Trp Lys Leu Thr Leu Val Ile 205 210 215 220	676
35	ttg gcc atc agc cct gtt ctt gga ctt tca gcc gcc atc tgg gca aag Leu Ala Ile Ser Pro Val Leu Gly Leu Ser Ala Ala Ile Trp Ala Lys 225 230 235	724
40	ata cta tct tca ttt act gat aaa gaa ctc ttg gcc tat gca aaa gct Ile Leu Ser Ser Phe Thr Asp Lys Glu Leu Leu Ala Tyr Ala Lys Ala 240 245 250	772
45	gga gca gta gct gaa gaa gtc tta gca gca atc aga act gtg att gcc Gly Ala Val Ala Glu Glu Val Leu Ala Ala Ile Arg Thr Val Ile Ala 255 260 265	820
50	ttt gga gga caa aag aaa gaa ctt gaa agg tac aac aaa aat tta gaa Phe Gly Gly Gln Lys Lys Glu Leu Glu Arg Tyr Asn Lys Asn Leu Glu 270 275 280	868
55	gaa gct aaa gga att ggg ata aag aaa gct atc acg gcc aac att tct Glu Ala Lys Gly Ile Gly Ile Lys Lys Ala Ile Thr Ala Asn Ile Ser 285 290 295 300	916
60	att ggt gcc gct ttc tta ttg atc tat gca tca tat gct ctg gct ttc Ile Gly Ala Ala Phe Leu Leu Ile Tyr Ala Ser Tyr Ala Leu Ala Phe 305 310 315	964
65	tgg tat ggg acc tcc ttg gtc ctc tcc agt gaa tat tct att gga caa Trp Tyr Gly Thr Ser Leu Val Leu Ser Ser Glu Tyr Ser Ile Gly Gln 320 325 330	1012
70	gta ctc act gtc ttc ttt tct gta tta att ggg gct ttt agt att gga Val Leu Thr Val Phe Phe Ser Val Leu Ile Gly Ala Phe Ser Ile Gly 335 340 345	1060
75	cag gca tcc cca agc att gaa gca ttt gca aac gca aga gga gca gct Gln Ala Ser Pro Ser Ile Glu Ala Phe Ala Asn Ala Arg Gly Ala Ala	1108

	350	355	360	
5	tat gaa atc ttc aag ata att gac aat aaa cca agc att gac agc tat Tyr Glu Ile Phe Lys Ile Ile Asp Asn Lys Pro Ser Ile Asp Ser Tyr 365 370 375 380			1156
10	tcg aag agt gga cat aaa cca gat aat att aag gga aat ttg gaa ttc Ser Lys Ser Gly His Lys Pro Asp Asn Ile Lys Gly Asn Leu Glu Phe 385 390 395			1204
15	aaa aat gtt cac ttc agt tac cct tct cga aaa gaa gtt aag atc tta Lys Asn Val His Phe Ser Tyr Pro Ser Arg Lys Glu Val Lys Ile Leu 400 405 410			1252
20	aag ggt ctc aac ctg aag gtt cag agt ggg cag aca gtg gcg ctg gtt Lys Gly Leu Asn Leu Lys Val Gln Ser Gly Gln Thr Val Ala Leu Val 415 420 425			1300
25	ggg aac agt ggc tgc ggg aag agc acg acc gtg cag ctg atg cag agg Gly Asn Ser Gly Cys Gly Lys Ser Thr Thr Val Gln Leu Met Gln Arg 430 435 440			1348
30	ctc tat gac ccc aca gat ggc atg gtc tgt att gat gga cag gac att Leu Tyr Asp Pro Thr Asp Gly Met Val Cys Ile Asp Gly Gln Asp Ile 445 450 455 460			1396
35	agg acc ata aat gta agg cat ctt cgg gaa att act ggt gtg gtg agt Arg Thr Ile Asn Val Arg His Leu Arg Glu Ile Thr Gly Val Val Ser 465 470 475			1444
40	cag gag cct gtg ttg ttt gcc acc acg ata gct gaa aac att cgc tat Gln Glu Pro Val Leu Phe Ala Thr Thr Ile Ala Glu Asn Ile Arg Tyr 480 485 490			1492
45	ggc cgc gaa aat gtc acc atg gat gag att gag aaa gct gtt aag gaa Gly Arg Glu Asn Val Thr Met Asp Glu Ile Glu Lys Ala Val Lys Glu 495 500 505			1540
50	gcc aat gcc tat gat ttt atc atg aaa cta cct aat aaa ttt gac act Ala Asn Ala Tyr Asp Phe Ile Met Lys Leu Pro Asn Lys Phe Asp Thr 510 515 520			1588
55	ctg gtt gga gag aga ggg gcc cag ctg agt ggt gga cag aaa cag aga Leu Val Gly Glu Arg Gly Ala Gln Leu Ser Gly Gly Gln Lys Gln Arg 525 530 535 540			1636
60	atc gcc att gct cgg gcc ctg gtt cgc aac ccc aag att ctt ctg ctg Ile Ala Ile Ala Arg Ala Leu Val Arg Asn Pro Lys Ile Leu Leu Leu 545 550 555			1684
65	gat gag gca acg tca gct ctg gac act gaa agt gaa gca gtg gtt cag Asp Glu Ala Thr Ser Ala Leu Asp Thr Glu Ser Glu Ala Val Val Gln 560 565 570			1732
70	gtg gcc ctg gat aag gcc aga aaa ggc cgg act acc att gtg ata gct Val Ala Leu Asp Lys Ala Arg Lys Gly Arg Thr Thr Ile Val Ile Ala 575 580 585			1780
75	cat cgt ttg tct aca gtt cgt aat gcc gat gtc att gct ggt ttt gat His Arg Leu Ser Thr Val Arg Asn Ala Asp Val Ile Ala Gly Phe Asp			1828

590

595

600

5	gat gga gtc att gtg gag aaa gga aat cat gat gaa ctc atg aaa gag Asp Gly Val Ile Val Glu Lys Gly Asn His Asp Glu Leu Met Lys Glu 605 610 615 620	1876
10	aag ggc att tac ttc aaa ctt gtc aca atg cag aca aca gga aat gaa Lys Gly Ile Tyr Phe Lys Leu Val Thr Met Gln Thr Arg Gly Asn Glu 625 630 635	1924
15	att gag tta gaa aat gcc act ggt gaa tcc aaa agt gaa agt gat gcc Ile Glu Leu Glu Asn Ala Thr Gly Glu Ser Lys Ser Glu Ser Asp Ala 640 645 650	1972
20	ttg gaa atg tct cca aaa gat tca ggg tcc agt tta ata aaa aga aga Leu Glu Met Ser Pro Lys Asp Ser Gly Ser Ser Leu Ile Lys Arg Arg 655 660 665	2020
25	tca act cgc agg agt ata cat gca cca caa ggc caa gac aga aag ctt Ser Thr Arg Arg Ser Ile His Ala Pro Gln Gly Gln Asp Arg Lys Leu 670 675 680	2068
30	ggt aca aaa gag gac ttg aat gag aat gta cct cca gtt tcc ttc tgg Gly Thr Lys Glu Asp Leu Asn Glu Asn Val Pro Pro Val Ser Phe Trp 685 690 695 700	2116
35	agg att ctg aag ctg aac tca act gaa tgg cct tat ttt gtg gtt gtt Arg Ile Leu Lys Leu Asn Ser Thr Glu Trp Pro Tyr Phe Val Val Gly 705 710 715	2164
40	ata ttt tgt gct att ata aac gga ggc ctg caa cca gca ttt tca ata Ile Phe Cys Ala Ile Ile Asn Gly Gly Leu Gln Pro Ala Phe Ser Ile 720 725 730	2212
45	ata ttt tca agg att ata ggg atc ttt acc cga gat gag gat cct gaa Ile Phe Ser Arg Ile Ile Gly Ile Phe Thr Arg Asp Glu Asp Pro Glu 735 740 745	2260
50	aca aaa cga cag aat agt aac atg ttt tct gta ttg ttt cta gtc ctt Thr Lys Arg Gln Asn Ser Asn Met Phe Ser Val Leu Phe Leu Val Leu 750 755 760	2308
55	gga att att tct ttt att aca ttt ttc ctc cag ggc ttc aca ttt ggc Gly Ile Ile Ser Phe Ile Thr Phe Phe Leu Gln Gly Phe Thr Phe Gly 765 770 775 780	2356
60	aaa gct ggg gag att ctc act aag cgg ctt cga tac atg gtt ttc aga Lys Ala Gly Glu Ile Leu Thr Lys Arg Leu Arg Tyr Met Val Phe Arg 785 790 795	2404
	tcc atg ctg aga cag gat gtc agc tgg ttt gat gac cct aaa aac acc Ser Met Leu Arg Gln Asp Val Ser Trp Phe Asp Asp Pro Lys Asn Thr 800 805 810	2452
	act gga gca ttg aca acc agg ctt gcc aat gat gcg gct caa gtt aaa Thr Gly Ala Leu Thr Thr Arg Leu Ala Asn Asp Ala Ala Gln Val Lys 815 820 825	2500
	ggg gct ata ggt tcc agg ctt gct gtc att acc cag aat ata gca aat Gly Ala Ile Gly Ser Arg Leu Ala Val Ile Thr Gln Asn Ile Ala Asn	2548

	830	835	840	
5	ctt ggg aca ggc att att ata tcc tta atc tat ggt tgg caa tta aca Leu Gly Thr Gly Ile Ile Ser Leu Ile Tyr Gly Trp Gln Leu Thr 845 850 855 860			2596
10	ctt tta ctc tta gca att gta ccc atc att gca ata gca gga gtt gtt Leu Leu Leu Ala Ile Val Pro Ile Ile Ala Ile Ala Gly Val Val 865 870 875			2644
15	gaa atg aaa atg ttg tct gga caa gca ctg aaa gat aag aaa gag cta Glu Met Lys Met Leu Ser Gly Gln Ala Leu Lys Asp Lys Lys Glu Leu 880 885 890			2692
20	gaa gga gct ggg aag att gct aca gaa gcc atc gaa aac ttc cga act Glu Gly Ala Gly Lys Ile Ala Thr Glu Ala Ile Glu Asn Phe Arg Thr 895 900 905			2740
25	gtt gtt tct ttg act cgg gag cag aag ttt gaa tac atg tat gca gag Val Val Ser Leu Thr Arg Glu Gln Lys Phe Glu Tyr Met Tyr Ala Gln 910 915 920			2788
30	agt ttg caa gta cca tac aga aac tac ttg agg aaa gca cac atc ttc Ser Leu Gln Val Pro Tyr Arg Asn Ser Leu Arg Lys Ala His Ile Phe 925 930 935 940			2836
35	ggg gtc tca ttt tct atc acc cag gca atg atg tat ttt tcc tat gtt Gly Val Ser Phe Ser Ile Thr Gln Ala Met Met Tyr Phe Ser Tyr Ala 945 950 955			2884
40	ggc tgt ttc cgg ttt ggt gcc tac ttg gtg gca aat gag ttc atg aac Gly Cys Phe Arg Phe Gly Ala Tyr Leu Val Ala Asn Glu Phe Met Asn 960 965 970			2932
45	ttt cag gat gtt ctt ttg gta ttc tca gct att gtc ttt ggt gcc atg Phe Gln Asp Val Leu Leu Val Phe Ser Ala Ile Val Phe Gly Ala Met 975 980 985			2980
50	gca gtg ggg cag gtc agt tca ttt gct ctc gac tat gcc aaa gcc aaa Ala Val Gly Gln Val Ser Phe Ala Pro Asp Tyr Ala Lys Ala Lys 990 995 1000			3028
55	gta tca gca gcc cac gtc atc atg atc att gaa aaa agc cct ctg att Val Ser Ala Ala His Val Ile Met Ile Ile Glu Lys Ser Pro Leu Ile 1005 1010 1015 1020			3076
60	gac agc tac agc cct cac ggc ctc aag cca aat acg ttg gaa gga aat Asp Ser Tyr Ser Pro His Gly Leu Lys Pro Asn Thr Leu Glu Gly Asn 1025 1030 1035			3124
65	gtg aca ttt aat gag gtc gtg ttc aac tat ccc act cga cca gac atc Val Thr Phe Asn Glu Val Val Phe Asn Tyr Pro Thr Arg Pro Asp Ile 1040 1045 1050			3172
70	ccc gtg ctc cag ggg ctg agc ctc gag gtg aag aag ggc cag acg ctg Pro Val Leu Gln Gly Leu Ser Leu Glu Val Lys Lys Gln Thr Leu 1055 1060 1065			3220
75	gcc ctc gta ggt agc agt ggc tgt ggg aag aag aca gtt gtt cag ctc Ala Leu Val Gly Ser Ser Gly Cys Gly Lys Ser Thr Val Val Gln Leu			3268

	1070	1075	1080	
	cta gag cgc ttc tat gac ccc ttg gct ggt tca gtg cta att gat ggc			3316
5	Leu Glu Arg Phe Tyr Asp Pro Leu Ala Gly Ser Val Leu Ile Asp Gly			
	1085 1090	1095	1100	
	aaa gag ata aag cac ctg aat gtc cag tgg ctc cga gca cac ctg ggc			3364
	Lys Glu Ile Lys His Leu Asn Val Gln Trp Leu Arg Ala His Leu Gly			
	1105	1110	1115	
10	atc gtg tct cag gag ccc atc ctg ttt gac tgc agc att gcc gag aac			3412
	Ile Val Ser Gln Glu Pro Ile Leu Phe Asp Cys Ser Ile Ala Glu Asn			
	1120	1125	1130	
15	att gcc tat gga gac aac agc cgg gtc gta tca cat gaa gag att atg			3460
	Ile Ala Tyr Gly Asp Asn Ser Arg Val Val Ser His Glu Ile Met			
	1135	1140	1145	
20	cag gca gcc aag gag gcc aac ata cac cac ttc atc gag aca ctc cct			3508
	Gln Ala Ala Lys Glu Ala Asn Ile His His Phe Ile Glu Thr Leu Pro			
	1150	1155	1160	
25	gag aaa tac aac acc aga gta gga gac aaa gga acc cag ctc tct ggt			3556
	Glu Lys Tyr Asn Thr Arg Val Gly Asp Lys Gly Thr Gln Leu Ser Gly			
	1165	1170	1175	1180
30	ggc cag aaa cag cgc att gcc ata gct cgc gct ctt gtt aga cag cct			3604
	Gly Gln Lys Gln Arg Ile Ala Ile Ala Arg Ala Leu Val Arg Gln Pro			
	1185	1190	1195	
35	cat att ttg ctt ttg gat gaa gct aca tca gct ctg gat aca gaa agt			3652
	His Ile Leu Leu Leu Asp Glu Ala Thr Ser Ala Leu Asp Thr Glu Ser			
	1200	1205	1210	
40	cat att ttg gtc caa gaa gcc ctg gac aaa gcc aga gaa ggc cgc acc			3700
	Glu Lys Val Val Gln Glu Ala Leu Asp Lys Ala Arg Glu Gly Arg Thr			
	1215	1220	1225	
45	tgc att ttg atc gcc cac cgc ttg tcc acc atc cag aat gca gat tta			3748
	Cys Ile Val Ile Ala His Arg Leu Ser Thr Ile Gln Asn Ala Asp Leu			
	1230	1235	1240	
50	ata gtg gtg ttt cag aat ggc aaa gtc aag gag cat ggc aca cat caa			3796
	Ile Val Val Phe Gln Asn Gly Lys Val Lys Glu His Gly Thr His Gln			
	1245	1250	1255	1260
55	cag ctg ctg gcc cag aaa ggc atc tat ttt tcc atg gtc agt gtc cag			3844
	Gln Leu Leu Ala Gln Lys Gly Ile Tyr Phe Ser Met Val Ser Val Gln			
	1265	1270	1275	
60	gct gga gca aag cgc tagtgaactg tggccatatg agctgttaaa tattttttaa			3899
	Ala Gly Ala Lys Arg			
	1280			
	tatttgtt aaaaatggc atattaatcaa agttaaagg tgagcactt ctggaaaaac			3959
	tatgttagac tacctgttta acatttctt ctgcactga agatcattcc accaaatcca			4019
	gagtcttcag attttataat taaaggaaacc aaaagaaca ttatctgtat gaataaaaata			4079
	ctgggtttaa ttgcattata aaattataga qtaattccaa qtagatttt ttaataaaatt			4139
	gtataattt tttttttttt ttatgtttaa cttactgttt tgctgaaaga ttatagaatgt			4199
	ggtaaaaaatgt actgaatgtt tgaataaaatgt gctagctata ataaaactaa acttttat			4259

aaaaaaaaaa aaaaaaaaaa

<210> 23
 <211> 1281
 5 <212> PRT
 <213> Canis familiaris

<400> 23
 10 Met Asp Pro Glu Gly Gly Arg Lys Gly Ser Ala Glu Lys Asn Phe Trp
 1 5 10 15
 Lys Met Gly Lys Ser Lys Lys Asn Glu Lys Lys Glu Lys Lys Pro
 20 25 30
 Thr Val Ser Thr Phe Ala Met Phe Arg Tyr Ser Asn Trp Leu Asp Arg
 35 40 45
 15 Leu Tyr Met Leu Val Gly Thr Met Ala Ala Ile Ile His Gly Ala Ala
 50 55 60
 Leu Pro Leu Met Met Leu Val Phe Gly Asn Met Thr Asp Ser Phe Ala
 65 70 75 80
 Asn Ala Gly Ile Ser Arg Asn Lys Thr Phe Pro Val Ile Ile Asn Glu
 20 85 90 95
 Ser Ile Thr Asn Asn Thr Gln His Phe Ile Asn His Leu Glu Glu Glu
 100 105 110
 Met Thr Thr Tyr Ala Tyr Tyr Tyr Ser Gly Ile Gly Ala Gly Val Leu
 115 120 125
 25 Val Ala Ala Tyr Ile Gln Val Ser Phe Trp Cys Leu Ala Ala Gly Arg
 130 135 140
 Gln Ile Leu Lys Ile Arg Lys Gln Phe Phe His Ala Ile Met Arg Gln
 145 150 155 160
 Glu Ile Gly Trp Phe Asp Val His Asp Val Gly Glu Leu Asn Thr Arg
 30 165 170 175
 Leu Thr Asp Asp Val Ser Lys Ile Asn Glu Gly Ile Gly Asp Lys Ile
 180 185 190
 Gly Met Phe Phe Gln Ser Ile Ala Thr Phe Phe Thr Gly Phe Ile Val
 195 200 205
 35 Gly Phe Thr Arg Gly Trp Lys Leu Thr Leu Val Ile Leu Ala Ile Ser
 210 215 220
 Pro Val Leu Gly Leu Ser Ala Ala Ile Trp Ala Lys Ile Leu Ser Ser
 225 230 235 240
 Phe Thr Asp Lys Glu Leu Leu Ala Tyr Ala Lys Ala Gly Ala Val Ala
 40 245 250 255
 Glu Glu Val Leu Ala Ala Ile Arg Thr Val Ile Ala Phe Gly Gly Gln
 260 265 270
 Lys Lys Glu Leu Glu Arg Tyr Asn Lys Asn Leu Glu Glu Ala Lys Gly
 275 280 285
 45 Ile Gly Ile Lys Lys Ala Ile Thr Ala Asn Ile Ser Ile Gly Ala Ala
 290 295 300
 Phe Leu Leu Ile Tyr Ala Ser Tyr Ala Leu Ala Phe Trp Tyr Gly Thr
 305 310 315 320
 Ser Leu Val Leu Ser Ser Gly Tyr Ser Ile Gly Gln Val Leu Thr Val
 50 325 330 335
 Phe Phe Ser Val Leu Ile Gly Ala Phe Ser Ile Gly Gln Ala Ser Pro
 340 345 350
 Ser Ile Glu Ala Phe Ala Asn Ala Arg Gly Ala Ala Tyr Glu Ile Phe
 355 360 365
 55 Lys Ile Ile Asp Asn Lys Pro Ser Ile Asp Ser Tyr Ser Lys Ser Gly
 370 375 380
 His Lys Pro Asp Asn Ile Lys Gly Asn Leu Glu Phe Lys Asn Val His
 385 390 395 400
 Phe Ser Tyr Pro Ser Arg Lys Glu Val Lys Ile Leu Lys Gly Leu Asn
 60 405 410 415

	Leu	Lys	Val	Gln	Ser	Gly	Gln	Thr	Val	Ala	Leu	Val	Gly	Asn	Ser	Gly
								420				425				430
	Cys	Gly	Lys	Ser	Thr	Thr	Val	Gln	Leu	Met	Gln	Arg	Leu	Tyr	Asp	Pro
								435				440				445
5	Thr	Asp	Gly	Met	Val	Cys	Ile	Asp	Gly	Gln	Asp	Ile	Arg	Thr	Ile	Asn
							450				455				460	
	Val	Arg	His	Leu	Arg	Glu	Ile	Thr	Gly	Val	Val	Ser	Gln	Glu	Pro	Val
							465				470				475	
10	Leu	Phe	Ala	Thr	Thr	Ile	Ala	Glu	Asn	Ile	Arg	Tyr	Gly	Arg	Glu	Asn
							485				490				495	
	Val	Thr	Met	Asp	Glu	Ile	Glu	Lys	Ala	Val	Lys	Glu	Ala	Asn	Ala	Tyr
							500				505				510	
	Asp	Phe	Ile	Met	Lys	Leu	Pro	Asn	Lys	Phe	Asp	Thr	Leu	Val	Gly	Glu
							515				520				525	
15	Arg	Gly	Ala	Gln	Leu	Ser	Gly	Gly	Gln	Lys	Gln	Arg	Ile	Ala	Ile	Ala
							530				535				540	
	Arg	Ala	Leu	Val	Arg	Asn	Pro	Lys	Ile	Leu	Leu	Asp	Glu	Ala	Thr	
							545				550				555	
20	Ser	Ala	Leu	Asp	Thr	Glu	Ser	Glu	Ala	Val	Val	Gln	Val	Ala	Leu	Asp
							565				570				575	
	Lys	Ala	Arg	Lys	Gly	Arg	Thr	Thr	Ile	Val	Ile	Ala	His	Arg	Leu	Ser
							580				585				590	
	Thr	Val	Arg	Asn	Ala	Asp	Val	Ile	Ala	Gly	Phe	Asp	Asp	Gly	Val	Ile
							595				600				605	
25	Val	Glu	Lys	Gly	Asn	His	Asp	Glu	Leu	Met	Lys	Glu	Lys	Gly	Ile	Tyr
							610				615				620	
	Phe	Lys	Leu	Val	Thr	Met	Gln	Thr	Arg	Gly	Asn	Glu	Ile	Glu	Leu	Glu
							625				630				635	
30	Asn	Ala	Thr	Gly	Glu	Ser	Lys	Ser	Glu	Ser	Asp	Ala	Leu	Glu	Met	Ser
							645				650				655	
	Pro	Lys	Asp	Ser	Gly	Ser	Ser	Leu	Ile	Lys	Arg	Arg	Ser	Thr	Arg	Arg
							660				665				670	
	Ser	Ile	His	Ala	Pro	Gln	Gly	Gln	Asp	Arg	Lys	Leu	Gly	Thr	Lys	Glu
							675				680				685	
35	Asp	Leu	Asn	Glu	Asn	Val	Pro	Pro	Val	Ser	Phe	Trp	Arg	Ile	Leu	Lys
							690				695				700	
	Leu	Asn	Ser	Thr	Glu	Trp	Pro	Tyr	Phe	Val	Val	Gly	Ile	Phe	Cys	Ala
							705				710				715	
40	Ile	Ile	Asn	Gly	Gly	Leu	Gln	Pro	Ala	Phe	Ser	Ile	Ile	Phe	Ser	Arg
							725				730				735	
	Ile	Ile	Gly	Ile	Phe	Thr	Arg	Asp	Glu	Asp	Pro	Glu	Thr	Lys	Arg	Gln
							740				745				750	
	Asn	Ser	Asn	Met	Phe	Ser	Val	Leu	Phe	Leu	Val	Leu	Gly	Ile	Ile	Ser
							755				760				765	
45	Phe	Ile	Thr	Phe	Phe	Leu	Gln	Gly	Phe	Thr	Phe	Gly	Lys	Ala	Gly	Glu
							770				775				780	
	Ile	Leu	Thr	Lys	Arg	Leu	Arg	Tyr	Met	Val	Phe	Arg	Ser	Met	Leu	Arg
							785				790				795	
50	Gln	Asp	Val	Ser	Trp	Phe	Asp	Asp	Pro	Lys	Asn	Thr	Thr	Gly	Ala	Leu
							805				810				815	
	Thr	Thr	Arg	Leu	Ala	Asn	Asp	Ala	Ala	Gln	Val	Lys	Gly	Ala	Ile	Gly
							820				825				830	
	Ser	Arg	Leu	Ala	Val	Ile	Thr	Gln	Asn	Ile	Ala	Asn	Leu	Gly	Thr	Gly
							835				840				845	
55	Ile	Ile	Ile	Ser	Leu	Ile	Tyr	Gly	Trp	Gln	Leu	Thr	Leu	Leu	Leu	Leu
							850				855				860	
	Ala	Ile	Val	Pro	Ile	Ile	Ala	Ile	Gly	Val	Val	Glu	Met	Lys	Met	
							865				870				875	
60	Leu	Ser	Gly	Gln	Ala	Leu	Lys	Asp	Lys	Lys	Glu	Leu	Gly	Ala	Gly	
							885				890				895	

Lys Ile Ala Thr Glu Ala Ile Glu Asn Phe Arg Thr Val Val Ser Leu
 900 905 910
 Thr Arg Glu Gln Lys Phe Glu Tyr Met Tyr Ala Gln Ser Leu Gln Val
 915 920 925
 5 Pro Tyr Arg Asn Ser Leu Arg Lys Ala His Ile Phe Gly Val Ser Phe
 930 935 940
 Ser Ile Thr Gln Ala Met Met Tyr Phe Ser Tyr Ala Gly Cys Phe Arg
 945 950 955 960
 Phe Gly Ala Tyr Leu Val Ala Asn Glu Phe Met Asn Phe Gln Asp Val
 10 965 970 975
 Leu Leu Val Phe Ser Ala Ile Val Phe Gly Ala Met Ala Val Gly Gln
 980 985 990
 Val Ser Ser Phe Ala Pro Asp Tyr Ala Lys Ala Lys Val Ser Ala Ala
 995 1000 1005
 15 His Val Ile Met Ile Ile Glu Lys Ser Pro Leu Ile Asp Ser Tyr Ser
 1010 1015 1020
 Pro His Gly Leu Lys Pro Asn Thr Leu Glu Gly Asn Val Thr Phe Asn
 1025 1030 1035 1040
 Glu Val Val Phe Asn Tyr Pro Thr Arg Pro Asp Ile Pro Val Leu Gln
 20 1045 1050 1055
 Gly Leu Ser Leu Glu Val Lys Lys Gly Gln Thr Leu Ala Leu Val Gly
 1060 1065 1070
 Ser Ser Gly Cys Gly Lys Ser Thr Val Val Gln Leu Leu Glu Arg Phe
 1075 1080 1085
 25 Tyr Asp Pro Leu Ala Gly Ser Val Leu Ile Asp Gly Lys Glu Ile Lys
 1090 1095 1100
 His Leu Asn Val Gln Trp Leu Arg Ala His Leu Gly Ile Val Ser Gln
 1105 1110 1115 1120
 Glu Pro Ile Leu Phe Asp Cys Ser Ile Ala Glu Asn Ile Ala Tyr Gly
 1125 1130 1135
 30 Asp Asn Ser Arg Val Val Ser His Glu Glu Ile Met Gln Ala Ala Lys
 1140 1145 1150
 Glu Ala Asn Ile His His Phe Ile Glu Thr Leu Pro Glu Lys Tyr Asn
 1155 1160 1165
 35 Thr Arg Val Gly Asp Lys Gly Thr Gln Leu Ser Gly Gly Gln Lys Gln
 1170 1175 1180
 Arg Ile Ala Ile Ala Arg Ala Leu Val Arg Gln Pro His Ile Leu Leu
 1185 1190 1195 1200
 Leu Asp Glu Ala Thr Ser Ala Leu Asp Thr Glu Ser Glu Lys Val Val
 40 1205 1210 1215
 Gln Glu Ala Leu Asp Lys Ala Arg Glu Gly Arg Thr Cys Ile Val Ile
 1220 1225 1230
 Ala His Arg Leu Ser Thr Ile Gln Asn Ala Asp Leu Ile Val Val Phe
 1235 1240 1245
 45 Gln Asn Gly Lys Val Lys Glu His Gly Thr His Gln Gln Leu Ala
 1250 1255 1260
 Gln Lys Gly Ile Tyr Phe Ser Met Val Ser Val Gln Ala Gly Ala Lys
 1265 1270 1275 1280
 Arg

50
 <210> 24
 <211> 4279
 <212> DNA
 55 <213> Canis familiaris
 <220>
 <221> CDS
 <222> (17) ... (3859)

	<400> 24		
	ggagcgcgag gtcggg atg gat cct gaa gga ggc cgt aag ggg agt gca gag	52	
	Met Asp Pro Glu Gly Gly Arg Lys Gly Ser Ala Glu		
	1 5 10		
5	aag aac ttc tgg aaa atg ggc aaa aaa agt aaa aaa gag aag aag aag	100	
	Lys Asn Phe Trp Lys Met Gly Lys Lys Ser Lys Lys Lys Glu Lys Lys		
	15 20 25		
10	gaa aag aaa cca act gtc agc acg ttt gca atg ttt cgc tat tca aat	148	
	Glu Lys Lys Pro Thr Val Ser Thr Phe Ala Met Phe Arg Tyr Ser Asn		
	30 35 40		
15	tgg ctt gat agg ttg tat atg ttg gtg ggg aca atg gct gcc atc atc	196	
	Trp Leu Asp Arg Leu Tyr Met Leu Val Gly Thr Met Ala Ala Ile Ile		
	45 50 55 60		
20	cat gga gct gca ctc cct ctc atg atg ctg gtt ttt gga aac atg aca	244	
	His Gly Ala Ala Leu Pro Leu Met Met Leu Val Phe Gly Asn Met Thr		
	65 70 75		
	gat agc ttt gca aat gca gga att tca aga aac aaa act ttt cca gtt	292	
	Asp Ser Phe Ala Asn Ala Gly Ile Ser Arg Asn Lys Thr Phe Pro Val		
	80 85 90		
25	ata att aat gaa agt att acg aac aat aca caa cat ttc atc aac cat	340	
	Ile Ile Asn Glu Ser Ile Thr Asn Asn Thr Gln His Phe Ile Asn His		
	95 100 105		
30	ctg gag gag aat atg acc acg tat gcc tat tat tac agt ggg atc ggt	388	
	Leu Glu Glu Met Thr Thr Tyr Ala Tyr Tyr Ser Gly Ile Gly		
	110 115 120		
35	gct ggc gtg ctg gtg gct gct tac atc cag gtt tca ttc tgg tgc ctg	436	
	Ala Gly Val Leu Val Ala Ala Tyr Ile Gln Val Ser Phe Trp Cys Leu		
	125 130 135 140		
40	gca gca gga aga cag ata ctc aaa att aga aaa caa ttt ttt cat gct	484	
	Ala Ala Gly Arg Gln Ile Leu Lys Ile Arg Lys Gln Phe Phe His Ala		
	145 150 155		
	atc atg cga cag gag att ggc tgg ttt gac gtg cat gac gtt ggg gag	532	
	Ile Met Arg Gln Ile Gly Trp Phe Asp Val His Asp Val Gly Glu		
	160 165 170		
45	ctt aac acc cgg ctc aca gac gat gtc tcc aaa atc aat gaa gga att	580	
	Leu Asn Thr Arg Leu Thr Asp Asp Val Ser Lys Ile Asn Glu Gly Ile		
	175 180 185		
50	ggc gac aaa att gga atg ttc ttt cca tca ata gca aca ttt ttc acc	628	
	Gly Asp Lys Ile Gly Met Phe Phe Gln Ser Ile Ala Thr Phe Phe Thr		
	190 195 200		
55	ggt ttt ata gtg ggg ttt aca cgt ggt tgg aag cta acc ctt gtg att	676	
	Gly Phe Ile Val Gly Phe Thr Arg Gly Trp Lys Leu Thr Leu Val Ile		
	205 210 215 220		
	ttg gcc atc agc cct gtt ctt gga ctt tca gcc atc tgg gca aag	724	
	Leu Ala Ile Ser Pro Val Leu Gly Leu Ser Ala Ala Ile Trp Ala Lys		
	225 230 235		
60			

	ata cta tct tca ttt act gat aaa gaa ctc ttg gcc tat gca aaa gct Ile Leu Ser Ser Phe Thr Asp Lys Glu Leu Leu Ala Tyr Ala Lys Ala 240 245 250	772
5	gga gca gta gct gaa gaa gtc tta gca gca atc aga act gtg att gcc Gly Ala Val Ala Glu Glu Val Leu Ala Ala Ile Arg Thr Val Ile Ala 255 260 265	820
10	ttt gga gga caa aag aaa gaa ctt gaa agg tac aac aaa aat tta gaa Phe Gly Gly Gln Lys Lys Glu Leu Glu Arg Tyr Asn Lys Asn Leu Glu 270 275 280	868
15	qaa gct aaa gga att ggg ata aag aaa gct atc acg gcc aac att tct Glu Ala Lys Gly Ile Gly Ile Lys Lys Ala Ile Thr Ala Asn Ile Ser 285 290 295 300	916
20	att ggt gcc gct ttc tta ttg atc tat gca tca tat gct ctg gct ttc Ile Gly Ala Ala Phe Leu Ile Tyr Ala Ser Tyr Ala Leu Ala Phe 305 310 315	964
25	tgg tat ggg acc tcc ttg gtc ctc tcc agt gaa tat tct att gga caa Trp Tyr Gly Thr Ser Leu Val Leu Ser Ser Glu Tyr Ser Ile Gly Gln 320 325 330	1012
30	gta ctc act gtc ttc ttt tct gta tta att ggg gct ttt agt att gga Val Leu Thr Val Phe Phe Ser Val Leu Ile Gly Ala Phe Ser Ile Gly 335 340 345	1060
35	cag gca tcc cca agc att gaa gca ttt gca aac gca aga gga gca gct Gln Ala Ser Pro Ser Ile Glu Ala Phe Ala Asn Ala Arg Gly Ala Ala 350 355 360	1108
40	tat gaa atc ttc aag ata att gac aat aaa cca agc att gac agc tat Tyr Glu Ile Phe Lys Ile Ile Asp Asn Lys Pro Ser Ile Asp Ser Tyr 365 370 375 380	1156
45	tcg aag agt gga cat aaa cca gat aat att aag gga aat ttg gaa ttc Ser Lys Ser Gly His Lys Pro Asp Asn Ile Lys Gly Asn Leu Glu Phe 385 390 395	1204
50	aaa aat gtt cac ttc agt tac cct tct cga aaa gaa gtt aag atc tta Lys Asn Val His Phe Ser Tyr Pro Ser Arg Lys Glu Val Lys Ile Leu 400 405 410	1252
55	aag ggt ctc aac ctg aag gtt cag agt ggg cag aca gtc gcg ctg gtt Lys Gly Leu Asn Leu Lys Val Gln Ser Gly Gln Thr Val Ala Leu Val 415 420 425	1300
60	ggg aac agt ggc tgc ggg aag agc acg acc gtc cag ctg atg cag agg Gly Asn Ser Gly Cys Gly Lys Ser Thr Thr Val Gln Leu Met Gln Arg 430 435 440	1348
	ctc tat gac ccc aca gat ggc atg gtc tgt att gat gga cag gac att Leu Tyr Asp Pro Thr Asp Gly Met Val Cys Ile Asp Gly Gln Asp Ile 445 450 455 460	1396
	agg acc ata aat gta agg cat ctt cgg gaa att act ggt gtg gtg agt Arg Thr Ile Asn Val Arg His Leu Arg Glu Ile Thr Gly Val Val Ser 465 470 475	1444

5	cag gag cct gtg ttg ttt gcc acc acg ata gct gaa aac att cgc tat Gln Glu Pro Val Leu Phe Ala Thr Thr Ile Ala Glu Asn Ile Arg Tyr 480 485 490	1492
10	ggc cgc gaa aat gtc acc atg gat gag att gag aaa gct gtt aag gaa Gly Arg Glu Asn Val Thr Met Asp Glu Ile Glu Lys Ala Val Lys Glu 495 500 505	1540
15	gcc aat gcc tat gat ttt atc atg aaa cta cct aat aaa ttt gac act Ala Asn Ala Tyr Asp Phe Ile Met Lys Leu Pro Asn Lys Phe Asp Thr 510 515 520	1588
20	ctg gtt gga gag aga ggg gcc cag ctg agt ggt gga cag aaa cag aga Leu Val Gly Glu Arg Gly Ala Gln Leu Ser Gly Gly Gln Lys Gln Arg 525 530 535 540	1636
25	atc gcc att gct cgg gcc ctg gtt cgc aac ccc aag att ctt ctg ctg Ile Ala Ile Ala Arg Ala Val Arg Asn Pro Lys Ile Leu Leu Leu 545 550 555	1684
30	gat gag gca acg tca gct ctg gac act gaa agt gaa gca gtg gtt cag Asp Glu Ala Thr Ser Ala Leu Asp Thr Glu Ser Glu Ala Val Val Gln 560 565 570	1732
35	gtg gcc ctg gat aag gcc aga aaa ggc cgg act acc att gtg ata gct Val Ala Leu Asp Lys Ala Arg Lys Gly Arg Thr Thr Ile Val Ile Ala 575 580 585	1780
40	cat cgt ttg tct aca gtt cgt aat gcc gat gtc att gct ggt ttt gat His Arg Leu Ser Thr Val Arg Asn Ala Asp Val Ile Ala Gly Phe Asp 590 595 600	1828
45	cat ggt gtc att gtg gag aaa gga aat cat gat gaa ctc atg aaa gag Asp Gly Val Ile Val Glu Lys Gly Asn His Asp Glu Leu Met Lys Glu 605 610 615 620	1876
50	aag ggc att tac ttc aaa ctt gtc aca atg cag aca aga gga aat gaa Lys Gly Ile Tyr Phe Lys Leu Val Thr Met Gln Thr Arg Gly Asn Glu 625 630 635	1924
55	att gag tta gaa aat gcc act ggt gaa tcc aaa aat gaa aat gat gtc Ile Glu Leu Glu Asn Ala Thr Gly Ser Lys Ser Glu Ser Asp Ala 640 645 650	1972
60	ttg gaa atg tct cca aaa gat tca ggg tcc agt tta ata aaa aga aga Leu Glu Met Ser Pro Lys Asp Ser Gly Ser Ser Leu Ile Lys Arg Arg 655 660 665	2020
65	tca act cgc agg agt ata cat gca cca ggc caa gac aga aag ctt Ser Thr Arg Arg Ser Ile His Ala Pro Gln Gly Gln Asp Arg Lys Leu 670 675 680	2068
70	ggc aca aaa gag gac ttg aat gag aat gta cct cca gtt tcc ttc tgg Gly Thr Lys Glu Asp Leu Asn Glu Asn Val Pro Pro Val Ser Phe Trp 685 690 695 700	2116
75	agg att ctg aag ctg aac tca act gaa tgg cct tat ttt gtg gtt ggt Arg Ile Leu Lys Leu Asn Ser Thr Glu Trp Pro Tyr Phe Val Val Gly 705 710 715	2164

	ata ttt tgt gct att ata aac gga ggc ctg caa cca gca ttt tca ata Ile Phe Cys Ala Ile Ile Asn Gly Gly Leu Gln Pro Ala Phe Ser Ile 720 725 730	2212
5	ata ttt tca agg att ata ggg atc ttt acc cga gat gag gat cct gaa Ile Phe Ser Arg Ile Ile Gly Ile Phe Thr Arg Asp Glu Asp Pro Glu 735 740 745	2260
10	aca aaa cga cag aat agt aac atg ttt tct gta ttg ttt cta gtc ctt Thr Lys Arg Gln Asn Ser Asn Met Phe Ser Val Leu Phe Leu Val Leu 750 755 760	2308
15	gga att att tct ttt att aca ttt ttc ctc cag ggc ttc aca ttt ggc Gly Ile Ile Ser Phe Ile Thr Phe Leu Gln Gly Phe Thr Phe Gly 765 770 775 780	2356
20	aaa gct ggg gag atc ctc act aag cgg ctt cga tac atg gtt ttc aga Lys Ala Gly Glu Ile Leu Thr Lys Arg Leu Arg Tyr Met Val Phe Arg 785 790 795	2404
25	tcc atg ctg aga cag gat gtc agc tgg ttt gat gac cct aaa aac acc Ser Met Leu Arg Gln Asp Val Ser Trp Phe Asp Asp Pro Lys Asn Thr 800 805 810	2452
30	act gga gca ttg aca acc agg ctt gcc aat gat gcg gct caa gtt aaa Thr Gly Ala Leu Thr Thr Arg Leu Ala Asn Asp Ala Ala Gln Val Lys 815 820 825	2500
35	ggg gct ata ggt tcc agg ctt gct gtc att acc cag aat ata gca aat Gly Ala Ile Gly Ser Arg Leu Ala Val Ile Thr Gln Asn Ile Ala Asn 830 835 840	2548
40	ctt tta ctc tta gca att gta ccc atc att gca ata gca gga gtt gtt Leu Leu Leu Ala Ile Val Pro Ile Ile Ala Ile Ala Gly Val Val 865 870 875	2644
45	gaa atg aaa atg ttg tct gga caa gca ctg aaa gat aag aaa gag cta Glu Met Lys Met Leu Ser Gly Gln Ala Leu Lys Asp Lys Glu Leu 880 885 890	2692
50	gaa gga gct ggg aag att gct aca gaa gcc atc gaa aac ttc cga act Glu Gly Ala Gly Lys Ile Ala Thr Glu Ala Ile Glu Asn Phe Arg Thr 895 900 905	2740
55	gtt gtt tct ttg act cgg gag cag aag ttt gaa tac atg tat gca cag Val Val Ser Leu Thr Arg Glu Gln Lys Phe Glu Tyr Met Tyr Ala Gln 910 915 920	2788
60	agt ttg caa gta cca tac aga aac tct ttg agg aaa gca cac atc ttc Ser Leu Gln Val Pro Tyr Arg Asn Ser Leu Arg Lys Ala His Ile Phe 925 930 935 940	2836
	ggg gtc tca ttt tct atc acc cag gca atg atg tat ttt tcc tat gct Gly Val Ser Phe Ser Ile Thr Gln Ala Met Met Tyr Phe Ser Tyr Ala 945 950 955	2884

5	ggc tgt ttc cgg ttt ggt gcc tac ttg gtg gca aat gag ttc atg aac Gly Cys Phe Arg Phe Gly Ala Tyr Leu Val Ala Asn Glu Phe Met Asn 960 965 970	2932
10	ttt cag gat gtt ctt ttg gta ttc tca gct att gtc ttt ggt gcc atg Phe Gln Asp Val Leu Leu Val Phe Ser Ala Ile Val Phe Gly Ala Met 975 980 985	2980
15	gca gtg ggg cag gtc agt tca ttt gct cct gac tat gcc aaa gcc aaa Ala Val Gly Gln Val Ser Ser Phe Ala Pro Asp Tyr Ala Lys Ala Lys 990 995 1000	3028
20	gta tca gca gcc cac gtc atc atc att gaa aaa agc cct ctg att Val Ser Ala Ala His Val Ile Met Ile Ile Glu Lys Ser Pro Leu Ile 1005 1010 1015 1020	3076
25	gac agc tac agc cct cac ggc ctc aag cca aat acg ttg gaa gga aat Asp Ser Tyr Ser Pro His Gly Leu Lys Pro Asn Thr Leu Glu Gly Asn 1025 1030 1035	3124
30	gtg aca ttt aat gag gtc gtg ttc aac tat ccc act cga cca gac atc Val Thr Phe Asn Glu Val Val Phe Asn Tyr Pro Thr Arg Pro Asp Ile 1040 1045 1050	3172
35	ccc gtg ctc cag ggg ctc gag ctg aag aag ggc cag acg ctg Pro Val Leu Gln Gly Leu Ser Leu Glu Val Lys Lys Gly Gln Thr Leu 1055 1060 1065	3220
40	gcc ctc gta ggt agc agt ggc tgg aag agc aca gtt gtt cag ctc Ala Leu Val Gly Ser Ser Gly Cys Gly Lys Ser Thr Val Val Gln Leu 1070 1075 1080	3268
45	cta gag cgc ttc tat gac ccc ttg gct ggt cta gtg cta att gat ggc Leu Glu Arg Phe Tyr Asp Pro Leu Ala Gly Ser Val Leu Ile Asp Gly 1085 1090 1095 1100	3316
50	aaa gag ata aag cac ctg aat gtc cag tgg ctc cga gca cac ctg ggc Lys Glu Ile Lys His Leu Asn Val Gln Trp Leu Arg Ala His Leu Gly 1105 1110 1115	3364
55	atc gtg tct cag gag ccc atc ctg ttg ttc gag tgc agc att gcc gag aac Ile Val Ser Gln Glu Pro Ile Leu Phe Asp Cys Ser Ile Ala Glu Asn 1120 1125 1130	3412
60	att gcc tat gga gac aac agc cgg gtc gta tca cat gaa gag att atg Ile Ala Tyr Gly Asp Asn Ser Arg Val Val Ser His Glu Glu Ile Met 1135 1140 1145	3460
65	cag gca gcc aag gag gcc aac ata cac cac ttc atc gag aca ctc cct Gln Ala Ala Lys Glu Ala Asn Ile His His Phe Ile Glu Thr Leu Pro 1150 1155 1160	3508
70	gag aaa tac aac acc aga gta gga gac aaa gga acc cag ctc tct ggt Glu Lys Tyr Asn Thr Arg Val Gly Asp Lys Gly Thr Gln Leu Ser Gly 1165 1170 1175 1180	3556
75	ggc cag aaa cag cgc att gcc cgc gct ctt gtt aga cag cct Gly Gln Lys Gln Arg Ile Ala Ile Ala Arg Ala Leu Val Arg Gln Pro 1185 1190 1195	3604

cat att ttg ctt ttg gat gaa gct aca tca gct ctg gat aca gaa agt His Ile Leu Leu Leu Asp Glu Ala Thr Ser Ala Leu Asp Thr Glu Ser	1200	1205	1210	3652
5 gaa aag gtt gtc caa gaa gcc ctg gac aaa gcc aga gaa ggc cgc acc Glu Lys Val Val Gln Glu Ala Leu Asp Lys Ala Arg Glu Gly Arg Thr	1215	1220	1225	3700
10 tgc att gtg atc gcc cac cgc ttg tcc acc atc cag aat gca gat tta Cys Ile Val Ile Ala His Arg Leu Ser Thr Ile Gln Asn Ala Asp Leu	1230	1235	1240	3748
15 ata gtg gtg ttt cag aat ggc aaa gtc aag gag cat ggc aca cat caa Ile Val Val Phe Gln Asn Gly Lys Val Lys Glu His Gly Thr His Gln	1245	1250	1255	3796
20 cag ctg ctg gcc cag aaa ggc atc tat ttt tcc atg gtc agt gtc cag Gln Leu Leu Ala Gln Lys Gly Ile Tyr Phe Ser Met Val Ser Val Gln	1265	1270	1275	3844
gct gga gca aag cgc tagtgaactg tggccatatg agctgttaaa tattttttaa Ala Gly Ala Lys Arg	1280			3899
25 tattttgtt aaacatggc atattaatcaa agttaaaaagg tgagcactta ctggaaaaac tatgttagaac tacctgttta acatttcttg ctgcaactga agatcattcc accaagtta gagtcttcag attttataat taaaggAACCAaaaagaaaca ttatctgtatg gaataaaata	3959	4019		
30 gttagttaa ttgttattataa aattttataga qtaatttcaa qtagattttgg ttaataaaatt gtataatttt ttgttattataa ttatgttaa cttactgtt tgctgaaaata ttatagaatg ggtaaaaaagt actgaatgtt tgaataaaagt gctagctata ataaaaactaa acttttatat	4079	4139	4199	4259
35 <210> 25 <211> 1281 <212> PRT <213> Canis familiaris				
40 <400> 25 Met Asp Pro Glu Gly Gly Arg Lys Gly Ser Ala Glu Lys Asn Phe Trp 1 5 10 15 Lys Met Gly Lys Lys Ser Lys Lys Glu Lys Lys Glu Lys Pro 20 25 30				
45 Thr Val Ser Thr Phe Ala Met Phe Arg Tyr Ser Asn Trp Leu Asp Arg 35 40 45 Leu Tyr Met Leu Val Gly Thr Met Ala Ala Ile Ile His Gly Ala Ala 50 55 60 Leu Pro Leu Met Met Leu Val Phe Gly Asn Met Thr Asp Ser Phe Ala 65 70 75 80				
50 Asn Ala Gly Ile Ser Arg Asn Lys Thr Phe Pro Val Ile Ile Asn Glu 85 90 95 Ser Ile Thr Asn Asn Thr Gln His Phe Ile Asn His Leu Glu Glu 100 105 110 Met Thr Thr Tyr Ala Tyr Tyr Tyr Ser Gly Ile Gly Ala Gly Val Leu 115 120 125				
55 Val Ala Ala Tyr Ile Gln Val Ser Phe Trp Cys Leu Ala Ala Gly Arg 130 135 140 Gln Ile Leu Lys Ile Arg Lys Gln Phe Phe His Ala Ile Met Arg Gln 145 150 155 160				
60 Glu Ile Gly Trp Phe Asp Val His Asp Val Gly Glu Leu Asn Thr Arg				

	165	170	175
	Leu Thr Asp Asp Val Ser Lys Ile Asn Glu Gly Ile Gly Asp Lys Ile		
	180	185	190
	Gly Met Phe Phe Gln Ser Ile Ala Thr Phe Phe Thr Gly Phe Ile Val		
5	195	200	205
	Gly Phe Thr Arg Gly Trp Lys Leu Thr Leu Val Ile Leu Ala Ile Ser		
	210	215	220
	Pro Val Leu Gly Leu Ser Ala Ala Ile Trp Ala Lys Ile Leu Ser Ser		
	225	230	235
10	Phe Thr Asp Lys Glu Leu Leu Ala Tyr Ala Lys Ala Gly Ala Val Ala		
	245	250	255
	Glu Glu Val Leu Ala Ala Ile Arg Thr Val Ile Ala Phe Gly Gly Gln		
	260	265	270
	Lys Lys Glu Leu Glu Arg Tyr Asn Lys Asn Leu Glu Glu Ala Lys Gly		
15	275	280	285
	Ile Gly Ile Lys Lys Ala Ile Thr Ala Asn Ile Ser Ile Gly Ala Ala		
	290	295	300
	Phe Leu Leu Ile Tyr Ala Ser Tyr Ala Leu Ala Phe Trp Tyr Gly Thr		
	305	310	315
20	Ser Leu Val Leu Ser Ser Glu Tyr Ser Ile Gly Gln Val Leu Thr Val		
	325	330	335
	Phe Phe Ser Val Leu Ile Gly Ala Phe Ser Ile Gly Gln Ala Ser Pro		
	340	345	350
25	Ser Ile Glu Ala Phe Ala Asn Ala Arg Gly Ala Ala Tyr Glu Ile Phe		
	355	360	365
	Lys Ile Ile Asp Asn Lys Pro Ser Ile Asp Ser Tyr Ser Lys Ser Gly		
	370	375	380
	His Lys Pro Asp Asn Ile Lys Gly Asn Leu Glu Phe Lys Asn Val His		
	385	390	395
30	Phe Ser Tyr Pro Ser Arg Lys Glu Val Lys Ile Leu Lys Gly Leu Asn		
	405	410	415
	Leu Lys Val Gln Ser Gly Gln Thr Val Ala Leu Val Gly Asn Ser Gly		
	420	425	430
	Cys Gly Lys Ser Thr Thr Val Gln Leu Met Gln Arg Leu Tyr Asp Pro		
35	435	440	445
	Thr Asp Gly Met Val Cys Ile Asp Gly Gln Asp Ile Arg Thr Ile Asn		
	450	455	460
	Val Arg His Leu Arg Glu Ile Thr Gly Val Val Ser Gln Glu Pro Val		
	465	470	475
40	Leu Phe Ala Thr Thr Ile Ala Glu Asn Ile Arg Tyr Gly Arg Glu Asn		
	485	490	495
	Val Thr Met Asp Glu Ile Glu Lys Ala Val Lys Glu Ala Asn Ala Tyr		
	500	505	510
45	Asp Phe Ile Met Lys Leu Pro Asn Lys Phe Asp Thr Leu Val Gly Glu		
	515	520	525
	Arg Gly Ala Gln Leu Ser Gly Gly Gln Lys Gln Arg Ile Ala Ile Ala		
	530	535	540
	Arg Ala Leu Val Arg Asn Pro Lys Ile Leu Leu Asp Glu Ala Thr		
50	545	550	555
	Ser Ala Leu Asp Thr Glu Ser Glu Ala Val Val Gln Val Ala Leu Asp		
	565	570	575
	Lys Ala Arg Lys Gly Arg Thr Thr Ile Val Ile Ala His Arg Leu Ser		
	580	585	590
55	Thr Val Arg Asn Ala Asp Val Ile Ala Gly Phe Asp Asp Gly Val Ile		
	595	600	605
	Val Glu Lys Gly Asn His Asp Glu Leu Met Lys Glu Lys Gly Ile Tyr		
	610	615	620
	Phe Lys Leu Val Thr Met Gln Thr Arg Gly Asn Glu Ile Glu Leu Glu		
	625	630	635
60	Asn Ala Thr Gly Glu Ser Lys Ser Glu Ser Asp Ala Leu Glu Met Ser		

	645	650	655
Pro Lys Asp Ser Gly Ser Ser Leu Ile Lys Arg Arg Ser Thr Arg Arg	660	665	670
Ser Ile His Ala Pro Gln Gly Gln Asp Arg Lys Leu Gly Thr Lys Glu	675	680	685
5 Asp Leu Asn Glu Asn Val Pro Pro Val Ser Phe Trp Arg Ile Leu Lys	690	695	700
Leu Asn Ser Thr Glu Trp Pro Tyr Phe Val Val Gly Ile Phe Cys Ala	705	710	715
10 Ile Ile Asn Gly Gly Leu Gln Pro Ala Phe Ser Ile Ile Phe Ser Arg	725	730	735
Ile Ile Gly Ile Phe Thr Arg Asp Glu Asp Pro Glu Thr Lys Arg Gln	740	745	750
Asn Ser Asn Met Phe Ser Val Leu Phe Leu Val Val Leu Gly Ile Ile Ser	755	760	765
15 Phe Ile Thr Phe Phe Leu Gln Gly Phe Thr Phe Gly Lys Ala Gly Glu	770	775	780
Ile Leu Thr Lys Arg Leu Arg Tyr Met Val Phe Arg Ser Met Leu Arg	785	790	795
20 Gln Asp Val Ser Trp Phe Asp Asp Pro Lys Asn Thr Thr Gly Ala Leu	805	810	815
Thr Thr Arg Leu Ala Asn Asp Ala Ala Gln Val Lys Gly Ala Ile Gly	820	825	830
Ser Arg Leu Ala Val Ile Thr Gln Asn Ile Ala Asn Leu Gly Thr Gly	835	840	845
25 Ile Ile Ile Ser Leu Ile Tyr Gly Trp Gln Leu Thr Leu Leu Leu	850	855	860
Ala Ile Val Pro Ile Ile Ala Ile Ala Gly Val Val Glu Met Lys Met	865	870	875
30 Leu Ser Gly Gln Ala Leu Lys Asp Lys Lys Glu Leu Glu Gly Ala Gly	885	890	895
Lys Ile Ala Thr Glu Ala Ile Glu Asn Phe Arg Thr Val Val Ser Leu	900	905	910
35 Thr Arg Glu Gln Lys Phe Glu Tyr Met Tyr Ala Gln Ser Leu Gln Val	915	920	925
Pro Tyr Arg Asn Ser Leu Arg Lys Ala His Ile Phe Gly Val Ser Phe	930	935	940
Ser Ile Thr Gln Ala Met Met Tyr Phe Ser Tyr Ala Gly Cys Phe Arg	945	950	955
40 Phe Gly Ala Tyr Leu Val Ala Asn Glu Phe Met Asn Phe Gln Asp Val	965	970	975
Leu Leu Val Phe Ser Ala Ile Val Phe Gly Ala Met Ala Val Gly Gln	980	985	990
Val Ser Ser Phe Ala Pro Asp Tyr Ala Lys Ala Lys Val Ser Ala Ala	995	1000	1005
45 His Val Ile Met Ile Ile Glu Lys Ser Pro Leu Ile Asp Ser Tyr Ser	1010	1015	1020
Pro His Gly Leu Lys Pro Asn Thr Leu Glu Gly Asn Val Thr Phe Asn	1025	1030	1035
50 Glu Val Val Phe Asn Tyr Pro Thr Arg Pro Asp Ile Pro Val Leu Gln	1045	1050	1055
Gly Leu Ser Leu Glu Val Lys Lys Gly Gln Thr Leu Ala Leu Val Gly	1060	1065	1070
Ser Ser Gly Cys Gly Lys Ser Thr Val Val Gln Leu Leu Glu Arg Phe	1075	1080	1085
55 Tyr Asp Pro Leu Ala Gly Ser Val Leu Ile Asp Gly Lys Glu Ile Lys	1090	1095	1100
His Leu Asn Val Gln Trp Leu Arg Ala His Leu Gly Ile Val Ser Gln	1105	1110	1115
60 Glu Pro Ile Leu Phe Asp Cys Ser Ile Ala Glu Asn Ile Ala Tyr Gly			1120

	1125	1130	
Asp Asn Ser Arg Val Val Ser His Glu Glu Ile Met Gln Ala Ala Lys	1140	1145	1150
	1155	1160	1165
Glu Ala Asn Ile His His Phe Ile Glu Thr Leu Pro Glu Lys Tyr Asn	1170	1175	1180
	1185	1190	1195
Thr Arg Val Gly Asp Lys Gly Thr Gln Leu Ser Gly Gly Gln Lys Gln	1200		
Arg Ile Ala Ile Ala Arg Ala Leu Val Arg Gln Pro His Ile Leu Leu	1205	1210	1215
	1220	1225	1230
Gln Glu Ala Leu Asp Lys Ala Arg Glu Gly Arg Thr Cys Ile Val Ile	1235	1240	1245
	1250	1255	1260
Ala His Arg Leu Ser Thr Ile Gln Asn Ala Asp Leu Ile Val Val Phe	1265	1270	1275
Gln Asn Gly Lys Val Lys Glu His Gly Thr His Gln Gln Leu Leu Ala			1280
Gln Lys Gly Ile Tyr Phe Ser Met Val Ser Val Gln Ala Gly Ala Lys			
Arg			

25 <210> 26
 <211> 4279
 <212> DNA
 <213> Canis familiaris

 30 <220>
 <221> CDS
 <222> (17)...(3859)

	<400> 26			
	ggagcgcgag	gtccggg	atg gat cct gaa gga ggc cgt aag ggg agt gca gag	
			Met Asp Pro Glu Gly Gly Arg Lys Gly Ser Ala Glu	
35	1	5	10	
	aag aac ttc tgg aaa atg ggc aaa aaa agt aaa aaa aaa gag aag aaa		100	
	Lys Asn Phe Trp Lys Met Gly Lys Ser Lys Lys Lys Glu Lys Lys			
	15	20	25	
40	gaa aag aaa cca act gtc agc acg ttt gca atg ttt cgc tat tca aat		148	
	Glu Lys Lys Pro Thr Val Ser Thr Phe Ala Met Phe Arg Tyr Ser Asn			
	30	35	40	
45	tgg ctt gat agg ttg tat atg ttg gtg ggg aca atg gct gcc atc atc		196	
	Trp Leu Asp Arg Leu Tyr Met Leu Val Gly Thr Met Ala Ala Ile Ile			
	45	50	55	60
50	cat gga gct gca ctc cct ctc atg atg ctg gtt ttt gga aac atg aca		244	
	His Gly Ala Ala Leu Pro Leu Met Met Leu Val Phe Gly Asn Met Thr			
	65	70	75	
	gat agc ttt gca aat gca gga att tca aga aac aaa act ttt cca gtt		292	
	Asp Ser Phe Ala Asn Ala Gly Ile Ser Arg Asn Lys Thr Phe Pro Val			
55	80	85	90	
	ata att aat gaa agt att acg aac aat aca caa cat ttc atc aac cat		340	
	Ile Ile Asn Glu Ser Ile Thr Asn Asn Thr Gln His Phe Ile Asn His			
	95	100	105	
60				

ctg gag gag gaa atg acc acg tat gcc tat tat tac agt ggg atc ggt	388
Leu Glu Glu Glu Met Thr Thr Tyr Ala Tyr Tyr Tyr Ser Gly Ile Gly	
110 115 120	
5 gct ggc gtc ctg gtc gct gct tac atc cag gtt tca ttc tgg tgc ctg	436
Ala Gly Val Leu Val Ala Ala Tyr Ile Gln Val Ser Phe Trp Cys Leu	
125 130 135 140	
10 gca gca gga aga cag ata ctc aaa att aga aaa caa ttt ttt cat gct	484
Ala Ala Gly Arg Gln Ile Leu Lys Ile Arg Lys Gln Phe Phe His Ala	
145 150 155	
15 atc atg cga cag gag att ggc tgg ttt gac gtc cat gac gtt ggg gag	532
Ile Met Arg Gln Ile Gly Trp Phe Asp Val His Asp Val Gly Glu	
160 165 170	
20 ctt aac acc cgg ctc aca gac gat gtc tcc aaa atc aat gaa gga att	580
Leu Asn Thr Arg Leu Thr Asp Asp Val Ser Lys Ile Asn Glu Gly Ile	
175 180 185	
25 ggc gac aaa att gga atg ttc ttt cca tca ata gca aca ttt ttc acc	628
Gly Asp Lys Ile Gly Met Phe Phe Gln Ser Ile Ala Thr Phe Phe Thr	
190 195 200	
30 ggt ttt ata gtc ggg ttt aca cgt ggt tgg aag cta acc ctt gtc att	676
Gly Phe Ile Val Gly Phe Thr Arg Gly Trp Lys Leu Thr Leu Val Ile	
205 210 215 220	
35 ttg gcc atc agc cct gtt ctt gga ctt tca gcc atc tgg gca aag	724
Leu Ala Ile Ser Pro Val Leu Gly Leu Ser Ala Ala Ile Trp Ala Lys	
225 230 235	
40 ata cta tct tca ttt act gat aaa gaa ctc ttg gcc tat gca aaa gct	772
Ile Leu Ser Ser Phe Thr Asp Lys Glu Leu Leu Ala Tyr Ala Lys Ala	
240 245 250	
45 gga gca gta gct gaa gaa gtc tta gca gca atc aga act gtc att gcc	820
Gly Ala Val Ala Glu Glu Val Leu Ala Ala Ile Arg Thr Val Ile Ala	
255 260 265	
50 ttt gga gga caa aag aaa gaa ctt gaa agg tac aac aaa aat tta gaa	868
Phe Gly Gly Gln Lys Lys Glu Leu Glu Arg Tyr Asn Lys Asn Leu Glu	
270 275 280	
55 gaa gct aaa gga att ggg ata aag aaa gct atc acg gcc aac att tct	916
Glu Ala Lys Gly Ile Gly Ile Lys Lys Ala Ile Thr Ala Asn Ile Ser	
285 290 295 300	
60 att ggt gcc gct ttc tta ttg atc tat gca tca tat gct ctg gct ttc	964
Ile Gly Ala Ala Phe Leu Leu Ile Tyr Ala Ser Tyr Ala Leu Ala Phe	
305 310 315	
tgg tat ggg acc tcc ttg gtc ctc tcc agt gaa tat act att gga caa	1012
Trp Tyr Gly Thr Ser Leu Val Leu Ser Ser Glu Tyr Thr Ile Gly Gln	
320 325 330	
55 gta ctc act gtc ttc ttt tct gta tta att ggg gct ttt agt att gga	1060
Val Leu Thr Val Phe Phe Ser Val Leu Ile Gly Ala Phe Ser Ile Gly	
335 340 345	

	cag gca tcc cca agc att gaa gca ttt gca aac gca aga gga gca gct Gln Ala Ser Pro Ser Ile Glu Ala Phe Ala Asn Ala Arg Gly Ala Ala 350	355	360	1108
5	tat gaa atc ttc aag ata att gac aat aaa cca agc att gac agc tat Tyr Glu Ile Phe Lys Ile Ile Asp Asn Lys Pro Ser Ile Asp Ser Tyr 365	370	375	380
10	tcg aag agt gga cat aaa cca gat aat att aag gga aat ttg gaa ttc Ser Lys Ser Gly His Lys Pro Asp Asn Ile Lys Gly Asn Leu Glu Phe 385	390	395	1204
15	aaa aat gtt cac ttc agt tac cct tct cga aaa gaa gtt aag atc tta Lys Asn Val His Phe Ser Tyr Pro Ser Arg Lys Glu Val Lys Ile Leu 400	405	410	1252
20	aag ggt ctc aac ctg aag gtt cag agt ggg cag aca gtg gcg ctg gtt Lys Gly Leu Asn Leu Lys Val Gln Ser Gly Gln Thr Val Ala Leu Val 415	420	425	1300
25	ggg aac agt ggc tgc ggg aag agc acg acc gtg cag ctg atg cag agg Gly Asn Ser Gly Cys Gly Lys Ser Thr Thr Val Gln Leu Met Gln Arg 430	435	440	1348
30	ctc tat gac ccc aca gat ggc atg gtc tgt att gat gga cag gag att Leu Tyr Asp Pro Thr Asp Gly Met Val Cys Ile Asp Gly Gln Asp Ile 445	450	455	1396
35	agg acc ata aat gta agg cat ctt cgg gaa att act ggt gtg gtg agt Arg Thr Ile Asn Val Arg His Leu Arg Glu Ile Thr Gly Val Val Ser 465	470	475	1444
40	cag gag cct gtg ttg ttt gcc acc acg ata gct gaa aac att cgc tat Gln Glu Pro Val Leu Phe Ala Thr Thr Ile Ala Glu Asn Ile Arg Tyr 480	485	490	1492
45	ggc cgc gaa aat gtc acc atg gat gag att gag aaa gct gtt aag gaa Gly Arg Glu Asn Val Thr Met Asp Glu Ile Glu Lys Ala Val Lys Glu 495	500	505	1540
50	gcc aat gcc tat gat ttt atc atg aaa cta cct aat aaa ttt gac act Ala Asn Ala Tyr Asp Phe Ile Met Lys Leu Pro Asn Lys Phe Asp Thr 510	515	520	1588
55	ctg gtt gga gag aga ggg gcc cag ctg agt ggt gga cag aaa cag aga Leu Val Gly Glu Arg Gly Ala Gln Leu Ser Gly Gly Gln Lys Gln Arg 525	530	535	1636
60	atc gcc att gct cgg gcc ctg gtt cgc aac ccc aag att ctt ctg ctg Ile Ala Ile Ala Arg Ala Leu Val Arg Asn Pro Lys Ile Leu Leu Leu 545	550	555	1684
65	gat gag gca acg tca gct ctg gac act gaa agt gaa gca gtg gtt cag Asp Glu Ala Thr Ser Ala Leu Asp Thr Glu Ser Glu Ala Val Val Gln 560	565	570	1732
70	gtg gcc ctg gat aag gcc aga aaa ggc cgg act acc att gtg ata gct Val Ala Leu Asp Lys Ala Arg Lys Gly Arg Thr Thr Ile Val Ile Ala 575	580	585	1780

	cat cgt ttg tct aca gtt cgt aat gcc gat gtc att gct ggt ttt gat His Arg Leu Ser Thr Val Arg Asn Ala Asp Val Ile Ala Gly Phe Asp 590 595 600	1828
5	gat gga gtc att gtg gag aaa gga aat cat gat gaa ctc atg aag gag Asp Gly Val Ile Val Glu Lys Gly Asn His Asp Glu Leu Met Lys Glu 605 610 615 620	1876
10	aag ggc att tac ttc aaa ctt gtc aca atg cag aca aca gga aat gaa Lys Gly Ile Tyr Phe Lys Leu Val Thr Met Gln Thr Arg Gly Asn Glu 625 630 635	1924
15	att gag tta gaa aat gcc act ggt gaa tcc aaa aat gaa aat gat gac Ile Glu Leu Glu Asn Ala Thr Gly Glu Ser Lys Ser Glu Ser Asp Ala 640 645 650	1972
20	ttg gaa atg tct cca aaa gat tca ggg tcc aat tta ata aaa aca aca Leu Glu Met Ser Pro Lys Asp Ser Gly Ser Ser Leu Ile Lys Arg Arg 655 660 665	2020
25	tca act cgc agg aat ata cat gca cca caa ggc caa gac aca aag aat Ser Thr Arg Arg Ser Ile His Ala Pro Gln Gly Asp Arg Lys Leu 670 675 680	2068
30	ggg aca aaa gag gac ttg aat gag aat gta cct cca gtt tcc ttc tgg Gly Thr Lys Glu Asp Leu Asn Glu Asn Val Pro Pro Val Ser Phe Trp 685 690 695 700	2116
35	agg att ctg aag ctg aac tca act gaa tgg cct tat ttt gtg gtt ggt Arg Ile Leu Lys Leu Asn Ser Thr Glu Trp Pro Tyr Phe Val Val Gly 705 710 715	2164
40	ata ttt tgt gct att ata aac gga ggc ctg caa cca gca ttt tca ata Ile Phe Cys Ala Ile Ile Asn Gly Gly Leu Gln Pro Ala Phe Ser Ile 720 725 730	2212
45	ata ttt tca agg att ata ggg atc ttt acc cga gat gag gat cct gaa Ile Phe Ser Arg Ile Ile Gly Ile Phe Thr Arg Asp Glu Asp Pro Glu 735 740 745	2260
50	aca aaa cga cag aat aat aac atg ttt tct gta ttg ttt cta gtc ctt Thr Lys Arg Gln Asn Ser Asn Met Phe Ser Val Leu Phe Leu Val Leu 750 755 760	2308
55	gga att att tct ttt att aca ttt ttc ctc cag ggc ttc aca ttt ggc Gly Ile Ile Ser Phe Ile Thr Phe Leu Gln Gly Phe Thr Phe Gly 765 770 775 780	2356
60	aaa gct ggg gag atc ctc act aag cgg ctt cga tac atg gtt ttc aca Lys Ala Gly Glu Ile Leu Thr Lys Arg Leu Arg Tyr Met Val Phe Arg 785 790 795	2404
65	tcc atg ctg aca cag gat gtc agc tgg ttt gat gac cct aaa aac acc Ser Met Leu Arg Gln Asp Val Ser Trp Phe Asp Asp Pro Lys Asn Thr 800 805 810	2452
70	act gga gca ttg aca acc agg ctt gcc aat gat gcg gct caa gtt aaa Thr Gly Ala Leu Thr Thr Arg Leu Ala Asn Asp Ala Ala Gln Val Lys 815 820 825	2500

ggg gct ata ggt tcc agg ctt gct gtc att acc cag aat ata gca aat Gly Ala Ile Gly Ser Arg Leu Ala Val Ile Thr Gln Asn Ile Ala Asn 830 835 840	2548
5 ctt ggg aca ggc att att ata tcc tta atc tat ggt tgg caa tta aca Leu Gly Thr Gly Ile Ile Ser Leu Ile Tyr Gly Trp Gln Leu Thr 845 850 855 860	2596
10 ctt tta ctc tta gca att gta ccc atc att gca ata gca gga gtt gtt Leu Leu Leu Ala Ile Val Pro Ile Ile Ala Ile Ala Gly Val Val 865 870 875	2644
15 gaa atg aaa atg ttg tct gga caa gca ctg aaa gat aag aaa gag cta Glu Met Lys Met Leu Ser Gly Gln Ala Leu Lys Asp Lys Lys Glu Leu 880 885 890	2692
20 gaa gga gct ggg aag att gct aca gaa gcc atc gaa aac ttc cga act Glu Gly Ala Gly Lys Ile Ala Thr Glu Ala Ile Glu Asn Phe Arg Thr 895 900 905	2740
25 gtt gtt tct ttg act cgg gag cag aag ttt gaa tac atg tat gca cag Val Val Ser Leu Thr Arg Glu Gln Lys Phe Glu Tyr Met Tyr Ala Gln 910 915 920	2788
30 agt ttg caa gta cca tac aga aac tct ttg agg aaa gca cac atc ttc Ser Leu Gln Val Pro Tyr Arg Asn Ser Leu Arg Lys Ala His Ile Phe 925 930 935 940	2836
35 ggg gtc tca ttt tct atc acc cag gca atg atg tat ttt tcc tat gct Gly Val Ser Phe Ser Ile Thr Gln Ala Met Met Tyr Phe Ser Tyr Ala 945 950 955	2884
40 ggc tgt ttc cgg ttt ggt gcc tac ttg gtc gca aat gag ttc atg aac Gly Cys Phe Arg Phe Gly Ala Tyr Leu Val Ala Asn Glu Phe Met Asn 960 965 970	2932
45 ttt cag gat gtt ctt ttg gta ttc tca gct att gtc ttt ggt gcc atg Phe Gln Asp Val Leu Leu Val Phe Ser Ala Ile Val Phe Gly Ala Met 975 980 985	2980
50 gca gtg ggg cag gtc agt tca ttt gct cct gac tat gcc aaa gcc aaa Ala Val Gly Gln Val Ser Ser Phe Ala Pro Asp Tyr Ala Lys Ala Lys 990 995 1000	3028
55 gta tca gca gcc cac gtc atc atg atc att gaa aaa agc cct ctg att Val Ser Ala Ala His Val Ile Met Ile Ile Glu Lys Ser Pro Leu Ile 1005 1010 1015 1020	3076
60 gac agc tac agc cct cac ggc ctc aag cca aat acg ttg gaa gga aat Asp Ser Tyr Ser Pro His Gly Leu Lys Pro Asn Thr Leu Glu Gly Asn 1025 1030 1035	3124
65 gtg aca ttt aat gag gtc gtg ttc aac tat ccc act cga cca gac atc Val Thr Phe Asn Glu Val Val Phe Asn Tyr Pro Thr Arg Pro Asp Ile 1040 1045 1050	3172
70 ccc gtg ctc cag ggg ctg agc ctc gag gtg aag aag ggc cag acg ctg Pro Val Leu Gln Gly Leu Ser Leu Glu Val Lys Lys Gly Gln Thr Leu 1055 1060 1065	3220

	gcc ctc gta ggt agc agt ggc tgt ggg aag agc aca gtt gtt cag ctc Ala Leu Val Gly Ser Ser Gly Cys Gly Lys Ser Thr Val Val Gln Leu 1070	1075	1080	3268
5	cta gag cgc ttc tat gac ccc ttg gct ggt tca gtc cta att gat ggc Leu Glu Arg Phe Tyr Asp Pro Leu Ala Gly Ser Val Leu Ile Asp Gly 1085	1090	1095	1100
10	aaa gag ata aag cac ctg aat gtc cag tgg ctc cga gca cac ctg ggc Lys Glu Ile Lys His Leu Asn Val Gln Trp Leu Arg Ala His Leu Gly 1105	1110	1115	3364
15	atc gtg tct cag gag ccc atc ctg ttt gac tgc agc att gcc gag aac Ile Val Ser Gln Glu Pro Ile Leu Phe Asp Cys Ser Ile Ala Glu Asn 1120	1125	1130	3412
20	att gcc tat gga gac aac aac agc cgg gtc gta tca cat gaa gag att gtg Ile Ala Tyr Gly Asp Asn Ser Arg Val Val Ser His Glu Glu Ile Val 1135	1140	1145	3460
25	cag gca gcc aag gag gcc aac ata cac cac ttc atc gag aca ctc cct Gln Ala Ala Lys Glu Ala Asn Ile His His Phe Ile Glu Thr Leu Pro 1150	1155	1160	3508
30	gag aaa tac aac acc aga gta gga gac aaa gga acc cag ctc tct ggt Glu Lys Tyr Asn Thr Arg Val Gly Asp Lys Gly Thr Gln Leu Ser Gly 1165	1170	1175	3556
35	ggc cag aaa cag cgc att gcc ata gct cgc gct ctt gtt aga cag cct Gly Gln Lys Gln Arg Ile Ala Ile Ala Arg Ala Leu Val Arg Gln Pro 1185	1190	1195	3604
40	cat att ttg ctt ttg gat gaa gct aca tca gct ctg gat aca gaa agt His Ile Leu Leu Asp Glu Ala Thr Ser Ala Leu Asp Thr Glu Ser 1200	1205	1210	3652
45	gaa aag gtt gtc caa gaa gcc ctg gac aaa gcc aga gaa ggc cgc acc Glu Lys Val Val Gln Glu Ala Leu Asp Lys Ala Arg Glu Gly Arg Thr 1215	1220	1225	3700
50	tgc att gtg atc gcc cac cgc ttg tcc acc atc cag aat gca gat tta Cys Ile Val Ile Ala His Arg Leu Ser Thr Ile Gln Asn Ala Asp Leu 1230	1235	1240	3748
55	ata gtg gtg ttt cag aat ggc aaa gtc aag gag cat ggc aca cat caa Ile Val Val Phe Gln Asn Gly Lys Val Lys Glu His Gly Thr His Gln 1245	1250	1255	3796
60	cag ctg ctg gcc cag aaa ggc atc tat ttt tcc atg gtc agt gtc cag Gln Leu Leu Ala Gln Lys Gly Ile Tyr Phe Ser Met Val Ser Val Gln 1265	1270	1275	3844
	gct gga gca aag cgc tagtgaactg tggccatatg agctgttaaa tattttttaa Ala Gly Ala Lys Arg 1280			3899
	tatttgtgtt aaaaatggc atttaatcaa agttaaaagg tgagcactta ctggaaaaac tatgttagaaat tacctgttta acatttcttg ctgcaactg agatcattcc accaaatgtca gagtcttcag attttataat taagggaaacc aaaaagaaaca ttatctgtatg gaataaaaaata ctgtatgtttaa ttccatataa aatattatata aatattccaa atgatcttttq ttataaaatt 4019			3959
				4079
				4139

gtataatttt	tgtttatatt	ttatttgtaa	cttactgcct	tgctgaaaga	ttatagaagt	4199
ggtaaaaaga	actgaatgtt	tgaataaagt	gctagctata	ataaaaactaa	acttttat	4259
caaaaaaaaaa						

5	<210>	27				
	<211>	1281				
	<212>	PRT				
	<213>	Canis familiaris				
10	<400>	27				
	Met Asp Pro Glu Gly Gly Arg Lys Gly Ser Ala Glu Lys Asn Phe Trp					
1	5	10	15			
	Lys Met Gly Lys Lys Ser Lys Lys Glu Lys Lys Glu Lys Pro					
	20	25	30			
15	Thr Val Ser Thr Phe Ala Met Phe Arg Tyr Ser Asn Trp Leu Asp Arg					
	35	40	45			
	Leu Tyr Met Leu Val Gly Thr Met Ala Ala Ile Ile His Gly Ala Ala					
	50	55	60			
	Leu Pro Leu Met Met Leu Val Phe Gly Asn Met Thr Asp Ser Phe Ala					
20	65	70	75	80		
	Asn Ala Gly Ile Ser Arg Asn Lys Thr Phe Pro Val Ile Ile Asn Glu					
	85	90	95			
	Ser Ile Thr Asn Asn Thr Gln His Phe Ile Asn His Leu Glu Glu Glu					
	100	105	110			
25	Met Thr Thr Tyr Ala Tyr Tyr Ser Gly Ile Gly Ala Gly Val Leu					
	115	120	125			
	Val Ala Ala Tyr Ile Gln Val Ser Phe Trp Cys Leu Ala Ala Gly Arg					
	130	135	140			
	Gln Ile Leu Lys Ile Arg Lys Gln Phe Phe His Ala Ile Met Arg Gln					
30	145	150	155	160		
	Glu Ile Gly Trp Phe Asp Val His Asp Val Gly Glu Leu Asn Thr Arg					
	165	170	175			
	Leu Thr Asp Asp Val Ser Lys Ile Asn Glu Gly Ile Gly Asp Lys Ile					
	180	185	190			
35	Gly Met Phe Phe Gln Ser Ile Ala Thr Phe Phe Thr Gly Phe Ile Val					
	195	200	205			
	Gly Phe Thr Arg Gly Trp Lys Leu Thr Leu Val Ile Leu Ala Ile Ser					
	210	215	220			
	Pro Val Leu Gly Leu Ser Ala Ala Ile Trp Ala Lys Ile Leu Ser Ser					
40	225	230	235	240		
	Phe Thr Asp Lys Glu Leu Leu Ala Tyr Ala Lys Ala Gly Ala Val Ala					
	245	250	255			
	Glu Glu Val Leu Ala Ala Ile Arg Thr Val Ile Ala Phe Gly Gly Gln					
	260	265	270			
45	Lys Lys Glu Leu Glu Arg Tyr Asn Lys Asn Leu Glu Glu Ala Lys Gly					
	275	280	285			
	Ile Gly Ile Lys Lys Ala Ile Thr Ala Asn Ile Ser Ile Gly Ala Ala					
	290	295	300			
	Phe Leu Leu Ile Tyr Ala Ser Tyr Ala Leu Ala Phe Trp Tyr Gly Thr					
50	305	310	315	320		
	Ser Leu Val Leu Ser Ser Glu Tyr Thr Ile Gly Gln Val Leu Thr Val					
	325	330	335			
	Phe Phe Ser Val Leu Ile Gly Ala Phe Ser Ile Gly Gln Ala Ser Pro					
	340	345	350			
55	Ser Ile Glu Ala Phe Ala Asn Ala Arg Gly Ala Ala Tyr Glu Ile Phe					
	355	360	365			
	Lys Ile Ile Asp Asn Lys Pro Ser Ile Asp Ser Tyr Ser Lys Ser Gly					
	370	375	380			
	His Lys Pro Asp Asn Ile Lys Gly Asn Leu Glu Phe Lys Asn Val His					
60	385	390	395	400		

Phe Ser Tyr Pro Ser Arg Lys Glu Val Lys Ile Leu Lys Gly Leu Asn			
405	410	415	
Leu Lys Val Gln Ser Gly Gln Thr Val Ala Leu Val Gly Asn Ser Gly			
420	425	430	
5 Cys Gly Lys Ser Thr Thr Val Gln Leu Met Gln Arg Leu Tyr Asp Pro			
435	440	445	
Thr Asp Gly Met Val Cys Ile Asp Gly Gln Asp Ile Arg Thr Ile Asn			
450	455	460	
10 Val Arg His Leu Arg Glu Ile Thr Gly Val Val Ser Gln Glu Pro Val			
465	470	475	480
Leu Phe Ala Thr Thr Ile Ala Glu Asn Ile Arg Tyr Gly Arg Glu Asn			
485	490	495	
15 Val Thr Met Asp Glu Ile Glu Lys Ala Val Lys Glu Ala Asn Ala Tyr			
500	505	510	
Asp Phe Ile Met Lys Leu Pro Asn Lys Phe Asp Thr Leu Val Gly Glu			
515	520	525	
20 Arg Gly Ala Gln Leu Ser Gly Gly Gln Lys Gln Arg Ile Ala Ile Ala			
530	535	540	
Arg Ala Leu Val Arg Asn Pro Lys Ile Leu Leu Asp Glu Ala Thr			
545	550	555	560
25 Ser Ala Leu Asp Thr Glu Ser Glu Ala Val Val Gln Val Ala Leu Asp			
565	570	575	
Lys Ala Arg Lys Gly Arg Thr Thr Ile Val Ile Ala His Arg Leu Ser			
580	585	590	
30 25 Thr Val Arg Asn Ala Asp Val Ile Ala Gly Phe Asp Asp Gly Val Ile			
595	600	605	
Val Glu Lys Gly Asn His Asp Glu Leu Met Lys Glu Lys Gly Ile Tyr			
610	615	620	
Phe Lys Leu Val Thr Met Gln Thr Arg Gly Asn Glu Ile Glu Leu Glu			
625	630	635	640
35 Asn Ala Thr Gly Glu Ser Lys Ser Glu Ser Asp Ala Leu Glu Met Ser			
645	650	655	
Pro Lys Asp Ser Gly Ser Ser Leu Ile Lys Arg Arg Ser Thr Arg Arg			
660	665	670	
40 35 Ser Ile His Ala Pro Gln Gly Gln Asp Arg Lys Leu Gly Thr Lys Glu			
675	680	685	
Asp Leu Asn Glu Asn Val Pro Pro Val Ser Phe Trp Arg Ile Leu Lys			
690	695	700	
Leu Asn Ser Thr Glu Trp Pro Tyr Phe Val Val Gly Ile Phe Cys Ala			
705	710	715	720
45 40 Ile Ile Asn Gly Gly Leu Gln Pro Ala Phe Ser Ile Ile Phe Ser Arg			
725	730	735	
Ile Ile Gly Ile Phe Thr Arg Asp Glu Asp Pro Glu Thr Lys Arg Gln			
740	745	750	
50 45 Asn Ser Asn Met Phe Ser Val Leu Phe Leu Val Leu Gly Ile Ile Ser			
755	760	765	
Phe Ile Thr Phe Phe Leu Gln Gly Phe Thr Phe Gly Lys Ala Gly Glu			
770	775	780	
Ile Leu Thr Lys Arg Leu Arg Tyr Met Val Phe Arg Ser Met Leu Arg			
785	790	795	800
55 50 Gln Asp Val Ser Trp Phe Asp Asp Pro Lys Asn Thr Thr Gly Ala Leu			
805	810	815	
Thr Thr Arg Leu Ala Asn Asp Ala Ala Gln Val Lys Gly Ala Ile Gly			
820	825	830	
60 55 Ser Arg Leu Ala Val Ile Thr Gln Asn Ile Ala Asn Leu Gly Thr Gly			
835	840	845	
Ile Ile Ile Ser Leu Ile Tyr Gly Trp Gln Leu Thr Leu Leu Leu			
850	855	860	
Ala Ile Val Pro Ile Ile Ala Ile Ala Gly Val Val Glu Met Lys Met			
865	870	875	880

<210> 28

<211> 52

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic oligonucleotide

60

	<400> 28	
	nntttttttt tttttttttt tttttttttt ttccgcggcg acttaagatc tt	52
5	<210> 29	
	<211> 27	
	<212> DNA	
	<213> Artificial Sequence	
10	<220>	
	<223> Synthetic oligonucleotide	
	<400> 29	
	ccatcctaat acgactcaact gtagggc	27
15	<210> 30	
	<211> 34	
	<212> DNA	
	<213> Canis familiaris	
20	<400> 30	
	gcaaatgctt caatgcttgg ggatgcctgt ccaa	34
25	<210> 31	
	<211> 33	
	<212> DNA	
	<213> Canis familiaris	
	<400> 31	
30	gagctgggtt cctttgtctc ctactctggt gtt	33
	<210> 32	
	<211> 23	
	<212> DNA	
	<213> Canis familiaris	
	<400> 32	
35	gcaaatgctg gttgcaggcc tcc	23